OA16848A

OA16848A - Indazoles

Info

Publication number: OA16848A
Application number: OA1201400022
Authority: OA
Inventors: Jotham Wadsworth Coe; Christoph Martin Dehnhardt; Peter Jones; Steven Wade Kortum; Yogesh Anil Sabnis; Florian Michel WAKENHUT; Gavin Alistair Whitlock
Original assignee: Pfizer Limited
Priority date: 2011-07-27
Filing date: 2012-07-11
Publication date: 2016-01-07

Abstract

The present invention relates to compounds of formula (I) to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

Description

INDAZOLES

The présent invention relates to îndazoles, pharmaceutical compositions comprising such compounds and their use as médicaments. More particularly, the présent invention provides 65 phenyl-1H-indazole dérivatives which are Janus Kinase (JAK) înhibitors and useful for the treatment of allergie and respiratory conditions, particularly chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the US 10 and is characterized by airflow obstruction that is not fully réversible with bronchodilators. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily cigarette smoke. Symptoms are typically breathing-related (e.g. chronic cough, exertional dyspnea, expectoration and wheeze). Patients expérience periods of stable disease interspersed with inflammatory exacerbations 15 resulting in acute décliné in lung function and often hospitalization.

Current treatment guidelines recommend bronchodilators as the mainstay of COPD drug treatment. However, anti-inflammatory inhaled corticosteroids (ICS) and bronchodilator/inhaled corticosteroid combination products, are extensively used. Whilst inhaled corticosteroids do 20 provide some benefits with respect to short term lung function improvements and exacerbation frequency, they do not address the corticosteroid-refractory inflammation which is characteristic of this disease and thought to play a key rôle in disease progression. There is a clear medical need for anti-inflammatory thérapies in COPD that will address the chronic inflammatory component of the disease and ultimately provide symptomatic relief, a réduction in exacerbation 25 frequency and an amelioration of exacerbation severity.

The Janus kinase (JAK) family of receptor associated tyrosine kinases, JAK 1, JAK 2, JAK 3 and tyrosine kinase 2 (TYK2), are involved in signal transduction associated with a variety of inflammatory cytokines. JAK kinases can function as either hetero or homo-dimers, 30 phosphorylating STAT transcription factors which regulate inflammatory gene transcription. Oral

JAK 1/JAK 3 înhibitors such as CP-690550 hâve shown impressive anti-inflammatory activity in inflammatory diseases such as rheumatoid arthritis and psoriasis.

Many JAK dépendent cytokines are thought to play key rôles in the pathology of COPD which 35 involves the interplay of multiple inflammatory cells such as T lymphocytes, neutrophils, macrophages and lung epithelium. For example the JAK 1/JAK 3 heterodimer plays a key rôle in T lymphocyte survival and activation whereas JAK 2 is thought to be critical for régulation of

neutrophil activation and apoptosis. JAK 1 and JAK 2 play an important rôle in IL-13 mediated inflammatory signaling in macrophages, which is thought to link acute inflammatory events to chronic progressive disease. Importantly JAK 1, JAK 2 and TYK 2 also play an important rôle in signaling mediated by IFNy, a cytokine associated with the chronic inflammation observed in

COPD, which modulâtes the activity of T cells, epithelium and macrophages whilst not being modulated by corticosteroids.

Macrophage phagocytosîs of bacteria is impaired in the lungs of COPD patients, potentially in part due to high local IFNy levels. In vitro studies with isolated patient cells hâve shown that JAK 10 inhibitors increase phagocytotic rate in the presence of IFNy. Consequently, as well as exerting a direct anti-inflammatory effect, JAK inhibitors may also increase the ability of the lung to maintain a stérile environment.

JAK inhibitors are therefore likely to hâve utility in the treatment of a range of inflammatory 15 diseases, including lung diseases such as COPD, asthma and pulmonary vascular disease.

Compounds which hâve a broad inhibitory activity across the range of Janus kinases, in particular, are likely to hâve a potent anti-inflammatory effect. However, such a selectivity profile can also lead to undesirable side-effects in systemically circulating compounds, particularly anémia and neutropenia associated with JAK 2 inhibition. For the treatment of lung diseases, it 20 is therefore particularly favourable to provide JAK inhibitors which can be administered by inhalation and which inhibit Janus kinases locally in the lung without having a significant systemic exposure.

There is thus a need to provide new JAK inhibitors that are potent, sélective inhibitors of Janus 25 kinases with appropriate metabolic stability and pharmacokinetic properties, particularly compounds which can be administered by inhalation and are active in lung tissue whilst having poor systemic pénétration or high systemic lability.

The invention therefore provides, as embodiment E1, a compound of formula (I):

(D or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein:

R¹ is halo;

R² is C_rCe alkyl optionally substituted by one or more fluorine atoms;

X is a bond, -CO-, -SO₂- or -CH₂-;

R³ is Aryl¹, Het¹ or Het², each of which is optionally substituted by 1 substituent -Y-R⁴ and/or 1-4 substituents each independently selected from R⁵;

n is 1 or 2;

Aryl¹ is phenyl or naphthyl;

Het¹ is (i) a 6-membered aromatic heterocycle containing 1-3 N atoms or (ü) a 5-membered aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms;

Het² is (i) a 10-membered bicyclic aromatic heterocycle containing 1-4 N atoms or (ii) a 925 membered bicyclic aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms or (iii) an 8-membered bicyclic aromatic heterocycle containing (a) 1-4 N atoms or (b) 1 O or S atom and 1-3 N atoms or (c) 2 O or S atoms and 0-2 N atoms;

Y is a bond or -O-;

R⁴ îs Aryl² or Het,

R⁵ is CrCe alkyl, C3-C8 cycloalkyl, halo, -CN, -OR⁶, -NR⁷R⁸, -SR⁶, -SOR⁹, -SO2R⁹, -COR⁶, OCOR⁶, -COOR⁶, -NR⁶COR⁶, -CONR⁷R⁸, -nr⁶so2r⁹, -so2nr⁷r⁸, -nr⁶conr⁷r⁸, -nr⁸coor⁹or -NR⁶SO₂NR⁷R⁸;

R⁶ is H, CrC_e alkyl or C₃-C₈ cycloalkyl, said CrC_e alkyl;

R⁷ and R⁸ are each independently H, CrC₆ alkyl or C₃-C₀ cycloalkyl or are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1-2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said heterocyclic ring being optionally substituted by one or more CrC₆ alkyl or C₃-C₈ cycloalkyl groups;

R⁹ is CrC₆ alkyl or C₃-C₈ cycloalkyl;

Aryl² is phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1-5 substituents selected from Ci-Ce alkyl, C3-C8 cycloalkyl, halo, -CN, -OR⁶, -NR⁷R⁸, -SR⁶, -SOR⁹, SO2R^g, -COR⁶, -OCOR⁶, -COOR⁶, -NR^eCOR®, -CONR⁷R⁸, -NR⁶SO2R⁹, -SO2NR⁷R⁸, NR⁶CONR⁷R⁸, -NR⁶COOR⁹ and -NR⁶SO₂NR⁷R⁸; and

Het³ is a 3 to 8-membered saturated or partially unsaturated monocyclic heterocycle, containing 1 or 2 heteroatoms selected from O and N, said heterocycle being optionally substituted by 1-5 substituents selected from Ci-C8 alkyl, C3-C8 cycloalkyl, halo, oxo, -OR⁶, -NR⁷R⁸, -SR⁶, -SOR⁹, SO2R⁹, -COR⁶, -OCOR⁶, -COOR⁶, -NR⁶COR⁶, -CONR⁷R⁸, -NR⁶SO2R⁹, -SO2NR⁷R⁸, NR⁶CONR⁷R⁸, -NR⁶COOR⁹ and -NR⁶SO₂NR⁷R⁸.

The invention also provides, as embodiment E2, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R², η, X and R³ are as defined in embodiment E1 and R’ is fluoro.

The invention also provides, as embodiment E3, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of

embodiments E1 or E2, η, X and R³ are as defined in embodiment E1 and R² is -CH₂CH₃ or CH₂CF₃.

The invention also provides, as embodiment E4, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, X and R³ are as defined in embodiment E1 and n is 1.

The invention also provides, as embodiment E5, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, X and R³ are as defined in embodiment E1 and n is 2.

The invention also provides, as embodiment E6, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1, E4 or E5, R³ is as defined in embodiment E1 and X is a bond.

The invention also provides, as embodiment E7, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1, E4 or ES, R³ is as defined in embodiment E1 and X is -CO-.

The invention also provides, as embodiment E8, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1, E4 or ES, R³ is as defined in embodiment E1 and X is -CH₂-,

The invention also provides, as embodiment E9, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of

embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1, E4 or E5, R³ is as defined in embodiment E1 and X is -SO₂-.

The invention also provides, as embodiment E10, a compound of formula (I), or a 5 pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1, E4 or E5, X is as defined in any one of embodiments E1, E6, E7, E8 or E9 and R³ is is phenyl, thiazolyl, quinolinyl, pyrimidinyl, [1,8]naphthyridinyl or pyridyl, each 10 of which is optionally substituted by 1 substituent -Y-R⁴ and 1-4 substituents each independently selected from R⁵.

The invention also provides, as embodiment E11, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said 15 compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1, E4 or E5, X is as defined in any one of embodiments E1, E6, E7, ΕΘ or E9 and R³ is phenyl, thiazolyl, quinolinyl, pyrimidinyl, [1,8]naphthyridinyl or pyridyl, each of which is optionally substituted by 1 substituent selected from piperdininyl, (fluorophenyl)oxy, 20 phenyloxy and morpholinyl and 1-2 substituents each independently selected from fluoro, chloro, cyano, methoxy and hydroxy.

The invention also provides, as embodiment E12, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said 25 compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1, E4 or E5, X is as defined in any one of embodiments E1, E6, E7, E8 or E9 and R³ is fluorophenyl, methoxyphenyl, thiazolyl, hydroxyphenyl, phenyl, quinolinyl, [1,8]naphthyridinyl, (piperidinyl)pyridyl, (piperidinyl)pyrîmidinyl, ((fluorophenyl)oxy)pyrimidinyl, 30 (phenyloxy)pyridyl, (morpholinyl)pyridyl, chloropyridyl or cyanopyridyl.

The invention also provides, as embodiment E13, a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein R¹ is as defined in either of 35 embodiments E1 or E2, R² is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1, E4 or E5, and -X-R³ is (fluorophenyl)carbonyl, (thiazolyl)carbonyl, benzyl, ((piperidinyl)pyrimidinyl)carbonyl, ((phenoxy)pyridyl)carbonyl,

((morpholinyl)pyridyl)sulphonyl, ((phenoxy)pyridyl)sulphonyl, (chloropyridyl)carbonyl, (cyanopyridyl)carbonyl, (fluorophenyl)carbonyl, (thiazolyl)carbonyl, (fluorophenyl)sulphonyl, ((fluorophenoxy)pyrimidinyl)carbonyl, (quinolinyl)methyl, (hydroxyphenyl)methyl, (cyanopyridyl)methyl, (methoxyphenyl)methyl, ((phenoxy)pyridyl)methyl, ((piperidinyl)pyridyl)methyl, ((cyanopyridyl)methyl, (fluorophenyl)methyl or ([1,8]naphthyridinyl)methyl.

The invention also provides, as embodiment E14, a compound of formula:

(la) or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein X is as defined in any one of embodiments E1, E6, E7, E8 or E9 and R³ is as defined in any one of embodiments E1, E10, E11 or E12 or-X-R³ is as defined in embodiment E13.

Particularly preferred compounds of formula (I) include:

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl)-(4-fluoro-phenyl)-methanone:

{2-[6-(2-Ethyl·5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl}-isothiazol-3-yl-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl}-isothiazol-3-yl-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4_l6,7-tetrahydro-imidazo [4,5-clpyridin-5-yl}-(5-piperidin-1-yl-pyrazin-2-yl)’methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydrcHmidazo [4,5-c]pyridin-5-yl}-(6'phenoxy-pyridin-3-yl)-methanone;

5-Ethyl-2-fluoro-4-{3-[5-(6-morpholin-4-yl-pyridine-3-sulfonyl)-4_l5_>6,7-tetrahydro-1H-imidazo[4,5-

c] pyridin-2-yl]-1 H-indazol-6-yl}-phenol;

ô-Ethyl-^-fluorcM-iS-ÎS-ie-phenoxy-pyridine-a-sulfonyOAôAy-tetrahydrci-IH-imidazo [4,5-c]pyridin-2-yl]-1H-indazol-6-yl)-phenol;

(5-Chloro-pyridin'2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazo(-3-yl]-4,5,7,8tetrahydro-1H-imidazo[4,5-d]azepin-6-yl)-methanone;

2-{2-[6-(2-EÎhyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-

d]azepine-6-carbonyl}-isonicotinonitrile;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-4,5,7,8-tetrahydro-1H-imidazo [4,5-d]azepin-6-yl}-(4-fluoro-phenyl)-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-4,5,7,8-tetrahydro-1H-imidazo [4,5-d]azepin-6-yl)-isothiazol-3-yl-methanone;

5-Ethyl-2-fluoro-4-{3-[5-(4-fluoro-benzenesulfonyl)-4,5,6,7-tetrahydro-1H-imidazo [4,5-c]pyridin-2-yl]-1H-indazol-6-yl)-phenol;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl}-[5-(2-fluoro-phenoxy)-pyrazin-2-yl]-methanone;

4- [3-(6-Benzyl-1,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1H-indazol-6-yl]-5-ethyl-2- fluoro-phenol;

(5-Chloro-pyridin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

5- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-innidazo [4,5-c]pyridine-5-carbonyl)-pyridine-2-carbonitrile;

5-{2-[6-(2-Ethyl·5-fluoro-4-hydroxy-phenyl)-1H-indazol·3-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-

d] azepine-6-carbonyl]-pyridine-2-carbonitrile;

5-Ethyl-2-fluoro-4-[3-(5-quinolin-6-ylmethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-phenol;

5-Ethyl-2-fluoro-4-{3-[5-(4-hydroxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]-1H30 indazol-6-yl)-phenol;

S’Ethyl^-fluorcM’iS-fSrfS-hydroxy-benzyOAS.e.y-tetrahydiO-IH-imidazoAS-cJpyridin^-ylj-IHindazol-6-yl}-phenol;

4-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-ylmethyl}-pyridine-2-carbonitrile;

5-Ethyl-2-fluoro-4-{3-[5-(3-methoxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]-1Hindazol-6-yl}-phenol;

5-ΕίΐΊνΙ-2-ΐΙυοΓθ-4-[3-(5-ρυΐηοιιη-3-νΙπθ^νΙ-4,5,6,7-ίθίΓΗΚνυΓθ-1Η-ΐηηΐΰ3ζο[4,5-ο]ρνπόΐη-2’7ΐ)-1Η’ indazol-6-yl]-phenol;

5-Ethyl-2-fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5c]pyridin-2-yl]-1H-indazol-6-yl)-phenol;

S-Ethyl^-fluonM-ia-tS-tSAS.O-tetrahydro^H-Il^jbipyridinyl-S'-ylmethylH.S.OJ-tetrahydrO1 H-imidazo[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;

3- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-ylmethyl)-pyridine-2-carbonitrile;

5-Ethyl-2-fluoro-4-{3-[5-(4-fluoro-benzyl)-4,5₎6₎7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]-1Hindazol-6-yl}-phenol;

5-Ethyl-2-fluoro-4-[3-(5-[1_I8]naphthyridin-2-ylmethyl-4,5,6,7-tetrahydro-1H-imidazo[

4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-phenol;

(2-{6-[5-Fluoro-4-hydroxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1H-indazol-3-yl}-1,4_I6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-(5-piperidin-1-yl-pyrazin-2-yl)-methanone;

(2-{6-[5-Fluoro-4-hydroxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1H-indazol-3-yl}-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-(4-fluoro-phenyl)-methanone;

4- [3-(5-Benzyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-lH-rndazol-6-yl]-2-fluoro-5(2,2,2-trifluoro-ethyl)-phenol;

or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait.

Other preferred compounds of formula (I) include:

{5-[(2’Dimethylamino-ethyl)-methyl-amino]-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

{2-[6-(2-Ethyl-5-fluoro-4hydroxy-phenyl)-1H-indazol·3-yl]-1_I4,6,7-tetrahydro-imidazo[4₎5c]pyridin-5-yl}-[5-(2-pyrrolid^nΊ-yl·ethylamino)-pyrazin-2-yl]-methanone;

[5-(2-Dimethylamino-ethylamino)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1Hindazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

[5-(4-Dimethylamino-piperidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl·5-fluoro-4-hydroxy-phenyl)-1Hindazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-yl}-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pyrazin-2-yl)-methanone;

[5-((R)-3-Dimethylamino-pyrrolidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

[5-((S)-3-Dimethylamino-pyrrolidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4“hydroxy-phenyl)IH’indazol-S-yn-IAej-tetrahydro-imidazo^.S-clpyridÎn-S-yll-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-etrahydroimidazo[4,5c]pyrrdin-

5-yl}-[5-(2-piperidin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 Ae.y-tetrahydro-imidazo^.Sc]pyridin-5-yl}-[5-(2-piperazin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5]pyridin-5-yl}-(4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,δ10 c]pyridin-5-yl}-(5-morpholin-4-yl-pyrazin-2-yl)-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-idazo[4,5c]pyridin5-yl)-[5-(4-methyl-piperidin-1-yl)-pyrazin-2-yl]-methanone;

(5-Cyclopentylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-

1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-yl}-[5-(2-morpholin-4-yl-ethylaiinino)-pyrazin-2-yl]-methanone;

{2-[6-(2-Ethyl·5-fluoro-4-hydroxy-phenyl)-1H-indazol·3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-yl}-(4-isopropyl-3,4,5,6-tetrahydro-2H-[1,2^,]bipyrazinyl·5'-yl)-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,520 c]pyridin-5-y l}-(5-pyr rolidin-1 -yl-pyrazin-2-yl)-nnethanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5]pyridin-5-yl)-[5-(ethyl-methyl-amino)-pyrazin-2-yl]-methanon:

(5-Cyclohexylamino-pyrazin-2-yl)-(2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-

1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

(5-Dimethylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-,4,6,7tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

(5-Azetidin-1-yl-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

2-Fluoro-4-{3-[5-(4-fluoro-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-6- yl)-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-5'-ylrnethyl)-4,5,6,7-tetrahydro-1Himidazo[4,5-c]pyridin-2-yl]-1H-indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2yl]-H-indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(4-methoxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(4-hydroxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]-1Hindazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(3-methoxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]-1Hindazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(3-hydroxy-benzyl)-4,5,6,7-tetrahydrO'1H-imidazo[4,5-c]pyridin-2-yl]-1Hindazol-6-yl}-5-(2,2,2-trifiuoro-ethyl)-phenol;

2-Fluoro-4-[3-(5-quinolin-6-ylmethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-[3-(5'quinolin-3-ylmethyl-4,5,6_l7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-[3-(5-[1,8]naphthyridin-3-ylmethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;

((3R,5S)-3,5-Dimethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5^,-yl)-{2-[6-(2-ethyl-5-fluoro-4hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone; {246-(2Έ^Ι-5-ίΙυοΓθ-4-1^Γθχν-ρήθΓ7ΐ)-1Η-ίΓΚ13ζοΙ-3^Ι]-1,4,6₁74θ1Γ3ΐΊνυΐΌ-ίπ^3ζο[4₎5c]pyridin-5-yl}-((S)-3-methyl-3,4,5,6-tetrahydro-2H-[1,2‘]bipyrazinyl-5'-yl)-methanone;

((2S,5R)-2_I5-Dimethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyi-5^l-yl)-{2-[6-(2-ethyl-5-fluoro-4hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-rnethanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-Îndazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5]pyridin-5-yl}-(3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)-methanone;

Most preferred is {2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-(5-piperidin-1-yl-pyrazin-2-yl)-methanone or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait.

The présent invention also provides: a method of treating a disease for which a JAK inhibltor is indicated, in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait; the use of a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, for the manufacture of a médicament for treating a disease or condition for which a JAK inhibitor is indicated; a compound of formula (I), or a pharmaceutically acceptable sait or solvaté thereof, for use as a médicament; a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable

solvaté of said compound or sait, for use in the treatment of a disease or condition for which a JAK inhibitor is indicated; a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, and a pharmaceutically acceptable excipient; a pharmaceutical composition for the treatment of a disease or condition for which a JAK inhibitor is indicated, comprising a compound of formula (I), or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait.

The disease or condition for which a JAK inhibitor is indicated is preferably an allergie or respiratory condition such as allergie rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma of ail types, chronic obstructive pulmonary disease (COPD), chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, chronic éosinophilie pneumonia, adult respiratory distress syndrome, exacerbation of airways hyperreactivity conséquent to other drug therapy, pulmonary vasulcar disease (including pulmonary arterial hypertension), acute lung injury, bronchiectasis, sinusitis, allergie conjunctîvitis, idiopathic pulmonary fibrosis or atopie dermatitis, particularly asthma or chronic obstructive pulmonary disease, most particularly chronic obstructive pulmonary disease.

Other diseases and conditions of interest are inflammation (including neuroinflammation), arthritis (including rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous arthritis, osteoarthritis and gouty arthritis), pain, fever, pulmonary sarcoisosis, silicosis, cardiovascular disease (including atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury), cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease (including Crohn’s disease and ulcerative colitis), nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabètes (including type 1 and type 2 diabètes), diabetic neurorpathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity.muscular dystrophy, polymyositis, Alzheimer's disease, skin flushing, eczema, psoriasis, atopie dermatitis and sunburn.

Types of asthma include atopie asthma, non-atopic asthma, allergie asthma, atopie bronchial

IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiologic disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, bronchitic asthma, emphysematous asthma, exerciseinduced asthma, allergen induced asthma, cold air induced asthma, occupational asthma,

infecttve asthma caused by bacterial, fungal, protozoal, or viral infection, non-allergic asthma, incipient asthma, wheezy infant syndrome and bronchiolytis.

The treatment of asthma includes palliative treatment for the symptoms and conditions of asthma such as wheezing, coughing, shortness of breath, tightness in the chest, shallow or fast breathing, nasal flaring (nostril size increases with breathing), rétractions (neck area and between or below the ribs moves inward with breathing), cyanosis (gray or bluish tint to skin, beginning around the mouth), runny or stuffy nose, and headache.

The présent invention also provides any of the uses, methods or compositions as defined above wherein the compound of formula (I), or pharmaceutically acceptable sait thereof, or pharmaceutically acceptable solvaté of said compound or sait, is used in combination with another pharmacologically active compound, particularly one of the functionally-defined classes or spécifie compounds listed below. Generally, the compounds of the combination will be administered together as a formulation in association with one or more pharmaceutically acceptable excipients.

Suitable agents for use in combination therapy with a compound of formula (I), or pharmaceutically acceptable sait thereof, or pharmaceutically acceptable solvaté of said compound or sait, particularly in the treatment of respiratory disease, include:

a 5-lipoxygenase activating protein (FLAP) antagonist;

a leukotriene antagonist (LTRA) such as an antagonist of LTB₄, LTC₄, LTD₄, LTE₄, CysLTi or CysLT₂, e.g. montelukast or zafirlukast;

a histamine receptor antagonist, such as a histamine type 1 receptor antagonist or a histamine type 2 receptor antagonist, e.g. loratidine, fexofenadine, desloratidine, levocetirizine, methapyrilene or cetirizine;

an a1-adrenoceptor agonist or an a2-adrenoceptor agonist, e.g. phenylephrine, methoxamine, oxymetazoline or methylnorephrine;

a muscarinic M3 receptor antagonist, e.g. tiotropium or ipratropium;

a dual muscarinic M3 receptor antagononist/p2 agonist;

a PDE inhibitor, such as a PDE3 inhibitor, a PDE4 inhibitor or a PDE5 inhibitor, e.g. theophylline, sildenafil, vardenafil, tadalafil, ibudilast, cilomilast or roflumilast;

sodium cromoglycate or sodium nedocromil;

a cyclooxygenase (COX) inhibitor, such as a non-selective inhibitor (e.g. aspirin or ibuprofen) or a sélective inhibitor (e.g. celecoxib or valdecoxib);

a glucocorticosteroid, e.g. fluticasone, mometasone, dexamethasone, prednisolone, budesonide, ciclesonide or beclamethasone;

an anti-inflammatory monoclonal antibody, e.g. infliximab, adalimumab, tanezumab, ranibizumab, bevacizumab or mepolizumab;

a β2 agonist, e.g. salmeterol, albuterol, salbutamol, fenoterol or formoterol, particularly a longacting β2 agonist;

an intigrin antagonist, e.g. natalizumab;

an adhesion molécule inhibitor, such as a VLA-4 antagonist;

a kinin Bi or B₂ receptor antagonist;

an immunosuppressive agent, such as an inhibitor of the IgE pathway (e.g. omalizumab) or cyclosporine;

a matrix metalloprotease (MMP) inhibitor, such as an inhibitor of MMP-9 or MMP-12;

a tachykinin NKi, NK₂ or NK₃ receptor antagonist;

a protease inhibitor, such as an inhibitor of elastase, chymase or catheopsin G;

an adenosine A_2a receptor agonist;

an adenosine A_2b receptor antagonist;

a urokinase inhibitor;

a dopamine receptor agonist (e.g. ropinirole), particularly a dopamine D2 receptor agonist (e.g. bromocriptine);

a modulator of the NFkB pathway, such as an IKK inhibitor;

a further modulator of a cytokine signalling pathway such as an inhibitor of JAK kinase, syk kinase, p38 kinase, SPHK-1 kinase, Rho kinase, EGF-R or MK-2;

a mucolytic, mucokinetic or anti-tussive agent an antibiotic;

an antiviral agent;

a vaccine;

a chemokine;

an épithélial sodium channel (ENaC) blocker or Epithelial sodium channel (ENaC) inhibitor;

a nucléotide receptor agonist, such as a P2Y2 agonist;

a thromboxane inhibitor;

niacin;

a 5-lipoxygenase (5-LO) inhibitor, e.g. Zileuton;

an adhesion factor, such as VLAM, ICAM or ELAM;

a CRTH2 receptor (DP₂) antagonist;

a prostaglandin D₂ receptor (DP,) antagonist;

a haematopoietic prostaglandin D2 synthase (HPGDS) inhibitor; interferon-β;

a soluble human TNF receptor, e.g. Etanercept;

a HDAC inhibitor;

a phosphoinositotide 3-kinase gamma (ΡΙ3Κγ) inhibitor;

a phosphoinositide 3-kinase delta (ΡΙ3Κδ) inhibitor;

a CXCR-1 or a CXCR-2 receptor antagonist;

an IRAK-4 inhibitor; and a TLR-4 or TLR-9 inhibitor;

including the pharmaceutically acceptable salts of the specifically named compounds and the 10 pharmaceutically acceptable solvatés of said specifically named compounds and salts.

Besides being useful for human treatment, compounds of formula (I) are also useful for veterinary treatment of companion animais, exotic animais and farm animais.

When used in the présent application, the following abbreviations hâve the meanings set out below:

AcOH is acetic acid;

APCI (in relation to mass spectrometry) is atmospheric pressure chemical ionization;

BOP is (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate;

Cale is calculated;

CDCI₃ is deuterochloroform;

CO₂Et is ethyl carboxylate;

DCC is N.N’-dicyclohexylcarbodîimide;

DCM is dichloromethane;

DEA is diethylamine;

DIAD is diisopropyl azodicarboxylate;

DIEA is N,N-diisopropylethylamine;

DIPEA is N,N-diisopropylethylamine;

DMA is N.N-dimethylacetamide;

DMF îs dimethylformamide;

DMSO-de is fully deuterated dimethyl sulphoxide;

EDC/EDCI is N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride;

ES (in relation to mass spectrometry) is electrospray;

Et is ethyl;

EtOAc is ethyl acetate

Ex is Example;

h is hour(s);

HATU is N,N,N’,N’-tetramethyl-0-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate;

HBTU is N.N.N'.N’-tetramethyl-O-ÎIH-benzotriazol-l-yOuronium hexafluorophosphate; HCl is hydrochloric acid;

1H NMR or ¹H NMR is proton nuclear magnetic résonance;

HOAt is 1 -hydroxy-7-azabenzotriazole;

HOBt is 1-hydroxybenzotriazole;

HPLC îs high performance liquid chromatography;

H₂SO₄ is sulphuric acid;

IPA is isopropyl alcohol;

iPr is isopropyl;

K₂CO₃ is potassium carbonate;

KMnO₄ is potassium permanganate;

KOH is potassium hydroxide;

KOAc is potassium acetate;

LCMS is liquid chromatography mass spectrometry;

LRMS is low resolution mass spectrometry;

NMM is 4-methylmorpholine;

Me is methyl;

MeCN is acetonitrile;

MeOD-d₄ is fully deuterated methanol;

MgSO₄ is magnésium sulphate;

2-MeTHF is 2-methyltetrahydrofuran;

min is mlnute(s);

MS is mass spectroscopy;

NaCI is sodium chloride;

NaH is sodium hydride;

NBS is N-bromosuccinimide;

NIS is N-iodosuccinimide;

NMP is N-methylpyrrolidine;

Obs is observed;

Pd(OAc)₂ is palladium(ll)acetate;

RT is rétention time;

SEM-CI is (2-chloromethoxy-ethyl)-trimethyl-silane;

SPhos is 2-dicyclohexylphosphinO’2’,6’-dimethoxybiphenyl;

STAB îs sodium (tri-acetoxy) borohydride;

TBTU is O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate;

TEA is triethylamine;

TFA is trifluoroacetic acid;

THF is tetrahydrofuran;

tBME is 2-mMethoxy-2-methyl-propane;

p-TsOH is para-toluene sulfonic acid.

Unless otherwise defined herein, scientific and technical terms used in connection with the présent invention hâve the meanings that are commonly understood by those of ordinary skill in the art.

The phrase “therapeutîcally effective is intended to qualify the amount of compound or pharmaceutical composition, or the combined amount of active ingrédients in the case of combination therapy. This amount or combined amount will achieve the goal of treating the relevant condition.

The term “treatment,” as used herein to describe the présent invention and unless otherwise qualified, means administration of the compound, pharmaceutical composition or combination to effect preventative, palliative, supportive, restorative or curative treatment. The term treatment encompasses any objective or subjective improvement in a subject with respect to a relevant condition or disease.

The term “préventive treatment,” as used herein to describe the présent invention, means that the compound, pharmaceutical composition or combination is administered to a subject to inhibit or stop the relevant condition from occurrîng in a subject, particularly in a subject or member of a population that is significantly predisposed to the relevant condition.

The term “palliative treatment, as used herein to describe the présent invention, means that the compound, pharmaceutical composition or combination is administered to a subject to remedy signs and/or symptoms of a condition, without necessarily modifying the progression of, or underlying etiology of, the relevant condition.

The term “supportive treatment, as used herein to describe the présent invention, means that the compound, pharmaceutical composition or combination is administered to a subject as a part of a regimen of therapy, but that such therapy is not limited to administration of the compound, pharmaceutical composition or combination. Unless otherwise expressly stated, supportive treatment may embrace préventive, palliative, restorative or curative treatment, particularly when the compounds or pharmaceutical compositions are combined with another component of supportive therapy.

The term restorative treatment, as used herein to describe the présent invention, means that the compound, pharmaceutical composition or combination is administered to a subject to modify the underlying progression or etiology of a condition. Non-limiting examples include an increase in forced expiratory volume in one second (FEV 1) for lung disorders, decreased rate of a décliné in lung function over time, inhibition of progressive nerve destruction, réduction of biomarkers associated and correlated with diseases or disorders, a réduction in relapses, improvement in qualîty of lîfe, reduced time spent in hospital during an acute exacerbation event and the like.

The term curative treatment,” as used herein to describe the présent invention, means that compound, pharmaceutical composition or combination is administered to a subject for the purpose of bringing the disease or disorder into complété remission, or that the disease or disorder is undetectable after such treatment.

The term “sélective”, when used to describe a functionally-defined receptor ligand or enzyme inhibitor means sélective for the defined receptor or enzyme subtype as compared with other receptor or enzyme subtypes in the same family. For instance, a sélective PDE5 inhibitor is a compound which inhibits the PDE5 enzyme subtype more potently than any other PDE enzyme subtype. Such selectivity is preferably at least 2 fold (as measured using conventional binding assays), more preferably at least 10 fold, most preferably at least 100 fold.

The term alkyl”, alone or in combination, means an acyclic, saturated hydrocarbon group of the formula C_nH_an+1 which may be linear or branched. Examples of such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl and hexyl. Unless otherwise specified, an alkyl group comprises from 1 to 6 carbon atoms.

The carbon atom content of alkyl and various other hydrocarbon-containing moieties is indicated by a prefix designating a lower and upper number of carbon atoms in the moiety, that is, the prefix C|-Cj indicates a moiety of the integer i to the integer “j carbon atoms, inclusive. Thus, for example, C_rC₆ alkyl refers to alkyl of one to six carbon atoms, inclusive.

The term hydroxy,” as used herein, means an OH radical.

Het³ is a saturated or partially saturated (i.e. non aromatic) heterocycle and may be attached via a ring nitrogen atom (when the heterocycle is attached to a carbon atom) or a ring carbon atom (in ail cases). Equally, when substituted, the substituent may be located on a ring nitrogen atom (if the substituent is joined through a carbon atom) or a ring carbon atom (in ail cases). Spécifie examples include oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, piperazinyl, azepanyl, oxepanyl, oxazepanyl and diazepinyl.

Het³ may be fully saturated or partially unsaturated, i.e. may hâve one or more degrees of unsaturation but may not be fully aromatic.

Het¹ is an aromatic heterocycle and may be attached via a ring carbon atom (in ail cases) or a ring nitrogen atom with an appropriate valency (when the heterocycle is attached to a carbon atom). Equally, when substituted, the substituent may be located on a ring carbon atom (in ail cases) or a ring nitrogen atom with an appropriate valency (if the substituent is joined through a carbon atom). Spécifie examples include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl.

Het^z is an aromatic heterocycle and may be attached via a ring carbon atom (in ail cases) or a ring nitrogen atom with an appropriate valency (when the heterocycle is attached to a carbon atom). Equally, when substituted, the substituent may be located on a ring carbon atom (in ail cases) or a ring nitrogen atom with an appropriate valency (if the substituent is joined through a carbon atom). Het² is aromatic and is therefore necessarîly a fused bicycle. Spécifie examples include imidazo[2,1-b][1,3]thiazolyl, benzofuranyl, benzothienyl, indolyl, benzimidazolyl, indazolyl, benzotriazolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[2,3-c]pyridyl, pyrrolo[3,2-c]pyridyl, pyrrolo[3,2-b]pyrîdyl, imidazo[4,5-b]pyrtdyl, imidazo[4,5-c]pyridyl, pyrazolo[4,3-d]pyridyl, pyrazolo[4,3-c]pyridyl, pyrazolofS^-cjpyridyl, pyrazolo[3,4-b]pyridyl, isoindolyl, indazolyl, purînyl, indolizinyl, imidazo[1,2-a]pyridyl, imidazotl.S-ajpyridyl, pyrazolo[1,5-a]pyridyl, pyrrolo[1,2bjpyridazinyl, imidazotl^-clpyrimidinyl, quinolinyl, isoquinolinyl, cinnolinyl, quînazolinyl, quînoxalinyl, phthalazinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, 1,5naphthyridinyl, 2,6-naphthyridinyl, 2,7-naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3djpyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrazino[2,3-b]pyrazinyl and pyrimido[4,5' djpyrimidine.

The term cycloalkyl means a means a monocyclic, saturated hydrocarbon group of the formula

CnHin-i· Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

Unless otherwise specified, a cycloalkyl group comprises from 3 to 8 carbon atoms.

The term oxo means a doubly bonded oxygen.

The term alkoxy” means a radical comprising an alkyl radical that is bonded to an oxygen atom, such as a methoxy radical. Examples of such radicals include methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy.

The term “halo means, fluoro, chloro, bromo or rodo.

As used herein, the terms “co-administration, “co-administered and “in combination with, referring to a combination of a compound of formula (I) and one or more other therapeutic agents, includes the following:

• simultaneous administration of such a combination of a compound of formula (I) and a further therapeutic agent to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components at substantially the same time to said patient, • substantially simultaneous administration of such a combination of a compound of formula(l) and a further therapeutic agent to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at substantially the same time by said patient, whereupon said components are released at substantially the same time to said patient, • sequential administration of such a combination of a compound of formula (I) and a further therapeutic agent to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at consecutive fîmes by said patient with a significant time interval between each administration, whereupon said components are released at substantially different times to said patient; and • sequential administration of such a combination of a compound of formula (I) and a further therapeutic agent to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components in a controlled manner.

The term 'excipient' is used herein to describe any ingrédient other than a compound of formula (I). The choice of excipient will to a large extent dépend on factors such as the particular mode of administration, the effect of the excipient on solubility and stabiiity, and the nature of the dosage form. The term excipient encompasses diluent, carrier or adjuvant.

One way of carrying out the invention is to administer a compound of formula (I) in the form of a prodrug. Thus, certain dérivatives of a compound of formula (I) which may hâve little or no pharmacological activity themselves can, when administered into or onto the body, be converted into a compound of formula (I) having the desired activity, for example by hydrolytic cleavage, particularly hydrolytic cleavage promoted by an esterase or peptidase enzyme. Such dérivatives are referred to as ‘prodrugs¹. Further information on the use of prodrugs may be found in ‘Prodrugs as Novel Delivery Systems’, Vol. 14, ACS Symposium Sériés (T. Higuchi and W. Stella) and ‘Bioreversible Carriers in Drug Design’, Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical Association). Reference can also be made to Nature Reviews/Drug Discovery, 2008, 7, 355 and Current Opinion in Drug Discovery and Development, 2007,10, 550.

Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities présent in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties’ as described, for example, in ‘Design of Prodrugs' by H. Bundgaard (Elsevier, 1985).

Thus, a prodrug in accordance with the invention is (a) an ester or amide derîvatlve of a carboxylic acid in a compound of formula (I); (b) an ester, carbonate, carbamate, phosphate or ether dérivative of a hydroxyl group in a compound of formula (I); (c) an amide, imine, carbamate or amine dérivative of an amino group in a compound form formula (I); (d) a thioester, thiocarbonate, thiocarbamate or sulphide dérivatives of a thiol group in a compound of formula (I); or (e) an oxime or imine dérivative of a carbonyl group in a compound of formula (I).

Some spécifie examples of prodrugs in accordance with the invention include:

(i) where the compound of formula (I) contains a carboxylic acid functionality (-COOH), an ester thereof, such as a compound wherein the hydrogen of the carboxylic acid functionality of the compound of formula (I) is replaced by Ci-C_a alkyl (e.g. ethyl) or (Ci-C₈alkyl)C(=O)OCH₂- (e.g. ’BuC(=O)OCH_r);

(ii) where the compound of formula (I) contains an alcohol functionality (-OH), an ester thereof, such as a compound wherein the hydrogen of the alcohol functionality of the compound of formula (I) is replaced by -CO(CrC₀ alkyl) (e.g. methylcarbonyl) or the alcohol is esterified with an amino acid;

(iii) where the compound of formula (I) contains an alcohol functionality (-OH), an ether thereof, such as a compound wherein the hydrogen of the alcohol functionality of the compound of formula (I) is replaced by (CrC₀ alkyl)C(=O)OCH₂- or -CH₂OP(=O)(OH)₂;

(iv) where the compound of formula (I) contains an alcohol functionality (-OH), a phosphate thereof, such as a compound wherein the hydrogen of the alcohol functionality of the compound of formula (I) is replaced by -P(=O)(OH)₂ or -P(=O)(ONa)₂ or -P(=O)(O)₂Ca²⁺;

(v) where the compound of formula (I) contains a primary or secondary amino functionality 10 (-NH₂or -NHR where R * H), an amide thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the compound of formula (I) is/are replaced by (Cj-Cjoïalkanoyl, -COCH₂NH₂ or the amino group is derivatised with an amino acid;

(vi) where the compound of formula (I) contains a primary or secondary amino functionality (-NH₂ or -NHR where R # H), an amine thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the compound of formula (I) is/are replaced by -CH₂OP(=O)(OH)₂.

Certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula 20 (I). It is also possible for two compounds of formula (I) to be joined together in the form of a prodrug. In certain circumstances, a prodrug of a compound of formula (I) may be created by internally linking two functional groups in a compound of formula (I), for instance by forming a lactone.

References below to compounds of formula (I) are taken to include the compounds themselves and prodrugs thereof. The invention includes such compounds of formula (I) as well as pharmaceutically acceptable salts of such compounds and pharmaceutically acceptable solvatés of said compounds and salts.

Pharmaceutically acceptable salts of the compounds of formula (I) include acid addition and base salts.

Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, 35 borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotînate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stéarate, succinate, tannate, tartrate, tosylate, trifluoroacetate, naphatlene-1,5disulfonic acid and xinofoate salts.

Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnésium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.

Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Sélection, and Use by Stahî and Wermuth (Wîley-VCH, 2002).

Pharmaceutically acceptable salts of compounds of formula (I) may be prepared by one or more of three methods:

(i) by reacting the compound of formula (I) with the desired acid or base;

(ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula (I) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or (iii) by converting one sait of the compound of formula (I) to another by réaction with an appropriate acid or base or by means of a suitable ion exchange column.

Ail three reactions are typically carried out in solution. The resulting sait may precipitate out and be collected by filtration or may be recovered by évaporation of the solvent. The degree of ionisation in the resulting sait may vary from completely ionised to almost non-ionised.

The compounds of formula (I), and pharmaceutically acceptable salts thereof, may exîst in unsolvated and solvated forms. The term 'solvaté’ is used herein to describe a molecular complex comprising the compound of formula (I), or a pharmaceutically acceptable sait thereof, and one or more pharmaceutically acceptable solvent molécules, for example, éthanol. The term ‘hydrate’ may be employed when said solvent is water.

A currently accepted classification System for organic hydrates is one that defines isolated site, channel, or metal-ion coordinated hydrates - see Polvmorphism in Pharmaceutical Solids by K.

R. Morris (Ed. H. G. Brittain, Marcel Dekker, 1995). Isolated site hydrates are ones in which the water molécules are isolated from direct contact with each other by intervening organic

molécules. In channel hydrates, the water molécules lie in lattice channels where they are next to other water molécules. In metal-ion coordinated hydrates, the water molécules are bonded to the métal ion.

When the solvent or water is tightly bound, the complex will hâve a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvatés and hygroscopic compounds, the water/solvent content will be dépendent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.

Also included within the scope of the invention are multi-component complexes (other than salts and solvatés) wherein the drug and at least one other component are présent in stoichiometric or non-stoichiometric amounts. Complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals. The latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could 15 also be a complex of a neutral molécule with a sait. Co-crystals may be prepared by melt crystallisation, by recrystallisation from solvents, or by physically grinding the components together - see Chem Commun, 17, 1889-1896, by O. Almarsson and M. J. Zaworotko (2004). For a general review of multi-component complexes, see J Pharm Sci, 64 (8), 1269-1288, by Haleblian (August 1975).

The compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline. The term 'amorphous’ refers to a state in which the material lacks long range order at the molecular level and, depending upon température, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray 25 diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid. Upon heating, a change from solid to liquid properties occurs which is characterised by a change of state, typically second order (‘glass transition’). The term ‘crystalline’ refers to a solid phase in which the material has a regular ordered internai structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated 30 sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order ('melting point’).

The compounds of formula (I) may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions. The mesomorphic state is intermediate between 35 the true crystalline state and the true liquid state (either melt or solution). Mesomorphism arising as the resuit of a change in température is described as ‘thermotropic’ and that resulting from the addition of a second component, such as water or another solvent, is described as ‘lyotropic’. Compounds that hâve the potential to form iyotropic mesophases are described as ‘amphiphilic’ and consist of molécules which possess an ionic (such as -COO Na , -COO K⁺, or SO3Na⁺) or non-ionic (such as -NN⁺(CH3)₃) polar head group. For more information, see Crvstals and the Polarizino Microscope by N. H. Hartshorne and A. Stuart, 4^,h Edition (Edward Arnold, 1970).

Hereinafter ail references to compounds of formula (!) include references to pharmaceutically acceptable salts, solvatés, multi-component complexes and liquid crystals thereof and to solvatés, multi-component complexes and liquid crystals of pharmaceutically acceptable salts thereof.

The compounds of formula (I) may exhibit polymorphism and/or one or more kînds of isomerism (e.g. optical, géométrie or tautomeric isomerism). The compounds of formula (I) may also be isotopically labelled. Such variation is implicit to the compounds of formula (I) defined as they are by reference to their structural features and therefore within the scope of the invention.

Compounds of formula (I) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound of formula (I) contains an alkenyl or alkenylene group, géométrie cis/trans (or Z/E) isomers are possible. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism ('tautomerism’) can occur. This can take the form of proton tautomerism in compounds of formula (I) containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.

The pharmaceutically acceptable salts of compounds of formula (I) may also contain a counterion which is optically active (e.g. d-lactate or l-lysine) or racemic (e.g. dl-tartrate or dlarginine).

Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.

Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a sait or dérivative) using, for example, chiral high pressure liquid chromatography (HPLC).

Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid.

The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person. Chiral compounds of formula (I) (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typicaliy HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typicaliy heptane or hexane, containing from 0 to 50% by volume of isopropanol, typicaliy from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typicaliy 0.1% diethylamine. Concentration of the eluate affords the enriched mixture. Chiral chromatography using sub-and supercritical fluids may be employed. Methods for chiral chromatography useful in some embodiments of the présent invention are known in the art (see, for example, Smith, Roger M., Loughborough University, Loughborough, UK; Chromatographie Science Sériés (1998), 75 (Supercritical Fluid Chromatography with Packed Columns), pp. 223-249 and references cited therein). In some relevant examples herein, columns were obtained from Chiral Technologies, Inc, West Chester, Pennsylvania, USA, a subsidiary of Daicel® Chemical Industries, Ltd., Tokyo, Japan.

When any racemate crystallises, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer. While both of the crystal forms présent in a racemic mixture hâve identical physical properties, they may hâve different physical properties compared to the true racemate. Racemic mixtures may be separated by conventional techniques known to those skilled in the art - see, for example, Stereochemistrv of Organic Compounds by E. L. Eliel and

S. H. Wilen (Wiley, 1994).

The présent invention includes ail pharmaceutically acceptable isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which prédominâtes in nature. Isotopically-labelled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Préparations using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed. In particular, hydrogen atoms may be replaced by deuterium atoms since such deuterated compounds are sometimes more résistant to metabolism.

Also included within the scope of the invention are active métabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug, often by oxidatation or dealkylation. Some examples of métabolites in accordance with the invention include (i) where the compound of formula (I) contains a methyl group, an hydroxymethyl dérivative thereof (-CH₃ -> -CH₂OH):

(il) where the compound of formula (I) contains an alkoxy group, an hydroxy dérivative thereof (-OR -> -OH);

(iii) where the compound of formula (I) contains a tertiary amino group, a secondary amino dérivative thereof (-NRR’ -> -NHR or -NHR);

(iv) where the compound of formula (I) contains a secondary amino group, a primary dérivative thereof (-NHR -> -NH₂);

(v) where the compound of formula (I) contains a phenyl moiety, a phénol dérivative thereof (-Ph -> -PhOH); and (vi) where the compound of formula (I) contains an amide group, a carboxyltc acid dérivative thereof (-CONH₂ -> COOH).

For administration to human patients, the total daily dose of a compound of formula (I) is typically in the range of 0.01 mg to 500mg depending, of course, on the mode of administration. In another embodiment of the présent invention, the total daily dose of a compound of formula (I) is typically in the range of 0.1 mg to 300mg. In yet another embodiment of the présent invention, the total daily dose of a compound of formula (I) is typically in the range of 1mg to 30mg. The total daily dose may be administered in single or divided doses and may, at the physician’s discrétion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 65kg to 70kg. The physician will readily be able to détermine doses for subjects whose weight faJIs outside this range, such as infants and the elderly.

In the case of dry powder inhalers and aérosols, the dosage unit is determined by means of a prefilled capsule, blister or pocket or by a System that utilises a gravimetrically fed dosing chamber. Units in accordance with the invention are typically arranged to administer a metered dose or puff containing from 1 to 5000 gg of drug. The overall daily dose will typically be in the range 1pg to 20mg which may be administered in a single dose or, more usually, as divided doses throughout the day.

A compound of formula (I) can be administered per se, or in the form of a pharmaceutical composition, which, as active constituent contains an efficacious dose of at least one compound of the invention, in addition to customary pharmaceutically innocuous excipients and/or additives.

Pharmaceutical compositions suitable for the delivery of compounds of the présent invention and methods for their préparation will be readily apparent to those skilled in the art. Such compositions and methods for their préparation may be found, for example, in Remington's Pharmaceutical Sciences. 19th Edition (Mack Publishing Company, 1995).

Compounds of formula (I) may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth. Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays and liquid formulations.

Liquid formulations include suspensions, solutions, syrups and élixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, éthanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.

Compounds of formula (I) may also be used in fast-dissolving, fast-disintegratîng dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986, by Liang and Chen (2001).

For tablet dosage forms, depending on dose, the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form.

In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised

starch and sodium alginate. Generally, the disintegrant will comprise from 1 weight % to 25 weight %. In one embodiment of the présent invention, the disintegrant will comprise from 5 weight % to 20 weight % of the dosage form. Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate. Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When présent, surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet. Tablets also generally contain lubricants such as magnésium stéarate, calcium stéarate, zinc stéarate, sodium stearyl fumarate, and mixtures of magnésium stéarate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 weight % to 10 weight %. In one embodiment of the présent invention, lubricants comprise from 0.5 weight % to 3 weight % of the tablet. Other possible ingrédients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.

Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.

Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may altematively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated. Formulations of tablets are discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).

Consumable oral films for human or veterinary use are typically pliable water-soluble or waterswellable thin film dosage forms which may be rapidly dissolving or mucoadhesive and typically comprise a compound of formula (I), a film-forming polymer, a binder, a solvent, a humectant, a plasticiser, a stabiliser or emulsifier, a viscosity-modifying agent and a solvent. Some components of the formulation may perform more than one function. The film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically présent in the range 0.01 to 99 weight %, more typically in the range 30 to 80 weight %. Other possible ingrédients include anti-oxidants, colorants, flavourings and flavour enhancers,

preservatives, salivary stimulating agents, cooling agents, co-solvents (including oils), émollients, bulking agents, anti-foaming agents, surfactants and taste-masking agents. Films in accordance with the invention are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper. This may be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuuming.

Solid formulations for oral administration may be formulated to be immédiate and/or modified release. Modified release includes delayed, sustained, pulsed, controlled, targeted and programmed release. Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Pharmaceutical Technology On-line, 25(2), 1-14, by Verma et al (2001). The use of chewing gum to achieve controlled release is described in WO-A-OO/35298.

Compounds of formula (I) may also be administered directly into the blood stream, into muscle, or into an internai organ. Such parentéral administration includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous administration. Suitable devices for parentéral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.

Compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.

The compounds of formula (I) can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aérosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, or as nasal drops. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin. Delivery by inhalation is the preferred route of administration for the compounds of the présent invention.

The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound of formula (I) comprising, for example, éthanol, aqueous éthanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the compound, a propellant as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogénisation, or spray drying.

Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnésium stéarate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.

A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 pg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1pl to 100pl. A typical formulation may comprise a compound of formula (I), propylene glycol, stérile water, éthanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.

Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for intranasal administration. Formulations for intranasal administration may be formulated to be immédiate and/or modified release using, for example, PGLA. Modified release includes delayed, sustained, pulsed, controlled, targeted and programmed release.

Compounds of formula (I) may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonie, pH-adjusted, stérile saline.

Compounds of formula (I) may be combined with soluble macromolecular entities, such as cyclodextrin and suitable dérivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste, bioavailability and/or stability when using any of the aforementioned modes of administration. Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or

solubiliser. Most commonly used for these purposes are alpha-, beta- and gammacyclodextrins, examples of which may be found in international patent publications WO-A91/11172, WO-A-94/02518 and WO-A-98/55148.

Inasmuch as it may désirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the présent invention that two or more pharmaceutical compositions, at least one of which contains a compound of formula (I), may conveniently be combined in the form of a kit suitable for coadministration of the compositions. Thus, a kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I), and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like. Such a kit is particularly suitable for administering different dosage forms, for example, oral and parentéral, for administering separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.

Ail the compounds of formula (I) can be made by the spécifie and general experimental procedures described below in combination with the common general knowledge of one skilled in the art (see, for example, Comprehensive Organic Chemistry, Ed. Barton and Ollis, Elsevier; Comprehensive Organic Transformations: A Guide to Functional Group Préparations, Larock, John Wiley and Sons). In the general methods that follow, R¹, R^s, R³, X and n hâve the meanings given in embodiment E1 described above unless otherwise stated.

Compounds of formula (I) can be made by reacting a compound of formula:

r³-x-lg’ (HO in which LG¹ is a suitable leaving group such as a halogen atom. The reaction will typically be carried out in a suitable inert solvent in the presence of a base such as diisopropylethylamine.

When X is -SO2-, for example, a sulphonyl chloride (LG¹=CI) may be used. In a typical procedure, a solution of the compound of formula (II) in DMF is treated with one équivalent of the sulphonyl chloride and 1 équivalent of diisopropylethylamine and stirred at room température. When X is -CH2-, an alkyl bromide (LG¹=Br) may be used. In a typical procedure, a solution of the compound of formula (II) in DMF is treated with 1.1 équivalents of the alkyl bromide and 1.1 équivalents of diisopropylethylamine and stirred at 50°C. When X is -CO-, an acid chloride (LG'=CI) may be used. In a typical procedure, a solution of the compound of formula (II) in DMF is treated with 1.1 équivalents of the acid chloride and 1.1 équivalents of diisopropylethylamine and stirred at room température.

Where X is a carbonyl group, the leaving group LG¹ may be created in situ from the corresponding carboxylic acid of formula

R³-CO₂H (IV) by using a condensation reagent such as HATU. In a typical procedure, a solution of the 20 compound of formula (il) in DMF is treated with 1.1 équivalents of HATU and 1.1 équivalents of diisopropylethylamine and stirred at room température for 30 minutes. An équivalent of the acid of formula (IV) is then added. For a general review on amide bond formation, see Chem. Soc. Rev., 2009, 38(2), 606-631

Where X is -CH₂-, an aldéhyde of formula:

R³-CHO (V) may alternatively be condensed with a compound of formula (II) under reducing conditions in order to provide the desired compound of formula (I). In a typical procedure, a solution of the 30 compound of formula (II) in DMF is treated with the 1.5 équivalents of the aldéhyde of formula (V), 2 équivalents of diisopropylethylamine and 1.5 équivalents of acetic acid and stirred at room température for one hour. Sodium triacetoxyborohydride (1.5 équivalents) is then added and stirring continued at room température.

Compounds of formula (II) can be assembled by successive aryl-heteroaryl and heteroarylheteroaryl organometallic coupling reactions. One example of of a possible reaction sequence is shown In Scheme 1 (PG = protecting group, LG = leaving group, M = métal species; where

multiple protecting groups are shown, they may be the same or different). Free NH groups will generally need to be protected during these reactions. Suitable protecting groups, their introduction and their removal are ail part of the common general knowledge of the skilled person - see, for instance, ‘Protective Groups in Organic Chemistry' by Wuts and Greene 5 (Wiley-Blackwell).

Suitable reaction conditions for the various steps necessary to préparé and react together the compounds in Scheme 1 may be found in the spécifie Préparations listed below. For a general review on organometallic cross-couping chemistry, see ‘Handbook of Organopalladium 10 Chemistry for Organic Synthesis’ (Volume 1) editied by Ei-ichi Negishi (John Wiley & Sons).

Scheme 1

(VIII)

Compounds of formula (I) can also be prepared by treating a compound of formula:

!

with an acid (e.g. concentrated hydrochloric acid). PG' is an acid-labile protecting group and 5 C=Y is a carbonyl group or an acid-labile, protected form of a carbonyl group (e.g. a ketal). The reaction will usually be performed in a suitable inert solvent with heating.

Compounds of formula (X) can be made from precursors of formula:

R³ /

Compounds of formula (XI) can be assembled using the aryl-heteroaryl bond forming reactions discussed above.

The skilled person will appreciate that many compounds of formula (I) may be interconverted by functional group manipulation.

The starting materials necessary for carrying out the methods described above are in many cases commercially available and may otherwise be described in the literature or in the Préparations below or may be made using analgous procedures to those described in the liternature or in the Préparations below.

Supplementing the general methods presented above, the following experimental details illustrate specifically how certain compounds of formula (I) may be prepared. Ail Examples are compounds of formula (I). Préparations are intermediates useful in the synthesis of compounds of formula (I).

The following HPLC methods hâve been used in the characterization of the Examples below:

Method A

HPLC conditions	Analytical (QC)	Préparative
Column	Gemini-NX 3pm C18 110A	Gemini-NX 5pmC18 21.2 x 100mm
Température	Ambient	Ambient
Détection	UV 225nm - ELSD - MS	UV 225nm - ELSD - MS
Injection volume	5pL	1000pL
Flow rate	1.5mL/min	18 mL/min
Mobile phase	A: H2O + 0.1% ammonium acetate B: MeCN + 0.1% ammonium acetate	A: H2O + 0.1%DEA B: MeCN + 0.1% DEA
Gradient	Time (min)	%B	Time (min)	%B
	0	5	0-1.0	5
	0-3.0	5-95	1.0-7.0	5-98
	3.0-4.0	95	7.0-9.0	98

	4.0-4.1	95-5	9.0-9.10	98-5
	4.1-5.0	5	9.10-10	5

Method B

HPLC conditions	Analytical (QC)	Préparative
Column	Gemini-NX3pm C18 110A	Gemini-NX 5pm C18 21.1x100mm
Température	Ambient	Ambient
Détection	UV 225nm - ELSD - MS	UV 225nm - ELSD - MS
Injection volume	5pL	1000pL
Flow rate	1.5mL/min	18 mL/min
Mobile phase	A: H2O + 0.1% formic B: MeCN + 0.1% formic acid	A: H2O + 0.1% formic B: MeCN + 0.1% formic acid
Gradient	Time (min)	%B	Time (min)	%B
	0	5	initial	20
	0-3.0	5-95	1	20
	3.0-4.0	95	5.4	70
	4.0-4.1	95-5	6.33	98
	4.1-5.0	5	6.4	20
			7	20

Method C

HPLC conditions	Préparative
Column	Phenomenex Luna C18 5pm-100Â 21.2 x 150mm
Température	Ambient

Détection	UV 254nm MS	- ELSD -
Injection volume	1OOOpL
Flow rate	18 mL/min
Mobile phase	A: H2O + 0.05% formic acid
B: MeCN formic acid	+ 0.05%
Gradient	Time (min)	%B
	0-2.5	5
	2.5-17.5	5-95
	17.5-22.5	95
	22.5-22.6	95-5
	22.6-23.0	5

Method D

HPLC conditions	Préparative
Column	Zorbax SB C18 5pm100Â 21.2 x 150mm
Température	Ambient
Détection	UV 254nm - ELSD - MS
Injection volume	1000pL
Flow rate	20 mL/min
Mobile phase	A: H2O + 0.05% NH4OAC B: MeCN + 0.05% NH4OAc
Gradient	Time (min)	%B
	0-2.5	5
	2.5-17.5	5-95
	17.5-22.5	95
	22.5-22.6	95-5

22.6-23.0 5

Method E

HPLC conditions	Préparative
Column	Luna Phenyl-Hexyl 5pm-100Â 21.2 x 150mm
Température	Ambient
Détection	UV 254nm - ELSD - MS
Injection volume	1000μΙ_
Flow rate	20 ml_/min
Mobile phase	A: H2O + 0.05% NH4OAC B: MeCN + 0.05% NH4OAC
Gradient	Time (min)	%B
	0-2.5	5
	2.5-17.5	5-95
	17.5-22.5	95
	22.5-22.6	95-5
	22.6-23.0	5

Method F

HPLC conditions	Préparative
Column	Xterra RP18 19-250mm
Température	Ambient
Détection	UV 254nm - ELSD - MS
Injection volume	1000pL
Flow rate	16 mL/min

Mobile phase	A: H2O + 0.05% NH4OAC B: MeCN + 0.05% NH4OAC
Gradient	Time (min)	%B
	0-2.5	5
	2.5-17.5	5-95
	17.5-22.5	95
	22.5-22.6	95-5
	22.6-25.0	5

Method G

HPLC conditions	Préparative
Column	Sunfire C18 30x100mm 5u
Température	Ambient
Détection	UV 254nm - ELSD - MS
Injection volume	1000pL
Flow rate	16 mL/min
Mobile phase	A: H2O + 0.05% NH4OAc B: MeCN + 0.05% NH4OAc
Gradient	Time (min)	%B
	0-2.5	5
	2.5-17.5	5-95
	17.5-22.5	95
	22.5-22.6	95-5
	22.6-25.0	5

Example 1 (2-r6-(2-EÎhvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vll-1.4,6.7-tetrahvdro-imidazo [4.5-clpvridin-5-vl)-(4-fluoro-Dhenvl)-methanone 'K

To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yi)-1Hrndazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 80pmol) in DMF (1mL), was added HATU (32mg, 84pmol), and DIPEA (56pL, 320pmol). The reaction mixture was stirred at room température for 30 minutes. 4-Fluoro-benzotc acid (11.2mg, 80pmol) was added to the reaction mixture and stirring was continued for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5mL) was added to the reaction mixture. The resulting solid was collected by filtration, washing with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method B to afford 7.7mg of the title compound.

LCMS (Method A): RT 2.52 min (100% area), ES m/z 500.182 [M+H]⁺.

Example 2 {2-[6-(2-Ε11τνΙ-5-(ΙυοΓθ-4-Ι·ΊνϋΓθχν-ρΐΊβηνΙ)-1Η-ΐηά3ΖθΙ-3-νΙ1-1.4.6,7-ΐθΐΓ3ΐΊνάΓθ-ΪΠΊΐΰ3ζο l4,5-clDvrÎdin-5-vl)-isothiazol-3-vl-methanone

The title compound was prepared from 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 80pmol) and isothiazole-3-carboxylic acid (11mg, 80pmol) using the same method as described in Example

1. The crude material was purified by HPLC Method A to afford 7.7mg of the title compound. LCMS (Method A) RT 2.39 min (100% area), ES m/z 489.143 [M+H]⁺.

Example 3 (2-[6-(2-Et|-ivl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vll-1,4.6,7-tetrahvdro-imidazo r4,5-clDvridin-5-vl}-isothiazol-3-vl-methanone

To a solution of N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1(tetrahydro-pyran-2-yl)-1H-indazole-3-carboxamidine (Préparation 9, 6.06g, 9.41 mmol) in éthanol (34mL) was added concentrated hydrochloric acid (12M, 15.8mL, 189mmol). The reaction mixture was heated at 65°C for 18 hours. The reaction mixture was concentrated in vacuo and recharged with fresh éthanol (34mL) and concentrated hydrochloric acid (12M, 15.8mL, 189mmol). The reaction mixture was heated at 65°C for a further 4 hours. Water (20mL) was added to the reaction mixture at 65°C and then the reaction was allowed to cool slowly to room température. The solvents were removed in vacuo and the residue was partitioned between 2-MeTHF (200mL) and saturated sodium hydrogen carbonate aqueous solution (100mL). The organic layer was washed with further saturated sodium hydrogen carbonate aqueous solution (100mL). The combined aqueous layers were re-extracted with 2MeTHF (250mL). The combined organic layers were dried over MgSO< and concentrated in vacuo to yield a brown foam. The crude material was dissolved in MeCN (150mL) and éthanol (30mL) and heated at 50°C for 2 days. The product crystallised from this solution and was collected by filtration and dried in vacuo to give the title compound as a crystalline white solid (3.53g) in an 80% yield.

¹H NMR (400 MHz, CD₃OD) δ ppm 1.04 (t, 3H), 2.52 (q, 2H), 2.81 (t, 2H), 2.91 (t, 2H), 3.62 (s, 2H), 3.80 (s, 2H), 6.87 (d, 1H), 6.92 (d, 1 H), 7.11 (d, 1H), 7.26-7.43 (m, 6H), 8.22 (d, 1H). LCMS: m/z 468 [M+H]⁺, 466 [M-H]'.

Example 4 {2-[6-(2-Ethvl-5-fluoro-4-hvdroxy-Dhenvl)-1H-indazol-3-vl1-1,4,6.7-tetrahvdro-imidazo r4.5-clDvridin-5-vl)-(5-Diperidin-1-vl-Dvrazin-2-vl)-methanone

To a solution of 5-piperidin-1-yl-pyrazine-2-carboxylic acid (Préparation 43, 10.7g, 51.8mmol) in DMF (200mL) was added DIPEA (24.6mL, 141 mmol) and HATU (21.5g, 56.5mmol) and the resulting mixture was stirred at room température for 10 minutes before being added dropwise to a suspension of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-phenol dihydrochloric acid sait (Préparation 11, 19.5g, 47.1 mmol) in DMF (200mL) over 30 minutes, using a further 75mL DMF to wash the vessel. The reaction mixture was then stirred at room température for 18 hours. A further portion of 5-piperidin-1-yl-pyrazine-2carboxylic acid (1.07g, 5.18mmol) in DMF (40mL) was treated with DIPEA (2.46mL, 14.1mmol) and activated with HATU (2.15g, 5.65mmol) and the resulting mixture was stirred at room température for 10 minutes before being added to the original reaction mixture which was then stirred for a further 4 hours at room température. The reaction mixture was poured onto water (1.2L) and the pH was adjusted to 7 with sodium hydroxide solution. The resulting suspension was stirred at room température for 30 minutes. The precipitate was collected by filtration, washed with water (400mL) and then dried under vacuum. The crude material was dissolved in éthanol (113mL) and treated with a 1M aqueous solution of sodium hydroxide. The reaction mixture was stirred at room température for 18 hours. The precipitate was collected by filtration, washed with a cold solution of 1:3 1M sodium hydroxide:ethanol (100mL) and dried under vacuum to give the sodium sait of the title compound, 16.14g. This material was dissolved in water (100mL) and treated with a 10% aqueous solution of citric acid (10mL) to adjust the pH to

4. A few drops of 1M sodium hydroxide solution were added to bring the pH to 7. The resulting suspension was stirred at room température for 1 hour and the solid was collected by filtration, washed with water and then dried under vacuum to give the title compound as a white solid (13.864g) in an 89% yield.

’H NMR (400 MHz, DMSO-d6) δ ppm 0.94 (t, 3H), 1.54-1.60 (m, 2H), 1.60-1.67 (m, 2H), 2.38 (q, 2H), 2.71-2.83 (m, 2H), 3.64-3.71 (m, 4H), 3.85-3.98 (m, 4H), 4.63-4.78 (m, 2H), 6.66 (d,

1H), 6.73 (d, 1H), 7.00-7.08 (m, 1H), 7.16-7.24 (m, 1H), 816-8.25 (m, 1H), 8.29 (s, 1H), 8.37 (s,

1H).

LCMS: m/z 567 [M+H1⁺, 565 [Μ-ΗΓ

Example 5 f2-f6-(2-Ethvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vl1-1.4.6.7-tetrahydro-imidazo [4,5-clDvrÎdin-5-vl]-(6-phenoxv-pyridin-3-vl)-methanone

The title compound was prepared from 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 80pmol) and 6-phenoxy-nicotinic acid (17mg, 80pmol) using the method of Example 1. The crude material was purified by HPLC Method A to afford 3.1 mg of the title compound.

LCMS (Method A): RT 2.67 min (100% area), ES m/z 575.213 [M+H]⁺.

Example 6

5-Ethvl-2-fluoro-4-i3-[5-(6-morpholin-4-vl-pvridine-3-sulfonvl)-4.5.6,7-tetrahvdro-1H-imidazof4,5c1pvridin-2-vl1-1H-indazol-6-vll·phenol

To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, δΟμιτιοΙ) in DMF (1mL), was added 6-morpholin-4-yl-pyridine-3-sulfonyl chloride (21 mg, 80pmol) and DI PEA (56pL, 320pmol). The reaction mixture was stirred at room température for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5mL) was added and the resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method A to afford 18.7mg of the title compound.

LCMS (Method A): RT 2.58 min (100% area), ES m/z 602.206 [M-H]'.

Example 7

5- EÎhvl-2-fluoro-4-{3-r5-(6-Phenoxv-ovridine-3-sulfonvl)-4.5.6.7-tetrahvdro-1H-imidazo [4,5-clpvridin-2-vH-1H-indazol-6-vl)-phenol

The title compound was prepared from 5-ethyl-2-fluoro-4-[3-(4,5,6,7-Îetrahydro-1 H-imidazopLSc]pyridin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 80pmol) and

6- phenoxy-pyridine-3-sulfonyl chloride (22mg, δΟμιτιοΙ) using the method of Example 6. The crude material was purified by HPLC Method A to afford 8.4mg of the title compound.

LCMS (Method A): RT 2.82 min (100% area),ES m/z 611.18 [M+H]⁺.

Example 8 (5-Chloro-pvridin-2-vlM2-[6-(2-ethvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-yll-4,5,7,8tetrabydro-IH-imidazo^.S-dlazepin-e-vIl-methanone

To a solution of 5-chloro-pyridine-2-carboxylic acid (13.2mg, 85pmol) in DMF (1mL) was added HATU (32mg, 85pmol) and the resulting reaction mixture was stirred at room température for 30

minutes. 5-Ethyl-2-fluoro-4-[3-( 1,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1H-indazol-6yl]-phenol trihydrobromide sait (Préparation 32, 50mg, 80pmol) and DI ΡΕΑ (56μΙ_, 320pmol) were added and stirring was continued at room température for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5mL) was added to the reaction mixture. The resulting 5 solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method A to afford 20.5mg of the title compound.

LCMS (Method A): RT 2.76 min (100% area), ES m/z 531.163 [M-H]'.

Example 9

2-f2-r6-(2-Ethvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vll-4.5.7.8-tetrahvdro-1H-imidazo[4,5dlazeDine-6-carbonvl)-isonicotinonitrile

The title compound was prepared from 4-cyano-pyridine-2-carboxylic acid (12.5mg, 85pmol) and 5-ethyl-2-fluoro-4'[3'(1,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1H-indazol-6-yl]15 phénol trihydrobromide sait (Préparation 32, 50mg, 80pmol) using the method of Example 8.

The crude material was purified by HPLC Method B to afford 6.5mg of the title compound. LCMS (Method A): RT 2.66 min (100% area), ES m/z 522.198 [M+H]⁺.

Example 10 {2-r6-(2-Ethvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vll-4,5,7,8-tetrahvdro-1H-imidazo r4,5-dlazeDin-6-vl}-(4-fluoro-Dhenvl)-methanone

The title compound was prepared from 4-fluoro-benzoic acid (12.5mg, 85pmol) and 5-ethyl-2fluoro-^-ES-OAô.e.T.S-hexahydro-imidazo^.S-dJazepin^yO-lH-indazol-e-ylJ-phenol trihydrobromide sait (Préparation 32, 50mg, 80pmol) using the method of Example 8. The 25 crude material was purified by HPLC Method B to afford 14.5mg of the title compound.

LCMS (Method A): RT 2.76 min (100% area), ES m/z 514.198 [M+H]⁺.

Example 11 (2-[6-(2-Ethvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vl1-4.5.7.8-Îetrahvdro-1H-imidazo i4.5-d]azeDin-6-vl}-isothiazol-3-vl-methanone

The title compound was prepared from isothiazole-3-carboxylic acid (11mg, 85pmol) and 5ethyl-2-fluoro-4-[3-(1,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 32, 50mg, 80pmol) using the method of Example 8. The crude material was purified by HPLC Method B to afford 10.3mg of the title compound.

LCMS (Method A): RT 2.54 min (100%area), ES m/z 503.159 [M+H]⁺.

Example 12

5-Ethvl-2-fluoro-4-(3-[5-(4-fluoro-benzenesulfonvl)-4.5,6,7-tetrahvdro-1H-imidazo r4,5-clDvridÎn-2-vl1-1H-indazol-6-vl}-Dhenol

To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 80pmol) in DMF (1mL), was added 4-fluoro-benzenesulfonyl chloride (16mg, 80pmol), and DIPEA (56μΙ_, 320pmol). The reaction mixture was stirred at room température for 4 hours. Saturated aqueous sodium hydrogen carbonate solution (5mL) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by reverse phase chromatography (Method C) to afford 7mg of the title compound.

’H NMR (400 MHz, CD₃OD) δ ppm 1.02 (t, 3H), 2.52 (q, 2H), 3.78-3.81 (m, 2H), 4.37-4.29 (m, 2H), 6.88-6.96 (m, 2H), 7.15 (d, 1H), 7.32-7.36 (m, 2H), 7.40 (s, 1H), 7.89-7.95 (m, 2H), 8.21 (d, 1H).

LCMS: m/z 536 [M+H]⁺.

Example 13 {2-f6-(2-Ethvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vn-1.4.6.7-tetrahvdro-imidazo r4,5-clDvridin-5-vlH5-(2fluoro-Dhenoxv)-Dvrazin-2-yl1-methanone

To a solution of 5-(2-fluoro-phenoxy)-pyrazine-2-carboxylic acid (Préparation 45, 19mg, 80pmol) in DMF (1mL) was added HBTU (32mg, 85pmol) and the resulting reaction mixture was stirred at room température for 30 minutes. 5-Ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 80pmol) and DIPEA (56pL, 320pmol) were added and stirring was continued at room température for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5mL) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method B to afford 8.3mg of the title compound.

LCMS (Method A): RT 2.97 min (100% area), ES m/z 594.199 [M-H]'.

Example 14

4-f3-(6-Benzvl-1,4.5.6,7,8-hexahvdro-imidazor4.5-d1azeDin-2-yl)-1H-indazol-6-vll-5-ethyl-2fluoro-phenol

To a solution of 5-ethyl-2-fluoro-4-[3-(1,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1Hindazol-6-yl]-phenol trihydrobromide sait (Préparation 32, 50mg, 80pmol) in DMF (1mL), was added benzyl bromide (14.4mg, 10pL, 85pmol), and DIPEA (56pL, 320pmol). The reaction mixture was heated at 50°C for 18 hours. The reaction mixture was then cooled to room température and partitioned between EtOAc (50mL) and water (50mL). The organic layer was washed with brine (50mL), dried over sodium sulfate and concentrated in vacuo to furnish a brown oil. The crude material was purified by reverse phase chromatography (Method C) to afford 4mg of the title compound.

¹H NMR (400 MHz, CD₃OD) δ ppm 1.02 (t, 3H), 2.55 (q, 2H), 3.0Θ-3.11 (m, 4H), 3.34-3.38 (m, 5 4H), 4.23 (s, 2H), 6.88-6.94 (m, 2H), 7.18 (d, 1H), 7.41-7.4 (m, 3H), 7.52-7.55 (m, 2H), 8.20 (d,

1H), 8.39 (brs, 1H).

LCMS: m/z 482 [M+H]\ 480 [M-H]'.

Example 15 (5-Chloro-Dyridin-2-vlM2-f6-(2-ethvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vll-1.4,6.7Îetrahvdro-imidazof4.5-clDvridin-5-vl)-methanone

To a solution of 5-chloro-pyridine-2-carboxylic acid (I2mg, 80pmol) in DMF (1mL) was added HBTU (32mg, 85pmol) and the resulting reaction mixture was stirred at room température for 30 minutes. 5-Ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-615 yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 80pmol) and DIPEA (56pL, 320pmol) were added and stirring was continued at room température for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5mL) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution, The crude material was purified by reverse phase chromatography (Method 20 C) to afford 3.3mg of the title compound.

¹H NMR (400 MHz, CD₃OD) δ ppm 1.02 (t, 3H), 2.52 (q, 2H), 2.88-2.96 (m, 2H), 3.79-3.82 (m, 2H), 4.15-4.19 (m, 2H), 6.82-6.96 (m, 2H), 7.08-7.18 (m, 1H), 7.39-7.41 (m, 1H), 7.69-7.71 (m, 1H), 7.99-8.01 (m, 1H), 8.19-8.21 (d, 1H), 8.38-8.42 (m, 1H).

LCMS: m/z 517 [M+H]⁺, 515 [M-H]'.

Example 16

5-f2-r6-f2-Ethvl-5-fluoro-4-hvdroxv-phenvlMH-indazol-3-vl1-1,4.6.7-tetrahvdro-imidazo f4.5-clDvridine-5-carbonvn-Dyridine-2-cafbonitrile

To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyrrdin-2-yl)-1H30 indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 80pmol) in DMF (ImL), was added 6-cyano-nicotinoyl chloride (Préparation 46, 17mg, 96pmol), and DIPEA (56pL, 320pmol). The reaction mixture was stirred at room température for 72 hours and then saturated aqueous sodium hydrogen carbonate solution (5mL) was added. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen 35 carbonate solution. The crude material was purified by reverse phase chromatography (Method

C) to afford 6.9mg of the title compound.

¹H NMR (400 MHz, CD₃OD) δ ppm 1.02 (t, 3H), 2.52 (q, 2H), 2.85-2.98 (m, 2H), 3.75-3.79 (m, 2H), 4.15-4.19 (m, 2H), 6.82-6.96 (m, 2H), 7.08-7.18 (m, 1H), 7.38-7.40 (m, 1 H). 8.00 (d, 1H), 8.15-8.20 (m, 2H), 8.22 (d, 1H).

LCMS: m/z 508 [M+H]⁺, 506 [M-H]’.

Example 17

5-f2-r6-(2-EÎhvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-yll-4,5.7.8-tetrahydro-1H-imidazo[4,5d1azepine-6-carbonvl}-pvridine-2-carbonitrile

To a solution of 5-ethyl-2-fluoro-4-[3-(1,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1Hindazol-6-yl]-phenol trihydrobromide sait (Préparation 32, 28mg, 44pmol) in DMF (1mL), was added 6-cyano-nicotinoyl chloride (Préparation 46, 20.9mg, 141pmol), and DIPEA (31 pL, 176pmol). The reaction mixture was stirred at room température for 18 hours and then saturated aqueous sodium hydrogen carbonate solution (5mL) was added. The resulting solid 15 was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method A to afford 10.3mg of the title compound.

LCMS (Method A): RT 2.69 min (100% area), ES m/z 522.198 [M-H]‘.

Example 18

5-Ethvl-2-fluoro-4-f3-(5-quinolin-6-vlmethvl-4.5,6,7-tetrahvdro-1H-imidazo[4,5-clpyridin-2-vl)-1Hindazol-6-vn-Dhenol

To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) in DMF (1mL), was 25 added quinoline-6-carbaldehyde (31 mg, 198pmol), DIPEA (34mg, 46pL, 264pmol) and AcOH (11.8mg, 11pL, 198pmol). The reaction mixture was stirred at room température for 1 hour.

STAB (42mg, 198pmol) was added and stirring was continued for 18 hours. The reaction mixture was partitioned between EtOAc (10mL) and saturated aqueous sodium hydrogen carbonate solution (10ml). The organic layer was washed with further saturated aqueous 30 sodium hydrogen carbonate solution (2 x 10mL), dried over magnésium sulfate and concentrated in vacuo to furnish a brown oil. The crude material was purified by HPLC Method A to afford 20.6mg of the title compound.

LCMS (Method A): RT 2.59 min (100% area), ES m/z 519.223 [M-H]'.

Example 19

5-EÎhvl-2-fluoro-4-{3-[5-(4-hvdroxv-benzvl)-4.5.6,7-tetrahvdro-1H-imidazo[4,5-clpyridin-2-vll-1Hindazol-6-vn-phenol

The title compound was prepared from 4-hydroxy-benzaldehyde (24.2mg, 198pmol) and 5ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 18. The crude material was purified by HPLC Method A to afford 31.4mg of the title compound.

LCMS (Method A): RT 2.32 min (100% area), ES m/z 482.207 [M-H]'.

Example 20

5-EthvÎ-2-fluoro-4-i345-(3-hvdroxv-benzvl)-4,5.6.7-tetrahydro-lH-imidazo[4,5-clDvridÎn-2-vll-1Hindazol-6-vl)-Dhenol

The title compound was prepared from 3-hydroxy-benzaldehyde (24.2mg, 198pmol) and 5ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 18. The crude material was purified by HPLC Method A to afford 39.6mg of the title compound.

LCMS (Method A): RT 2.39 min (100% area), ES m/z 484.207 [M+H]⁺.

Example 21

4- f246-(2-Ethvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vll-1,4.6.7-tetrahvdro-imidazo[4.5clPvridin-5-vlmethvl)-pyridine-2-carbonitrile

The title compound was prepared from 4-formyl-pyridine-2-carbonitrile (26mg, 198pmol) and 520 ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)'1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 18. The crude material was purified by HPLC Method B to afford 16mg of the title compound.

LCMS (Method B): RT 1.75 min (100% area), ES m/z 494.203 [M+H]⁺.

Example 22

5- Ethvl-2-fluoro-4-(345-(3-methoxv-benzvl)-4,5,6.7-tetrahvdro-1H-imidazof4.5-clpyridin-2-vri-1Hindazol-e-vll-phenol formic acid sait

To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) in DMF (ImL), was 30 added 3-methoxy-benzaldehyde (27mg, 198pmol), DIPEA (34mg, 46pL, 264pmol) and AcOH (11.8mg, 11pL, 198pmol). The reaction mixture was stirred at room température for 1 hour. STAB (42mg, 198pmol) was added and stirring was continued for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5ml) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen 35 carbonate solution. The crude material was purified by HPLC Method B to afford 30.1 mg of the title compound.

LCMS (Method A): RT 2.64 min (100% area), ES m/z 496.223 [M-H]'.

Example 23

5-Ethvl-2-fluoro-4-r3-(5-quinolin-3-vlmethvl-4,5.6.7-tetrahvdro-lH-imidazo[4,5-clpyridin-2-vl)-1Hindazol-6-vll-phenol

The title compound was prepared from quinoline-3-carbaldehyde (31 mg, 198pmol) and 5-ethyl2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 22. The crude material was purified by HPLC Method B to afford 14.3mg of the title compound.

LCMS (Method A): RT 2.59 min (100% area), ES m/z 519.223 [M+H]⁺.

Example 24

5-Ethvl-2-fluoro-4-(3-[5-(6-phenoxv-pvridin-3-vlmethvl)-4,5.6.7-tetrahvdro-1 H-imidazo[4.5c]pvridin-2-yll-1H-indazol-6-vl)-phenol

The title compound was prepared from 6-phenoxy-pyridine-3-carbaldehyde (39mg, 198pmol) and 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]phénol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 22. The crude material was purified by HPLC Method A to afford 24.7mg of the title compound. LCMS (Method B): RT 2.53 min (100% area), ES m/z 561.234 [M+H]⁺.

Example 25 5-Ethvl-2-fluoro-4-{3-[5-(3.4.5_t6-tetrahvdro-2H41.2^,lbipyridinyl-5^l“Vlmethvn-4.5.6.7-tetrahvdro1 H-imidazo(4,5-clpyridin-2-vl1-1 H-indazol-6-vll-phenol

The title compound was prepared from 3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carbaldehyde (38mg, 198pmol) and S-ethyl^-fluoro^-fO-^.S.e.y-tetrahydro-IH-imidazojAS-cJpyrÎdin-^-yl)1 H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 22. The crude material was purified by HPLC Method A to afford 22.1 mg of the title compound.

LCMS (Method B): RT 2.22 min (100% area), ES m/z 552.281 [M+H]⁺.

Example 26

S-të-ie-fë-Ethvl-S-fluoro^-hvdroxv-phenvD-IH-indazol-S-yll-IAe.T-tetrahvdro-imidazolASοίρνπάίη-δ-νίΓΤΊθΙΐΊνίΡρνΓΐόΐηθ^-οΒ^οηίΐΓίΙθ

The title compound was prepared from 3-formyl-pyridine-2-carbonitrile (26mg, 198pmol) and 5ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4_l5-c]pyridin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 22. The crude material was purified by HPLC Method A to afford 14.9mg of the title compound.

LCMS (Method A): RT 1.46 min (100% area), ES m/z 494.203 [M+H]⁺.

Example 27

5-Ethvl-2-fluoro-4-(3-i5-(4-fluoro-benzvl)-4.5.6.7-tetrahvdro-1H-imidazo[4,5-clDyridin-2-vll-1Hindazol-6-ylTphenol

The title compound was prepared from 4-fluoro-benzaldehyde (25mg, 198pmol) and 5-ethyl-2fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 22. The crude material was purifîed by HPLC Method A to afford 3.4mg of the title compound.

LCMS (Method A): RT 2.77 min (100% area), ES m/z 486.203 [M+H]⁺.

Example 28

5-Ethvl-2-fluoro-4-r3-(5-[1.81naphthvridin-2-vlmethvl-4,5.6.7-tetrahydro-1H-imidazof

4.5-clpyridin-2-vl)-1H-indazol-6-vll-phenol

The title compound was prepared from [1_t8]naphthyridine-2-carbaldehyde (31 mg, 198pmol) and 5-ethyl-2-fluoro-4'[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]phenol trihydrobromide sait (Préparation 25, 50mg, 132pmol) using the method of Example 22. The crude material was purifîed by HPLC Method B to afford 22.5mg of the title compound. LCMS (Method B): RT 2.28 min (100% area), ES m/z 520.218 [M+H]⁺.

Example 29 (2-f645-Fluoro-4-hvdroxv-2-(2.2.2-trifiuoro-ethvl)-phenvll-1H-indazoL3-ylM.4.6.7-tetrahvdroimidazof4.5-clpvridin-5-vl)-(5-Diperidin-1 -vl-pyrazin-2-vl)-methanone diethvlamine sait

The title compound was prepared from 5-piperidin-1-yl-pyrazine-2-carboxylic acid (Préparation 44, 35mg, 168pmol) and 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-irnidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (Préparation 39,100mg, 168pmol) using the method of Example 8. The crude material was purifîed by HPLC Method A to afford 29.0mg of the title compound as the diethylamine sait.

LCMS (Method B): RT 2.66 min (100% area), ES m/z 621.227 [M+H]⁺.

Example 30 (2-{645-Fluoro-4-hvdroxv-2-(2,2.2-trifluoro-ethvl)-phenvl1-1H-indazol-3-vl)-1.4.6.7-tetrahvdroimidazor4,5-clpvridin-5-vl)-(4-fluoro-phenyl)-methanone diethvlamine sait

The title compound was prepared from 4-fluoro-benzoic acid (24mg, 168pmol) and 2-fluoro-4[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)phenol (Préparation 39, 100mg, 168pmol) using the method of Example 8. The crude material was purifîed by HPLC Method A to afford 33.3mg of the title compound.

LCMS (Method B): RT 2.62 min (100% area), ES m/z 554.154 [M+H]⁺.

Example 31

4- [3-(5-Benzvl-4,5,6.7-tetrahydro-1 H-imidazo[4,5-clDvridin-2-vl')-1H-indazol-6-vl1-2-fluoro-5(2,2,2-trifluoro-ethyl)-Dhenol diethvlamine sait

To a solution of 2-ίΙυθΓθ-4-[3-(4,5,6,7-ίε1Γ3ΐιγθΓθ-1Η-ΪΓηίΡ3ζο[4,5-ο]ργ^ίη-2-γΙ)-1Η-ϊηΰ3ζοΙ-6·7ΐ]-

5- (2,2,2-trifluoro-ethyl)-phenol (Préparation 39, 100mg, 168pmol) in DMF (1mL), was added benzyl bromide (28.8mg, 20pL, 168pmol), and DlPEA (120pL, 672pmol). The reaction mixture was heated at 80°C for 3 hours. The reaction mixture was then cooled to room température and saturated aqueous sodium hydrogen carbonate solution (5mL) was added. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method A to afford 10.6mg of the title compound.

LCMS (Method A): RT 2.67 min (100% area), ES m/z 522.184 [M+H]⁺.

Example 32 (5-r(2-Dimethvlamino-ethvl)-meÎhvl-aminol-Dvrazin-2-vn-f2-l6-(2-ethvl-5-fluoro-4-hvdroxvphenvl)-1H-indazol-3-vll-1,4.6,7-tetrahvdro-Îmidazoi4.5-clpyridin-5-vl)-methanone

To a solution of (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-

6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80mg, 0.154mmol) in DMSO (1mL) were added DIPEA (0.08mL, 0.463mmol) and Ν,Ν,Ν-trîmethylethylendiamine (31.56mg, 0.308mmol) and the mixture stirred at room température for 18 hours. The crude reaction mass was purified by prep-HPLC Method C to afford the title compound as an off white solid (25 mg, 28 %).

1H NMR (400 MHz, DMSO) δ (ppm): 1.01 (t, 3H), 2.18(s, 6H), 2.44(m, 4H), 2.78(bs, 2H), 3.13(s, 3H), 3.70(t, 3H), 3.94(bs, 2H), 4.66-4.76(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.09(d, 1H), 7.37(s, 1H), 8.12(s, 1H), 8.31(d, 1H), 8.38(d, 1H), 12.51(s, 1H), 13.21 (s, 1H);

LCMS: Rt = 2.59 min; m/z 584[M+H]+

Example 33 (246-(2-Ethvl-5-fluoro-4-hvdroxy-phenvl)-1H-indazol-3-vl1-1,4,6.7-tetrahvdro-imidazo[4,5clDvridin-5-vl}-r5-(2-Dvrrolidin-1-vl-ethylamino)-pvrazin-2-vll-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (50 mg, 96pmol) and (2-(pyrrolidin-1-yl)ethanamine, 50mg, 132pmol) using the method of Example

32. The crude material was purified by HPLC Method E to afford (30 mg, 52%) of the title compound.

1H NMR (400 MHz, DMSO) Ô(ppm): 0.98-1.01 (t, 3H), 1.13(s, 3H), 1.22(bs, 2H), 1.68(bs, 3H), 1.90(s, 1H), 2.11 (s, 1H), 2.60(t, 2H), 2.78(bs, 3H), 3.42(m, 2H), 3.91(bs, 2H), 4.64-4.68(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.08(d, 1H), 7.36(s, 1H), 7.60(bs, 1H), 7.95(s, 1H), 8.29-8.33(m, 2H), 9.80(bs, 1H), 12.52(s, 1H), 13.22(s, 1H);

LCMS: Rt = 5.71 min; m/z 596.4[M+H]+.

Example 34 r5-(2-Dimethvlamino-eÎhvlamino)-Dvrazin-2-vl]-{2-[6-(2-ethvl-5-fluoro-4-hvdroxv-phenvl)-1Hindazol-3-vl1-1.4.6.7-teÎrahvdro-imidazof4,5-clDvridin-5-vl}-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 193pmol) and N.N-dimethylethylendiamine, (34 mg, 386 pmol) using the method of Example 32. The crude material was purified by HPLC Method E to afford (50 mg, 46%) of the title compound as white solid.

1H NMR (400 MHz, DMSO) ô(ppm): 1.03(t, 3H)_t 2.18(s, 6H), 2.40-2.45(m, 4H), 2.77(bs, 2H), 2.93-2.98(m, H), 3.16(s, 3H), 3.38-3.44(m, 2H), 3.78(m, 2H), 4.66(m, 2H), 6.90(d, 1H), 6.99(d, 1H), 7.09(d, 1H), 7.37(s, 1H), 7.53(bs, 1H), 7.96(s, 1H), 8.29(s, 2H):

LCMS: Rt = 2.53 min; m/z 570[M+H]+.

Example 35 r5-(4-DÎmethylamino-piDeridin-1-vl)-Dvrazin-2-vll-{2-l6-(2-ethvl-5-fluoro-4-hvdroxy-Dhenvl)-1Hindazol-S-vll-l^.e^-tetrahvdro-imidazo^.S-clDvridin-S-vD-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 pmol) and 4-N₁N-dimethylaminopiperidine, (40 mg, 308 pmol) using the method of Example 32. The crude material was purified by HPLC Method C to afford (60mg , 64%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.01(t, 3H), 1.39-1.41 (m, 2H), 1.83-1.86(m, 2H), 2.18(s, 6H), 2.32-2.38(m, 2H), 2.78(bs, 2H), 2.95-3.01 (t, 2H), 3.90(s, 2H), 3.92-3.94(m, 2H), 4.424.45(m, 2H), 4.67-4.75(m, 2H), 6.87(d, 1H), 6.92(d, 1H), 7.03(bs, 1H), 7.37(s, 1H), 8.33-8.39(m, 3H), 12.50(bs, 1H), 13.22(bs, 1H);

LCMS: Rt = 5.46 min; m/z 610.4[M+H]+

Example 36

f2-r6-(2-Ethvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vl1-1.4,6.7-tetrahydro-imidazof4,5clPvridin-5-vB-i5-fethvl-(2-hvdroxv-ethyl)-amino1-pvrazin-2-yl)-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (120 mg, 231 pmol) and N-ethylaminoethanol, (41 mg, 463pmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (60mg, 64%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 0.99-1.03(t. 3H), 1.13-1.16(t, 3H), 2.32-2.41(m, 2H), 2.78(bs, 2H), 2.94-2.97(m„ 1H), 3.61 (bs, 5H), 3.94(m, 2H), 4.65-4.86(m, 3H), 6.90(d, 1H), 7.00(d, 1H), 7.09(bs, 1H), 7.36(s, 1 H), 8.14(s, 1H), 8.31-8.38(m, 2H), 9.82(bs, 1H), 12.51(bs, 1H), 13.20(bs, 1H);

LCMS: Rt = 2.69 min; m/z 571.4[M+H]+.

Example 37 r5-((R)-3-Dimethvlamino-PYrrolidin-1-vl)-pvrazin-2-vll-(2“f6-(2-ethvl-5-fluoro-4-hvdroxv-phenvl)“ IH-indazol-S-vll-IAej-tetrahvdro-imidazolAS-clpyridin-S-vn-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 pmol) and (R)-3-dimethylaminopyrrolidine, (35 mg, 308 pmol) using the method of Example 32. The crude material was purified by HPLC Method C to afford (35 mg, 38%) of the title compound as white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.03(t, 3H), 1.75(m, 2H), 2.21 (s, 6H), 2.79-2.81 (m, 3H), 3.20(m, 2H), 3.41-3.47(m, 2H), 3.71 (m, 1H), 3.77-3.81 (m, 1H), 3.92(bs, 2H), 4.66-4.74(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.09(d, 1H), 7.37(s, 1H), 7.98(s, 1H), 8.31 (d, 1H), 8.39(m, 1H), 12.50(S, 1H), 13.21 (s, 1H);

LCMS: Rt = 2.61 min; m/z 596.4[M+H]+.

Example 38 r5-((S)-3-Dimethvlamino-pvrrolidin-1-vl)-Pvrazin-2-vl1-(2-[6-(2-ethvl-5-fluoro-4-hvdroxy-phenvl)1H-indazol-3-viM,4,6.7-tetrahvdro-imidazor4,5-clovridin-5-vl)-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 pmol) and (S)-3-dimethylaminopyrrolidine, (35 mg, 308 pmol) using the method of

Example 32. The crude material was purified by HPLC Method C to afford (38 mg, 40%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.03(t, 3H), 1.75-1.83(m, 2H), 2.21(s, 6H), 2.79-2.81(m,

3H), 3.18-3.23(m, 2H), 3.43-3.45(m, 2H), 3.69-3.77(m, 1H), 3.79-3.81(m, 1H), 3.90(bs, 2H),

4.66(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.09(d, 1H), 7.37(s, 1H), 7.98(s, 1H), 8.32(m, 1H), 8.39(m, 1H), 12.51 (s, 1H), 13.22(s, 1H);

LCMS: Rt = 2.61 min; m/z 596.4[M+H]+.

Example 39 i2-f6-(2-Ethvl-5-fiuoro-4-hvdroxv-ohenvl)-1H-indazol-3-vl1-1.4.6,7-etrahvdroimidazo[4.5clpvridin5-vl)-f5-(2-piperidin-1-vl-ethvlamino)-pvrazin-2-vl1-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (120 mg, 231 pmol) and(2-(piperidine-1-yl)ethanamine, (59 mg, 463 pmol) using the method of Example 32. The crude material was purified by HPLC Method G to afford (38 mg, 27%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.09 (t, 3H), 1.39 (Brs, 2H), 1.39-1.50 (m, 3H), 2.32 (m, 3H), 2.43-2.54 (m, 4H), 2.77 (Brs, 2H), 3.33-3.42 (m, 2H), 3.90 (Brs, 2H), 4.68 (m, 2H), 6.906.92 (d. 1H), 7.00-7.03 (d, 1H), 7.09 (m, 1H), 7.37 (s, 1H), 7.48 (s, 1H) 7.94 (s, 1 H), 8.29-8.32 (s, 2H),;

LCMS: Rt = 2.64 min; m/z 610.2 [M+H]+.

Example 40 (2-r6-(2-Ethvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vl1-1,4.6.7-tetrahvdro-imidazof4.5c1pvridin-5-vll·Γ5-(2-piperazin-1-vl-ethvlamino)-pvrazin-2-vl^methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 pmol) and (2-(piperazinyl-1-yl)ethanamine, (40 mg, 309 pmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (26 mg, 28%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 0.97-1.00 (t, 3H), 1.20 (s, 2H), 2.40-2.43 (m, 2H), 2.50 (s, 2H), 2.76 (Brs, 2H), 3.51-3.54 (d, 2H), 3.64 (Brs, 4H), 3.87-3.93 (d, 2H), 4.41-4.42 (m, 1H), 4.64-4.68 (d, 2H) 6.87-6.89 (d, 1H), 6.97-7.08 (m, 2H), 7.34 (s, 1H), 8.29 (s, 2H), 8.37 (s, 1H), 9.79 (s, 1H), 12.48 (s, 1 H), 13.17 (s, 1H);

LCMS: Rt = 2.59 min; m/z 612.4 [M+H]+.

Example 41 (2-[6-(2-EÎhvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vn-1,4,6,7-Îetrahvdro-imidazo(4,51pvrίdin-5-vll·(4-methvl-3.4_l5,6-tetrahvdro-2H-Γ1.2Ίbipvrazinvl-5'-vll·meΐhanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-! H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 pmol) and 1-methyl-piperazine, (31 mg, 309 pmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (21 mg, 23%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 0.90-1.03 (m, 6H), 2.22 (s, 3H), 2.40-2.49 (m, 4H), 2.78 5 (Brs, 2H), 3.67 (s, 3H), 3.88 (m, 2H), 4.66 (m, 2H), 6.90-6.92 (d, 1 H), 7.00-7.03 (d, 2H), 7.37(s,

1H) 8.32 (S, 3H), 9.82 (s, 1H), 12.50 (s, 1H), 13.20 (s, 1 H);

LCMS: Rt = 2.63min; m/z 582.6 [M+H]+.

Example 42 {2-[6-(2-EÎhvl-5-fluoro-4-hvdroxv-Dhenvl)-1H-indazol-3-vn-1.4.6.7-tetrahvdro-imidazol4,5clPvridin-5-vl)-(5-morpholin-4-vi-Dvrazin-2-vl)-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 154 pmol) and morpholine, (34 mg, 386 pmol) using the method of Example 32. The crude 15 material was purified by HPLC Method F to afford (42 mg, 38%) of the title compound as offwhite solid.

1H NMR (400 MHz, DMSO) δ (ppm): 0.99-1.03(t, 3H), 2.78 (Brs, 2H), 3.65-3.72(q, 8H), 3.88 (d, 2H), 4.67-4.77(m, 2H), 6.90 (d, 1 H), 2H) 7.00-7.11 (m, 2H), 7.37 (s, 1H), 8.26 (s, 2H), 8.42 (s, 1H), 12.50 (s, 1H), 13.20 (s, 1H);

LCMS: Rt = 3.23 min; m/z 569.4 [M+H]+.

Example 43 (2-f6-(2-Ethvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vll-1,4,6.7-tetrahvdro-idazol4.5clpvridin5-vlH5-(4-methvi-piDeridin-1-vl)-pyrazin-2-vll-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 154 pmol) and 4-methyl-piperidine, (38 mg, 386 pmol) using the method of Example 32. The crude material was purified by HPLC Method F to afford (34 mg, 30%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 0.92-0.93 (d, 3H), 0.99-1.03 (t, 3H), 1.10-1.16 (m, 2H), 1.69-1.75 (m, 3H), 1.85 (s, 1H), 2.78 (Brs, 2H), 2.91-2.98 (t, 2H), 3.93 (Brs, 2H), 4.42-4.45 (d, 2H), 4.66-4.75 (m, 2H) 6.90-6.92 (d, 1H), 7.00-7.03 (d, 2H), 7.37 (s, 1H), 8.31-8.39 (m, 3H), 12.51 (s, 1H), 13.21 (s, 1H);

LCMS: Rt = 3.11 min; m/z 581.4 [M+HJ+.

Example 44 (5-CvclODentvlamino-Dvrazin-2-vl)-(2-f6-(2-ethvl-5-fluoro-4-hydroxv-Dhenvl)-1H-indazol-3-vlllAej-tetrabydro-imidazo^.s-clpyridin-S-vn-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyi)-1H-indazol·3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (90mg, 173 pmoi) and cylopenylamine, (30mg, 347 pmol) using the method of Example 32.

The crude material was purified by HPLC Method G to afford (28 mg, 28%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.03 (t, 3H), 1.45-1.51 (m, 2H), 1.56-1.57 (m, 2H), 1.69 (m, 2H), 1.93-1.95 (m, 2H), 2.53 (m, 1H), 2.78 (Brs, 2H), 3.16 (s, 1H), 3.91 (Brs, 2H), 4.14-4.19 10 (m 1H), 4.64 (m ,2H), 6.90-6.92 (d, 1H), 7.00-7.03 (d, 1H), 7.09 (d, 1H), 7.37 (s, 1 H), 7.62 (s,

1H) 7.88(s, 1H), 8.29 (s, 2H),;

LCMS: Rt = 2.98 min; m/z 567.6 [M+HJ+.

Example 45 (2-[6-(2-Ethvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-yl1-1.4,6.7-tetrahvdro-imidazoi4,5clPvridin-5-vlM5-(2-morpholin-4-vl-ethvlamino)-pyrazin-2-vl1-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4_t5-c]pyridin-5(4H)-yl)methanone (100mg, 193 pmol) and 2-morpholin-4-yl-ethylamine, (30mg, 347 pmol) using the method of 20 Example 32. The crude material was purified by HPLC Method F to afford (28 mg, 28%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 0.99-1.03(t, 3H), 2.49-2.57 (m, 2H), 2.77(Brs, 2H), 3.16 (s, 2H), 3.32 (s, 3H), 3.56-3.58 (m, 2H), 2H) 3.90 (m,2H) 4.69 (m,2H) 6.90-6.92 (d, 1H), 7.00-7.03 (d, 1H), 7.09 (m, 1H), 7.37 (s, 1H), 7.53 (Brs, 1H), 7.95 (s, 1H), 8.29 (s,2H);

LCMS: Rt = 5.89 min; m/z 612.4 [M+HJ+.

Example 46 (2-[6-(2-Ethvl-5-fluoro-4-hvdroxv-phenvO-1H-indazol-3-vll-1.4,6.7-tetrahvdro-imidazo[4,5οίρνπΰίη-δ-νΙΐ-Α-ίΒΟΡΓΟΡνΙ-βΑδ,θ-ΐΒίΓΒΐΊνϋΓο-ΖΗ-Π^ΊόίρνΓΒΖΐηνΙ-ΰ'-νΡ-πΊθΙΐΊΒηοηΒ

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 pmol) and1-isopropyl-piperazrne, (40mg, 308pmol) using the method of Example 32.

The crude material was purified by HPLC Method D to afford (18 mg, 19%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 0.95-1.03(m, 9H), 2.53(m, 4H), 2.68-2.78(m, 3H), 3.65(s, 4H), 3.89-3.95(m, 2H), 4.70(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.09(d, 1H), 7.37(s, 1H), 8.31 (m, 2H), 8.39(d, 1H), 9.82(bs, 1H), 12.51 (s, 1H), 13.20(s, 1H);

LCMS: Rt = 6.52 min; m/z 610.4[M+H]+.

Example 47 {2-[6-(2-Ethvl5-fluoro-4-hvdroxv-ohenvl)-1H-indazol-3-vl1-1.4.6,7-tetrahvdro-imidazor4,501ρνΓίόΪη-5-νΙΗ5-ρνΓΓο^ίη-1-νΙ-ρνΓ3ζΐη-2-νΙ)-πΊ6ΐ1Ί3ηοηθ

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 pmol) and pyrrolidine (22 mg, 308pmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (18 mg, 19%) of the title compound as offwhite solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.01(t, 3H), 1.97(bs, 4H), 2.78(bs, 2H), 3.50(s, 4H), 3.93(bs, 2H), 4.65-4.76(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.08(d, 1H), 7.36(s, 1H), 7.96(s, 1H),

8.31 (d, 1H), 8.39(s, 1H), 9.86(bs, 1H), 12.52(s, 1H), 13.22(s, 1H);

LCMS: Rt = 2.85min; m/z 553.4[M+H]+.

Example 48 i2-f6-(2-Ethvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vll-1.4.6.7-tetrahvdro-imidazo[4,5lpvridin-5-vn-f5-(ethvl-methvl-amino)-pvrazin-2-vll-methanon

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 pmol) and ethyl-methylamine (18 mg, 308pmol) using the method of Example 32. The crude material was purified by HPLC Method E to afford (38 mg, 46%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.01(t, 3H), 1.12(t, 3H), 2.78(m, 2H), 3.11 (s, 3H), 3.65(m, 2H), 3.93(m, 2H), 4.76(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.09(d, 1 H), 7.37(s, 1H), 8.13(s, 1H),

8.31 (m, 1H), 8.39(s, 1H), 9.84(bs, 1H), 12.51 (s, 1 H), 13.22(s, 1H);

LCMS: Rt = 2.85 min; m/z 541.6[M+H]+.

Example 49 (5-Cvclohexvlamino-pvrazin-2-vl)-i2-f6-(2-ethvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vll-

1,4.6,7-tetrahydro-imidazo[4,5-clpyridin-5-vl}-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (126 mg, 243 pmol) and cyclohexylamine (48 mg,487 pmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (29 mg, 20%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 0.99-1.04(m, 3H), 1.18-1.35(m, 6H), 1.62-1.84(m, 6H), 1.90-1.93(m, 1H), 2.78(m, 2H), 3.32(m, 1H), 3.76-3.91 (m, 2H), 4.66-4.72(m, 2H), 6.90(d, IH), 7.00(d, 1H), 7.09(d, 1H), 7.37(s, 1H), 7.51(bs, 1H), 7.88(s, 1H), 8.23(s, 1H), 12.50(bs, 1H), 13.22(bs, 1H);

LCMS: Rt = 3.06 min; m/z 581.6[M+H]+.

Example 50 (S-Dimethvlamino-Dvrazin^-vl'l-të-ie-të-ethvl-S-fluoro^-hvdrOxv-DhenvD-IH-indazol-S-vIl-Ae,?tetrahvdro-imidazol4.5-clDvridin-5-vl)-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-41^ΓθχγρΐΊθηνΙ)-1Η-^3ζοΙ-3-γΙ)-6,7^ΐΙ^Γθ-1Η-ίπ^3ζο[4,5-ο]ργ^ίη-5(4Η)-γΙ)!τιβίΐΊ3ηοηθ (80mg, 154 ymol) and dimethylamine HCl (25 mg, 308 pmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (17 mg, 21%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.01(t, 3H), 2.79(m, 2H), 3.15(s, 6H), 3.93(m, 2H), 4.70(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.01 (d, 1H), 7.09(d, 1H), 7.37(s, 1H), 8.15(s, 1H),

8.31 (m, 1H), 8.40(s, 1H), 9.84(bs, 1H), 12.51 (s, 1H), 13.20(s, 1H);

LCMS: Rt = 2.81 min; m/z 527.4[M+H]+.

Example 51 (5-Azetidin-1-vl-Dvrazin-2-vl)-{2-[6-(2-ethvl-5-fluoro-4-hvdroxy-Dhenvh-1 H-indazol-3-vll-1,4,6.7tetrahvdro-imidazof4,5-clDvridin-5-yl)-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80mg, 154 pmol) and azetdine HCl (29 mg, 308 pmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (19 mg, 23%) of the title compound as off-white solid.

1H NMR (400 MHz, DMSO) δ (ppm): 1.03(t, 3H), 2.43-2.49(m, 2H), 2.78(bs, 2H), 3.37(m, 2H), 3.87-3.95(m, 2H), 4.13(t, 4H), 4.65-4.70(m, 2H), 6.90(d, 1H), 7.00(d, 1H), 7.09(d, 1H), 7.37(s, 1H), 7.83(s, 1H), 8.33-8.37(m, 2H), 9.84(bs, 1H), 12.52(s, 1H), 13.21 (s, 1H);

LCMS: Rt = 2.78 min; m/z 539.4[M+H]+.

Example 52

2-Fluoro-4-{3-r5-(4-fluoro-benzvl)-4.5.6.7-tetrahvdro-1H-imidazoi4,5-clDvridin-2-vll-1H-indazol-6vl)-5-(2,2,2-trifiuoro-ethvl)-Dhenol

To a solution of 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]5-(2,2,2-trifluoro-ethyl)-phenol (Préparation 39, 100 mg, 0.21 mmol) and KOAc (22.75 mg, 0.23

mmol) in MeOH (1ml_), 4-fluorobenzaldehyde (57.54 mg, 0.46 mmol) was added and the mixture stirred at room température for 1 hr followed by portionwise addition of sodium triacetoxy borohydride (162.12 mg, 0.76 mmol) over 2hrs. The mixture was thereafter stirred at room température for 18 hrs. The reaction mixture was concentrated and the residue partitioned between saturated sodium bicarbonate solution & ethyl acetate. The organic phase was dried over sodium sulphate, evaporated in vacuo, purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as a light yellow solid in 30.35 % yield, 35 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 2.66(m, 2H), 2.76-2.80(m, 2H), 3.44-3.56(m, 4H), 3.71 (s, 2H), 7.07-7.10(m, 2H), 7.13-7.19(m, 2H), 7.36(s, 1 H), 7.41-7.43(m, 2H), 8.29-8.36(m, 1H), 10.13(s, 1H), 12.21-12.34(m, 1H), 13.19(s, 1 H);

LCMS: Rt = 3.17 min; m/z 540.4 [M+H]+

Example 53

2-Fluoro-4-(3-r5-(3.4.5,6-tetrahvdro-2H-f1.2^l1bipvridinvl-5'-vlmethvl)-4,5,6.7-tetrahvdro-1Himidazo[4.5-clDvridin-2-vll-1H-indazol-6-vl)-5-(2.2.2-trifluoro-ethyl)-Dhenol

The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 3,4,5,6tetrahydro-2H-[1,2']bipyridinyl-5'-carbaldehyde (88.2 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 16.99 % yield, 22 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 1.53(m, 6H), 2.64(m, 2H), 2.73-2.77(m, 2H), 3.41-3.57(m, 10H), 6.78(d, 1H), 7.02-7.10(m, 2H), 7.14-7.17(m, 1H), 7.36(s, 1H), 7.48(d, 1H), 8.03(s, 1H), 8.30-8.35(m, 1H), 10.15(s, 1H), 12.22-12.34(m, 1H), 13.20(s, 1H);

LCMS: Rt = 3.17 min; m/z 606.2 [M+H]+

Example 54

2-Fluoro-4-f3-i5-(6-Dhenoxv-Dvridin-3-vlmethvl)-4.5,6,7-tetrahvdro-1H-imidazof4.5-clDvridin-2vn-H-indazol-6-vl)-5-(2.2.2-trifluoro-ethvl)-phenol

The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 6phenoxy-pyridine-3-carbaldehyde (92.3 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 23.6 % yield, 31 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 2.67(m, 2H), 2.77(m, 2H), 3.45-3.56(m, 4H), 3.70(s, 2H), 6.78(d, 1H), 7.00-7.22(m, 6H), 7.36(s, 1H), 7.39-7.43(t, 2H), 7.84(d, 1H), 8.11 (s, 1H), 8.308.35(m, 1H), 10.15(3, 1 H), 12.24-12.36(m, 1H), 13.21 (s, 1H);

LCMS: Rt = 3.20 min; m/z 615.4 [M+H]+

Example 55

2-Fluoro-4-(3-r5-(4-methoxv-benzvl)-4.5,6,7-tetrahvdro-1H-imidazor4,5-clDvridin-2-vn-1H indazol-6-vl)-5-(2.2.2-trifluoro-ethvl)-phenol

The title compound was prepared from 2-fluoro-4-[3-(4₁5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 4methoxybenzaldehyde (63.1 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOHDCM) to afford the title compound as an off white solid in 22.1 % yield, 26 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 2.65(m, 2H), 2.73-2.79(m, 2H), 3.37-3.47(m, 2H), 3.503.56(m, 2H), 3.64(s, 2H), 3.75(s, 3H), 6.90-6.92(m, 2H), 7.02-7.10(m, 2H), 7.l3-7.16(m, 1H),

7.27-7.29(m, 2H), 7.36(s, 1H), 8.29-8.36(m, 1H), 10.13(s, 1H), 12.20-12.35(m, 1H), 13.19(s, 1H);

LCMS: Rt = 3.15 min; m/z 552.2 [M+H]+

Example 56

2-Fluoro-4-{3-f5-(4-hvdroxv-benzvl)-4.5.6,7-tetrahvdro-1H-imidazo[4,5-clpyridin-2-vll-1Hindazol-6-vl)-5-(2.2,2-trifluoro-ethyl)-Dhenol

The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 4hydroxybenzaldehyde (56.6 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOHDCM) to afford the title compound as an off white solid in 24.4 % yield, 28 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 2.66(m, 2H), 2.73-2.78(m, 2H), 3.40-3.43(m, 2H), 3.473.56(m, 2H), 3.59(s, 2H), 6.72-6.74(d, 2H), 7.02-7.10(m, 2H), 7.14-7.18(m, 3H), 7.36(s, 1H), 8.29-8.36(m, 1H), 9.27(s, 1H), 10.13(s, 1H), 12.20-12.32(m, 1H), 13.19(s, 1H);

LCMS: Rt = 2.86 min; m/z 538.2 [M+H]+

Example 57

2-Fluoro-4-{3-[5-(3-methoxv-benzvl)-4.5.6.7-tetrahvdro-1H-imidazof4.5-clpyridin-2-vl1-1Hindazol-6-vl)-5-(2,2,2-Îrifluoro-ethvl)-phenol

The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 316848 methoxybenzaldehyde (63.1 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOHDCM) to afford the title compound as an off white solid in 21.2 % yield, 25 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 2.66(m, 2H), 2.76-2.80(m, 2H), 3.45-3.56(m, 4H), 3.69(s,

7.36(s, 1H), 8.29-8.36(m, 1H), 10.15(s, 1H), 12.23-12.35(m, 1H), 13.20(s, 1H);

LCMS: Rt = 3.14 min; m/z 552 [M+H]+

Example 58

2-Fluoro-4-i3-r5-(3-hvdroxv-benzvl)-4,5.6,7-tetrahvdro-1H-imidazoi4.5-c1pvridin-2-vl1-1Hindazol-6-vl)-5-(2,2,2-trifluoro-ethvl)-Dhenol

The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 3hydroxybenzaldehyde (56.6 mg, 0.46 mmol) using the method of Example 51. The crude 15 material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOHDCM) to afford the title compound as an off white solid in 26.1 % yield, 30 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 2.66(m, 2H), 2.76-2.81 (m, 2H), 3.43-3.53(m, 4H), 3.63(s, 2H), 6.64-6.66(d, 1H), 6.76-6.81 (m, 2H), 7.02-7.16(m, 4H), 7.36(s, 1H), 8.30-8.32(m, 1H), 9.28(d, 1H), 10.13(s, 1 H), 12.21-12.33(m, 1H), 13.19(s, 1H);

LCMS: Rt = 2.90 min; m/z 538.2 [M+H]+

Example 59

2-Fluoro-4-[3-(5-auinolin-6-vlmethvl-4,5.6,7-tetrahvdro-1H-imidazo(4.5-clovridin-2-yl)-1Hindazol-6-vl1-5-(2.2,2-Îrifluoro-ethyl)-phenol

The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and quinoline-6-carbaldehyde (72.9 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOHDCM) to afford the title compound as an off white solid in 22.9 % yield, 28 mg.

1H NMR (400 MHz, DMSO) Ô (ppm): 2.67(m, 2H), 2.83.2.89(m, 2H), 3.49-3.55(m, 4H), 3.93(s, 2H), 7.01-7.17(m, 3H), 7.36(s, 1H), 7.51(m, 1H), 7.80(d, 1H), 7.95(s, 1H), 7.99(d, 1H), 8.298.38(m, 2H), 8.87(d, 1H), 10.13(s, 1H), 12.21-12.33(m, 1H), 13.19(s, 1H);

LCMS: Rt = 2.90 min; m/z 573.6 [M+H]+

Example 60

2-Fluoro-4-i3-(5-auinolin-3-vlmethvl-4,5,6.7-tetrahvdro-lH-imidazoi4_l5-clDvridin-2-yl)-1Hindazol-6-yl1-5-(2,2,2-trifluoro-ethvl)-Dhenol

The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and quinoline-3-carbaldehyde (72.9 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOHDCM) to afford the title compound as an off white solid in 27.8 % yield, 34 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 2.67-2.70(m, 2H), 2.83.2.90(m, 2H), 3.47-3.58(m, 4H), 3.95(S, 2H), 7.01-7.17(m, 3H), 7.36(s, 1H), 7.59(t, 1H), 7.74(t, 1H), 8.02(t, 2H), 8.29-8.38(m, 2H), 8.93(d, 1H), 10.14(s, 1H), 12.23-12.36(m, 1H), 13.20(s, 1H);

LCMS: Rt = 2.97 min; m/z 573.6 [M+HJ+

Example 61

2-F!uoro-4-[3-(5-[1.8lnaDhthvridin-3-vlmethvl-4,5.6,7-tetrahvdro-1H-imidazo[4.5-clDvridin-2-vl)1H-indazol-6-vll-5-(2.2,2-trifluoro-ethyl)-Dhenol

The title compound was prepared from 2-fluoro-4-[3-(4,5_t6,7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and [1,8]naphthyridine-3-carbaldehyde (146.1 mg, 0.92 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 9.0 % yield, 22 mg.

1H NMR (400 MHz, DMSO) δ (ppm): 2.72(m, 2H), 2.89.2.92(m, 2H), 3.50-3.54(m, 2H), 3.603.63(m, 2H), 4.08(s, 2H), 7.02-7.17(m, 3H), 7.36(s, 1H), 7.61-7.64(m, 1H), 7.82-7.85(m, 1H), 8.29-8.38(m, 2H), 8.44-8.47(m, 2H), 9.06(m, 1H), 10.15(s, 1H), 12.26-12.39(m, 1H), 13.21(s, 1H);

LCMS: Rt = 2.86 min; m/z 574.2 [M+HJ+

Example 62 ((3R,5S)-3.5-Dimethvl-3,4.5.6-tetrahvdro-2H-f1,2^>lbiDvrazinvl-5'-vl)-{2-f6-(2-eÎhvl-5-fluoro-4hvdroxv-phenvl)-1H-indazol-3-vll-1.4.6,7-tetrahvdro-imidazor4.5-clpvridin-5-vl}-methanone To a stirring solution of (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1Hindazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (150mg, 0.154mmol) in DMSO (1.5mL) were added DIPEA (0.143mL, 0.87mmol) and (2R,6S)-2,6-Dimethyl-piperazine1-carboxylic acid tert-butyl ester (124mg, 0.58mmol) and the mixture stirred at room température for 18 hours. The crude reaction mass was purified by prep-HPLC Method F to afford (3R,5S)-5'-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carbonyl}-3,5-dimethyl-2,3,5,6-tetrahydro-[1,2^,]bipyrazinyl4-carboxylic acid tert-butyl ester as an off white solid (80 mg, 40 %).

LCMS: Rt = 3.18 min; m/z 696.6 [M+H]+.

To a stirring solution of (3R,5S)-5'-{2-[6-(2-Ethyl-5-fluoro*4-hydroxy-phenyl)-1H-indazol-3-yl]-

1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carbonyl}-3,5-dimethyl-2_l3₁5₎6-tetrahydro[1,2']bipyrazinyl-4-carboxylic acid tert-butyl ester (80mg, 0.114mmol) in dioxane (3mL), 10% dioxane-HCI (2mL) was added and the mixture stirred at RT for 18 hours. The reaction mass was evaporated in vacuo and the resulting solid triturated with ether to afford the title compound (HCl sait) as an off white solid (62mg 91%).

1H NMR (400 MHz, DMSO) : 1.06 (t, 3H), 1.22-1.34 (s, 6H), 2.94 (Brs, 2H), 3.01-3.07 (t, 2H),

3.32 (Brs, 2H), 3.97 (m, 2H), 4.61-4.64 (d, 2H), 4.84 (s, 2H), 6.94 (d, 1H), 7.03 (d, 1H), 7.32 (s, 1 H), 7.58 (s, 1 H), 8.41 -8.48 (m, 3H), 9.27 (m, 1 H), 9.64 (m, 1 H), 9.79 (s, 1 H), 14.33 (s, 1 H); LCMS: Rt = 2.65 min; m/z 596.4 [M+H]+.

Example 63 (2-Î6-(2-Ethyl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vll-1,4.6.7-tetrahvdro-imidazof4,5c1ovridin-5-vB-((S)-3-methvl-3,4.5,6-tetrahvdro-2H-i1.2']bipyrazinvl-5'-vl)-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (200 mg, 386pmol) and (S)-2-methyl-piperazine-1 -carboxylic acid tert-butyl ester (155mg, 773 pmol) using the method from Example 61. After purification by HPLC Method E and deprotection using HCI/dioxan, the title compound (58 mg, 25% yield over two steps) was obtained as offwhite solid (HCI-salt).

1H NMR (400 MHz, DMSO) : 0.82 (t, 3H), 1.23-1.31 (s, 3H), 2.93 (Brs, 2H), 3.07-3.18 (m, 3H), 3.97 (Brs, 2H), 4.50-4.53 (d, 2H), 4.83 (s, 2H), 6.93-6.95 (d, 1H), 7.03-7.06 (d, 1H), 7.28- 7.30 (m, 1H), 7.57 (s, 1H), 8.37 (m, 1H), 8.44 (s, 1H), 8.49 (s, 1H), 9.24 (s, 1H), 9.40 (m, 1H), 9.94 (s, 1H), 14.25 (s, 1H);

LCMS: Rt = 2.61 min; m/z 582.4 [M+HJ+.

Example 64 ((2S.5R)-2.5-Dimethvl-3,4,5,6-Îetrahvdro-2H-f1.2^l1bipvrazinvl-5^,-yl)-{2-r6-(2-ethvl-5-fluoro-4hvdroxv-phenvl)-1H-indazol-3-vl1-1,4,6.7-tetrahvdro-imidazo[4,5-clpyridin-5-vB-methanone The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 193pmol) and (2S,5R)-2,5-Dimethyl-piperazine-1 -carboxylic acid tert-butyl ester (84mg, 386 pmol) using the method from Example 61. After purification by HPLC Method E and

deprotection using HCI/dioxan, the title compound (43 mg, 37% yield over two steps) was obtained as off-white solid (HCI-salt).

1H NMR (400 MHz, DMSO) : 0.82 (t, 3H), 1.33-1.34 (m, 6H), 2.95 (Brs, 3H), 3.11-3.14 (d, 1H), 3.37 (s, 1H), 3.51-3.62 (m, 5H), 3.83 (Brs, 2H), 4.01 (m, 1H), 4.84 (m, 3H), 6.94-6.96 (d, 1 H), 7.03-7.06 (d, 1H), 7.31 (Brs, 1H), 7.58 (s, 1H), 8.36 (s, 2H), 8.49 (s, 1H), 9.33 (m, 1H), 9.53 (s, 1H), 14.33 (s, 1H);

LCMS: Rt = 2.55 min; m/z 596.2 [M+HJ+.

Example 65 f2-f6-(2-Ethvl-5-fluoro-4-hvdroxv-phenvl)-1H-indazol-3-vll-1,4,6,7-tetrahvdro-imidazo[4,5lDvridin-5-vl)-(3_l4,5.6-tetrahvdro-2H-i1.2'lbiDvrazÎnyl-5'-vl)-methanone

The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (200 mg, 386pmol) and piperazine-1-carboxylic acid tert-butyl ester (144mg, 773 pmol) using the method from Example 61. After purification by HPLC Method E and deprotection using HCI/dioxan, the title compound (64 mg, 29% yield over two steps) was obtained as off-white solid (HCI-salt).

1H NMR (400 MHz, DMSO) : 1.00-1.03 (t, 3H), 2.94 (Brs, 2H), 3.22 (s, 4H), 3.93-3.95 (m, 6H), 4.84 (s, 2H), 6.94-6.96 (d, 1H), 7.03-7.06 (d, 1H), 7.30-7.33 (m, 1H), 7,58 (s, 1H), 8.42 (s, 2H), 8.50 (s, 1H), 9.29 (Brs, 2H), 9.95 (s, 1H), 14.30 (s, 1 H);

LCMS: Rt = 2.48 min; m/z 568.2 [M+H]+.

Préparation 1

6-Bromo-1-(tetrahydro-Dvran-2-yl)-1H-indazole-3-carbaldehvde

To a solution of 6-bromo-1H-indazole-3-carbaldehyde (13.97g, 61.9mmol) in DCM (150mL) was added p-TsOH (2.36g, 12.4mmol) and the mixture was cooled to 0°C. 3,4-Dihydro-2H-pyran (8.47mL, 92.8mmol) was added dropwise to the solution and the reaction was stirred at room température overnight. The reaction mixture was diluted with DCM (200mL) and washed with a solution of saturated aqueous sodium hydrogen carbonate (500mL). The aqueous layer was reextracted with DCM (500mL) and the combined organic layers were washed with brine (2 x 1L), dried over MgSO₄ and concentrated in vacuo to yield a black oil. The crude material was refluxed in cyclohexane (20mL) and filtered while hot. The filtrate was concentrated in vacuo and the residue was stirred in heptane for 48 hours. The resulting solid was collected by filtration to give the title compound (13.87g) in a 73% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.71-1.80 (m, 3H), 2.10-2.20 (m, 2H), 2.49-2.57 (m, 1H),

3.76-3.82 (m, 1H), 3.98-4.03 (m, 1H), 5.78 (dd, 1H), 7.46 (dd, 1H), 7.87 (d, 1H), 8.16 (d, 1H),

10.22 (s, 1H).

Préparation 2

6-Bromo-1-(Îetrahvdro-pyran-2-vl)-1H-indazole-3-carbonitrile

To a solution of 6-bromo-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carbaldehyde (Préparation 1, 60g, 194mmol) in MeCN (1.5L) was added triethylamîne (68.5mL, 485mmol) and hydroxylamine hydrochloride (20g, 291 mmol). The reaction was heated at 60°C for 3 hours. The reaction was cooled to 0°C, further triethylamîne (220ml_, 1.55mol) was added and TFAA (109mL, 776mmol) was added dropwise. The reaction was allowed to warm to room température and stirred for 2 hours. Water (2L) was added to the reaction mixture and the resulting solid was collected by filtration. The solid was dissolved in DCM (1L) and the resulting solution was washed with water (2 x 500mL). The organic layer was dried over MgSO₄ and concentrated in vacuo to give the title compound as a white solid (58.59g) in a 99% yield.

’H NMR (400 MHz, CDCI₃) δ ppm 1.71-1.80 (m, 3H), 2.08-2.18 (m, 2H), 2.43-2.50 (m, 1H), 3.73-3.79 (m, 1H), 3.92-3.96 (m, 1H), 5.77 (dd, 1H), 7.47 (dd, 1H), 7.69 (d, 1H), 7.93 (d, 1H).

Préparation 3

4-Bromo-5-ethyl-2-fluoro-Dhenol

To a solution of 5-ethyl-2-fluoro-phenol (WO-2007/002313, 76.36g, 545mmol) in MeCN (2.5L) was added copper (II) bromide (361.5g, 1.619mol). The resulting suspension was stirred at room température overnight. The solvent was removed in vacuo and the residue was suspended in EtOAc (3L) and filtered through a pad of Arbocel®. The filtrate was washed with water (2L) and brine (2L), dried over MgSO₄ and concentrated in vacuo to furnish the title compound (119g) in 100% yield.

’H NMR (400 MHz, CDCI₃) δ ppm 1.19 (t, 3H), 2.86 (q, 2H), 5.20 (s, 1H), 6.90 (d, 1H), 7.25 (d, 1H).

Préparation 4 i2-(4-Bromo-5-ethvl-2-fluoro-phenoxvmethoxv)-ethvri-trimeÎhvl-silane

To a solution of 4-bromo-5-ethyl-2-fluoro-phenol (Préparation 3, 80g, 365mmol) in DCM (1L) was added DIPEA (70mL, 401 mmol) and SEM-CI (71 mL, 401 mmol). The resulting solution was stirred at room température for 18 hours. The reaction mixture was washed with water (1L), dried over MgSO₄ and concentrated in vacuo to yield the crude product. This material was purified by silica gel chromatography eluting with 30% DCM in heptane to give the title compound as a pale yellow oil (109.8g, 86%).

’H NMR (400 MHz, CDCI₃) δ ppm 0.00 (s, 9H), 0.92-0.97 (m, 2H), 1.19 (t, 3H), 2.67 (q, 2H),

3.77-3.81 (m, 2H), 5.22 (s, 2H), 7.08 (d, 1H), 7.25 (d, 1H).

Préparation 5

242-Ethvl-5-fluoro-4-(2-trimethvlsilanvl-ethoxvmethoxv)-phenvll-4.4.5,5-tetramethylf1,3,21dioxaborolane

To a solution of [2-(4-bromo-5-ethyl-2-fluoro-phenoxymethoxy)-ethyl]-trimethyl-silane {Préparation 4, 105g, 300.6mmol) in dioxane (1L) was added bis(pinacolato)diboron (76.4g, 300.6mmol) and KOAc (88.5g, 902mmol). The resulting suspension was degassed with nitrogen, Pd(dppf)CI₂ (24.54g, 30.1 mmol) was added and the reaction was heated at reflux for 18 hours. The reaction was cooled to room température and the solvent was removed in vacuo. The resulting black solid was suspended in EtOAc (2L) and fiitered through Arbocel®, washing with further EtOAc. The filtrate was washed with water (1.5L) and brine (1.5L), dried over MgSO₄ and concentrated in vacuo to yield the title compound as a black oil (155.5g, 130%) that was used crude in the next step.

¹H NMR (400 MHz, CDCI₃) δ ppm 0.00 (s, 9H), 0.93-0.97 (m, 2H), 1.17 (t, 3H), 1.32 (s, 12H), 2.86 (q, 2H), 3.73-3.82 (m, 2H). 5.25 (s, 2H), 7.01 (d, 1H), 7.47 (d, 1H).

Préparation 6

6-r2-Ethvl-5-fluoro-4-(2-trimethvlsilanvl-ethoxvmethoxv)-phenvl1-1-(tetrahvdro-pyran-2-vl)-1Hindazole-3-carbonitrile

To a solution of 6-bromo-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carbonitrile (Préparation 2, 28.5g, 93mmol) and 2-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-4,4,5,5tetramethyl-[1,3,2]dioxaborolane (Préparation 5, 73.8g, 112mmol) in dioxane (500mL) was added a solution of potassium phosphate (59.2g, 279mmol) in water (120mL). The mixture was degassed with nitrogen and then tetrakis (triphenylphosphine) palladium(O) (10.8g, 9.3mmol) was added. The reaction mixture was heated at 110°C for 18 hours. The reaction mixture was concentrated in vacuo and the residue was redissolved in EtOAc (1L) and fiitered through Arbocel®, washing with EtOAc (2 x 500mL). The combined organic phases were concentrated in vacuo to gîve a brown oil. The residue was purified by column chromatography on silica gel eluting with 10% EtOAc in heptane to give the title compound as a viscous oil (37.4g) in an 81% yield.

’H NMR (400 MHz, CDCI₃) δ ppm 0.00 (s, 9H), 0.97 (t, 2H), 1.06 (t, 3H), 1.66-1.77 (m, 3H), 2.05-2.17 (m, 2H), 2.44-2.48 (m, 3H), 3.67-3.73 (m, 1H), 3.82 (t, 2H), 3.90-3.94 (m, 1H), 5.28 (s, 2H), 5.77 (dd, 1H), 6.95 (d, 1H), 7.13 (d, 1H), 7.25 (d, 1H), 7.58 (s, 1H), 7.80 (d, 1H).

Préparation 7

6-r2-Ethvl-5-fluoro-4-(2-trimethvlsilanvl-ethoxvmethoxv)-Dhenvl1-1-(tetrahvdro-Dvran-2-vl)-1Hindazole-3-carboximidic acid methyl ester •

To a solution of 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-1-(tetrahydropyran-2-yl)-1H-indazole-3-carbonitrile (Préparation 6, 37.42g, 75.6mmol) in methanol (700mL) was added sodium methoxide (12.21g, 226.8mmol) and the reaction mixture was then stirred at room température for 18 hours. The solvent was removed in vacuo and the residue was 5 partitioned between EtOAc (1L) and water (500mL). The organic layer was washed with water (500mL), dried over MgSO₄ and concentrated in vacuo to give the title compound as a gum (37.26g) in a 94% yield.

’H NMR (400 MHz, CDCI₃) δ ppm 0.00 (s, 9H), 0.97 (t, 2H), 1.06 (t, 3H), 1.61-1.76 (m, 3H), 2.03-2.15 (m, 2H), 2.47-2.56 (m, 3H), 3.67-3.72 (m, 1H), 3.82 (t, 2H), 3.97-4.01 (m, 1H), 4.03 (s, 10 3H), 5.28 (s, 2H), 5.71 (dd, 1H), 6.97 (d, 1 H), 7.12 (d, 1H), 7.15 (d, 1H), 7.46 (s, 1H), 8.03 (d,

1H), 8.45 (s, 1H).

LCMS: m/z 528 M+H⁺.

Préparation 8

N-(1-Benzvl-4.4-diethoxv-piperidin-3-vl)-6-[2-ethvl-5-fluoro-4-(2-trimethvlsilanvl-ethoxvmethoxv)phenvll-1 -(tetrahydro-pyran-2-vl)-1 H-indazole-3-carboxamidine

To a solution of 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-1-(tetrahydropyran-2-yl)-1H-indazole-3-carboximidic acid methyl ester (Préparation 7, 17.15g, 32.49mmol) in éthanol (100mL) was added a solution of 1-benzyl-4,4-diethoxy-piperidin-3-ylamine (Tetrahedron, 1995, 51, 13447-13454; 9.51g, 34.2mmol) in éthanol (70mL). Acetic acid (3.56mL, 62.1 mmol) was added and the reaction mixture was heated at 50°C for 18 hours. The reaction mixture was concentrated in vacuo and the residue was partitioned between EtOAc (400mL) and saturated sodium hydrogen carbonate aqueous solution (300mL). The organic layer was washed with further saturated sodium hydrogen carbonate aqueous solution (300mL).

The combined aqueous layers were re-extracted with EtOAc (400mL). The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with DCM:methanol:ammonia (80:20:2) to give the title compound (11.31 g) in a 45% yield.

¹H NMR (400MHz, CDCI_3l) δ ppm 0.00 (s, 9H), 0.95-0.99 (m, 2H), 1.04-1.07 (m, 3H), 1.11-1.19 (m, 6H), 1.58-1.82 (m. 4H), 1.84-1.93 (m, 2H), 2.06-2.31 (m, 3H), 2.46-2.55 (m, 2H), 2.55-2.71 (m, 3H), 2.71-2.85 (m, 1H), 3.47-3.75 (m, 7H), 3.80-3.84 (m, 2H), 3.95-4.05 (m, 1 H), 5.27 (s,

2H), 5.68-5.76 (m, 1H), 6.98-7.01 (m, 1H), 7.11-7.24 (m, 5H), 7.29-7.36 (m, 2H), 7.44-7.49 (m, 1H), 8.11-8.28 (m, 1H).

LCMS: m/z 774 M+H⁺.

Préparation 9

N-(1-Benzvl-4_<4-diethoxv-piperidin-3-vl)-6-(2-ethvl-5-fluoro-4-hvdroxv-phenvl)-1-(tetrahvdropyran-2-vÎ)-1H-indazole-3-carboxamidine

To a solution of N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-[2-ethyl-5-fluoro-4-(2-trimethylsilanylethoxymethoxy)-phenyl]-1 -(tetrahydro-pyran-2-yl)-1 H-indazole-3-carboxamidine (Préparation 8, 7.28g, 9.4mmol) in éthanol (32mL) was added concentrated hydrochloric acid (12M, 3.92mL, 47mmol) and the resulting solution was allowed to stir at room température for 18 hours. The reaction mixture was cooled to 0°C and neutralised by dropwise addition of a saturated aqueous solution of sodium hydrogen carbonate (150mL). The mixture was extracted with EtOAc (2 x 200mL). The combined organic layers were washed with further saturated aqueous sodium hydrogen carbonate solution (100mL), dried over MgSO₄ and concentrated in vacuo to give the title compound as a foam (6.06g).

’H NMR (400MHz, CDCI₃) δ ppm 1.01-1.05 (m, 3H), 1.11-1.19 (m, 6H), 1.58-1.82 (m, 3H), 1.841.93 (m, 2H), 2.06-2.22 (m, 2H), 2.23-2.35 (m, 1H), 2.43-2.49 (m, 2H), 2.55-2.71 (m, 3H), 2.792.89 (m, 1H), 3.44-3.68 (m, 7H), 3.95-4.05 (m, 1H), 4.17-4.26 (m, 1H), 5.68-5.76 (m, 1H), 6.876.95 (m, 2H), 7.11-7.24 (m, 4H), 7.29-7.36 (m, 2H), 7.44-7.49 (m, 1H), 8.13-8.24 (m, 1H). LCMS: m/z 644 M+H⁺.

Préparation 10

4.4-Diethoxv-3-(f6-[2-ethvl-5-fluoro-4-(2-trimethvlsilanvl-ethoxvmethoxy)-phenvll-1-ftetrahvdropvran-2-vl)-1H-indazole-3-carboximidovll-amino}-piperidine-1-carboxylic acid tert-butyl ester

To a solution of 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-1-(tetrahydropyran-2-yl)-1H-indazole-3-carboximidic acid methyl ester (Préparation 7, 31.4g, 59.5mmol) in éthanol (140mL) was added a solution of 3-amino-4,4-diethoxy-piperidine-1-carboxylic acid tertbutyl ester (US-2004/0229862, 18.02g, 62.48mmol) in éthanol (100mL). Acetic acid (6.81 mL, 119mmol) was added and the reaction mixture was heated at 50°C for 18 hours. The reaction mixture was concentrated in vacuo and azeotroped with toluene (TOOmL) to give the title compound as a foam (54.7g).

¹H NMR (400MHz, CDCI_3l) δ ppm 0.03 (s, 9H), 0.96-1.00 (m, 2H), 1.05-1.08 (m, 3H), 1.17-1.31 (m, 6H), 1.46 (s, 9H), 1.69-1.75 (m, 2H), 1.93-2.19 (m, 4H), 2.52-2.58 (m, 2H), 3.47-3.58 (m, 2H), 3.59-3.70 (m, 4H), 3.70-3.75 (m, 4H), 3.84-3.88 (m, 2H), 3.92-4.07 (m, 3H), 5.32 (s, 2H), 5.94-5.99 (m, 1H), 7.01 (d, 1H), 7.21 (d, 1H), 7.27 (d, 1H), 7.69 (s, 1H), 8.10 (s, 1H).

LCMS: m/z 784 M+H⁺.

Préparation 11

5-Ethvl-2-fluoro-4-Î3-(4.5.6,7-teÎrahvdro-1H-imidazo[4.5-clpvridin-2-vl)-1H-indazol-6-vll-phenol dihvdrochloric acid sait

To a solution of 4,4-όΐθΙΐΊθχγ-3-{[6-[2-ΘΐΐΊγΙ-5-ίΙυοΓθ-4-(2-ΜΓηθΙΐΊγΐ3ίΐ3ηγΙ-θίΙιοχγΓηΘίΙ’ΐοχγ)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboximidoyl]-amino}-piperidine-1-carboxylic acid tert-butyl ester (Préparation 10, 46.65g, 55.27mmol) in éthanol (200mL) was added concentrated hydrochloric acid (12M, 100mL, 1.2mol) and the resulting solution was stirred at room température for 18 hours. The reaction mixture was concentrated in vacuo and azeotroped with toluene (100mL) and DCM (2 x 100mL). The resulting gum was dried under vacuum for 3 hours. The crude material was triturated in MeCN (300mL) and the resulting solid was collected by filtration. The solid was dissolved in éthanol (250mL) and treated with concentrated hydrochloric acid (12M, 77.2mL, 927mmol). The resulting solution was heated at 40°C for 18 hours, then at 50°C for 2 hours. The solvents were removed in vacuo and the resulting gum was triturated in MeCN (200mL). The solid which formed was collected by filtration, washed with further MeCN (200mL) and dried under vacuum to give the title compound as a beige solid (23.5g, 88% yield, dihydrochloride sait).

¹H NMR (400 MHz, CD₃OD) δ ppm 1.05 (t, 3H), 2.53 (q, 2H), 3.22 (t, 2H), 3.73 (t, 2H), 4.55 (s, 2H), 6.90-6.96 (m, 2H), 7.35 (d, 1H), 7.58 (s, 1H), 8.21 (d, 1H).

LCMS: m/z 378 M+H⁺

Préparation 12

1- Bromo-2-ethyl-5-fluoro-4-methoxv-benzene

To a solution of 4-ethyl-1-fluoro-2-methoxy-benzene (WO-2010/090537, 12.2g, 79.1 mmol) in MeCN (150mL) was added a solution of NBS (14.4g, 80.7mmol) in MeCN (50mL). The resulting solution was stirred at room température for 18 hours. The solvent was removed in vacuo and the residue was diluted with dîethyl ether (150mL). Precipitated solid was removed by filtration and the filtrate was washed with sodium sulfite aqueous solution (100mL) and brine (100mL), dried over MgSCL and concentrated in vacuo to give the title compound as a yellow oil (18g) in a 97% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.21 (t, 3H), 2.69 (q, 2H), 3.87 (s, 3H), 6.82 (d, 1H), 7.24 (d, 1H).

Préparation 13

2- (2-Ethvl-5-fluoro-4-methoxv-phenvl)-4.4.5.5-tetramethvl-[1.3.21dioxaborolane

To a solution of 1-bromo-2-ethyl-5-fluoro-4-methoxy-benzene (Préparation 12, 18.0g,

77.2mmol) in dioxane (100mL) were added SPhos (4.12g, lO.Ommol), 4,4,5,5-tetramethyl-1,3,2dioxaborolane (14.8g, 116mmol) and triethylamine (10.7mL, 77.2mmol). The reaction mixture was degassed with nitrogen prior to the addition of dichlorobis(acetonitrile)palladium (II) (801mg, 3.09mmol). The reaction mixture was then heated at 110°C for 18 hours, cooled to

room température and filtered through a pad of Celite, washing with EtOAc. The solvent was removed in vacuo and the residue was redissolved in EtOAc (30mL) and washed with water (30mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The crude material was triturated with methanol and the resulting solid was collected by filtration to 5 give the title compound as a beige solid (13.8g) in a 64% yield.

’H NMR (400 MHz, CDCI₃) δ ppm 1.18 (t, 3H), 1.32 (s, 12H), 2.87 (q, 2H), 3.89 (s, 3H), 6.76 (d,

1H), 7.46 (d, 1H). LCMS: m/z 281 M+H⁺.

Préparation 14

6-(2-Ethvl-5-fluoro-4-methoxv-phenvl)-1-(tetrahvdro-Dvran-2-vl)-1H-indazole

To a solution of 6-bromo-1-(tetrahydro-pyran-2-yl)-1H-indazole (WO-2010/027500, 2.25g, 8.0mmol) and 2-(2-ethyl-5-fluoro-4-methoxy-phenyl)-4,4_t5,5-tetramethyl-[1,3,2]dioxaborolane (Préparation 13, 2.24g, 8.0mmol) in dioxane (32mL) was added potassium phosphate (5.1 g, 15 24mmol) as a solution in water (8mL). The reaction mixture was degassed with nitrogen and treated with tetrakis (triphenylphosphine) palladium(O) (1.85g, 1.6mmol). The reaction mixture was heated at 110°C for 18 hours, cooled to room température and filtered through a pad of Arbocel®, washing with EtOAc (2 x 100mL). The filtrate was washed with water (100mL), dried over MgSO₄ and concentrated in vacuo. The crude material was purified by column 20 chromatography on silica gel elutrng with 10% EtOAc in heptane to give the title compound as a white solid (2.024g) in a 71% yield.

Ή NMR (400 MHz, CDCI₃) δ ppm 1.12 (t, 3H), 1.62-1.81 (m, 3H), 2.07-2.17 (m, 2H), 2.54-2.63 (m, 3H), 3.70-3.76 (m, 1H), 3.95 (s, 3H), 4.01-4.07 (m, 1H), 5.71 (dd, 1H), 6.90 (d, 1H), 7.01 (d, 1 H), 7.09 (dd, 1 H), 7.46 (s, 1 H), 7.71 (d, 1 H), 8.05 (s, 1 H).

Préparation 15

6-(2-Ethvl-5-fluoro-4-methoxy-phenyl)-lH-indazole

To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazole (Préparation 14, 1.8g, 5.07mmol) in methanol (100mL) was added concentrated hydrochloric 30 acid (12M) and the resulting solution was heated at 60°C overnîght, cooled to room température and concentrated in vacuo. The residue was redissolved in EtOAc (50mL) and washed with saturated sodium hydrogen carbonate aqueous solution (50mL). The organic layer was dried over MgSO₄ and concentrated in vacuo to yield the title product (1.465g) in 95% yield.

Ή NMR (400 MHz, CDCI₃) δ ppm 1.09 (t, 3H), 2.56 (q, 2H), 3.95 (s, 3H), 6.90 (d, 1H), 6.98 (d, 35 1 H), 7.10 (dd, 1 H), 7.38 (s, 1 H), 7.76 (d, 1 H), 8.14 (br s, 1 H), 10.69 (br s, 1 H)

LCMS: m/z 271 M+H⁺.

Préparation 16

6-(2-Ethvl-5-fluoro-4-methoxv-Dhenvl)-3-iodo-1H-indazole

To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1H-indazole (Préparation 15, 1.46g, 5.4mmol) in DMF (20mL) was added KOH (1.14g, 20.3mmol) and the mixture was stirred for 5 minutes. A solution of iodine (2.75g, 10.8mmol) in DMF (5ml_) was slowly added and the reaction was stirred at room température for 30 minutes. The reaction mixture was diluted with water (100mL) and extracted with EtOAc (100mL). The organic layer was washed with water (2 x 100mL) and saturated sodium metabisulfite aqueous solution (1Q0mL), dried over MgSO₄ and concentrated in vacuo to furnish the title compound (1.94g) in a 91% yield.

’H NMR (400 MHz, CDCI₃) δ ppm 1.08 (t, 3H), 2.55 (q, 2H), 3.95 (s, 3H), 6.90 (d, 1 H), 6.97 (d, 1 H), 7.16 (dd, 1 H), 7.37 (s, 1 H), 7.52 (d, 1 H), 10.64 (br s, 1 H).

LCMS: m/z 397 M+H⁺.

Préparation 17

6-(2-Ethvl-5-fluoro-4-methoxv-phenyl)-3-iodo-1-(tetrahvdro-Dvran-2-vl)-1H-indazole

To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1H-indazole (Préparation 16, 1.94g, 4.9mmol) in DCM (10mL) was added p-TsOH (187mg, 982pmol) and the mixture was cooled to 0°C. 3,4-Dihydro-2H-pyran (660pL, 7.4mmol) was added dropwise to the solution and the reaction was stirred at room température overnight. The reaction mixture was diluted with DCM (5mL) and washed with saturated sodium hydrogen carbonate aqueous solution (20mL). The organic layer was dried over MgSO₄ and concentrated in vacuo to yield a black oil. The residue was purified by column chromatography (Biotage SNAP 10g) eluting with a gradient of 20% EtOAc in heptane to give the title compound as a colourless oil (2.09g) in an 89% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.11 (t, 3H), 1.60-1.64 (m, 1H), 1.72-1.76 (m, 2H), 2.02-2.10 (m, 2H), 2.50-2.58 (m, 3H), 3.69-3.73 (m, 1H), 3.95 (s, 3H), 4.01-4.05 (m, 1H), 5.68 (dd, 1H), 6.90 (d, 1H), 7.10 (d, 1H), 7.15 (dd, 1H), 7.42-7.46 (m, 2H).

LCMS: m/z 481 M+H⁺.

Préparation 18

6-Î2-EthvÎ-5-fluoro-4-methoxv-phenvl)-1-(teÎrahvdro-Dvran-2-vl)-3-ÎrimeÎhvlstannanvl-1Hindazole

To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1-(tetrahydro-pyran-2-yl)-1Hindazole (Préparation 17, 2.09g, 4.35mmol) in toluene (24mL) was added 1,1,1,2,2,2hexamethyl-distannane (1mL, 4.79mmol) followed by tetrakis (triphenylphosphine) palladium(O) (100mg, 87pmol). The reaction mixture was degassed with nitrogen and heated at 100°C for 18 hours. The reaction was then cooled to room température and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 10% EtOAc in heptane to give the title compound as a colourless oil (1.47g) in a 65% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 0.47 (t, 9H), 1.12 (t, 3H), 1.60-1.64 (m, 1 H), 1.73-1.78 (m, 2H), 2.05-2.18 (m, 2H), 2.57 (q, 2H), 2.59-2.67 (m, 1H), 3.70-3.76 (m, 1H), 3.95 (s, 3H), 4.064.09 (m, 1H), 5.74 (dd, 1H), 6.91 (d, 1H), 7.00-7.06 (m, 2H), 7.48 (s, 1H), 7.68 (s, 1H). LCMS: m/z 519 M+H⁺.

Préparation 19

6.7- Dihvdro-4H-imidazoF4,5-clDvridine-1,5-dicarboxvlic acid di-tert-butvl ester

To a solution of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (21.3g, 109mmol) in methanol (250mL) was added DIPEA (47.3mL, 272mmol) and a solution of di-tert-butyl dicarbonate (59.3g, 272mmol) in methanol (130mL). The reaction mixture was stirred at room température for 18 hours and concentrated in vacuo to yield an oil. The residue was redissolved in EtOAc (500mL) and the resulting solution was washed with water (500mL), dried over MgSO₄ and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 30% EtOAc in DCM to yield the title compound as a white solid (26.85g) in 76% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.48 (s, 9H), 1.60 (s, 9H), 2.61-2.92 (m, 2H), 3.62-3.72 (m, 2H), 4.59-4.65 (m, 2H), 7.98 (s, 1H).

Préparation 20

1.4.6.7- Tetrahydro-imidazor4.5-clDvridine-5-carboxvlic acid tert-butyl ester

To a solution of 6,7-dihydro-4H-imidazo[4_t5-c]pyridine-1,5-dicarboxylic acid di-tert-butyl ester (Préparation 19, 26.8g, 82.9mmol) in methanol (210mL) was added 1M sodium hydroxide aqueous solution (170mL, 170mmol). The resulting mixture was stirred at room température for 1 hour. The reaction mixture was diluted with 10% citric acid aqueous solution (250mL), basified to pH8 and extracted with DCM (2 x 500mL). The combined organic layers were dried over MgSO₄ and concentrated in vacuo to give the title compound as a brown foam (18.5g) in a 97% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.47 (s, 9H), 2.64-2.72 (m, 2H), 3.68-3.75 (m, 2H), 4.43-4.53 (m, 2H), 7.52 (s, 1H).

Préparation 21

2-lodo-1,4.6.7-tetrahvdro-imidazof4,5-clpvridine-5-carboxylic acid tert-butyl ester

To a solution of 1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester (Préparation 20, 18.g, 80.62mmol) in THF (300mL) was added NIS (27.2g, 121 mmol). The reaction mixture was stirred at room température for 1 hour. The reaction mixture was diluted with EtOAc (800mL), washed with sodium thiosulfate aqueous solution (3 x 700mL) and brine (500mL), dried over MgSO₄ and concentrated in vacuo to give the title compound as a yellow solid (18.25g) in a 64.8% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.46 (s, 9H), 2.66-2.74 (m, 2H), 3.64-3.75 (m, 2H), 4.42-4.54 5 (m, 2H).

Préparation 22

2-lodo-1-(2-trimeÎhvlsilanvl-ethoxvmethvl)-1.4.6,7-tetrahvdro-imidazor4,5-clPvridine-5-carboxvlic acid tert-butyl ester

To a solution of 2-iodo-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester (Préparation 21, 17.25g, 49.4mmol) in THF (250mL) was added NaH (60% in paraffin oil, 2,08g, 51.9mmol) and the resulting solution was stirred at room température for 1.5 hours. The reaction mixture was cooled to 0°C and SEM-CI (9.18mL, 51.9mmol) was added dropwise. The reaction was stirred at room température for 18 hours, cooled to 0°C and quenched carefully with water (500mL). The resulting solution was extracted with EtOAc (2 x 500mL) and the combined organics layers were dried over MgSO₄, filtered through a pad of silica and concentrated in vacuo to give the title compound (23.4g) in a 99% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 0.00 (s, 9H), 0.90-0.95 (m, 2H), 1.47 (s, 9H), 2.64-2.76 (m, 2H), 3.54 (t, 2H), 3.63-3.75 (m, 2H), 4.43-4.57 (m, 2H), 5.15 (s, 2H).

Préparation 23

2-F6-(2-Ethyl-5-f luoro-4-methoxv-Dhenvl)-1 -(tetrahvdro-Dvran-2-vl)-1 H-indazol-3-vl1-1-(2trimeÎhvlsilanvl-ethoxvmethvl)-1.4,6,7-tetrahvdro-imidazof4,5-clpvridine-5-carboxvlic acid tertbutyl ester

To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-3trimethylstannanyl-1 H-indazole (Préparation 18, 735mg, 1.53mmol) in toluene (6mL) was added 2-iodo-1-(2-trimethylsilanyl-ethoxymethyl)-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester (Préparation 22, 805mg, 1.68mmol), copper (I) iodide (60mg, 310pmol) and tetrakis (triphenylphosphine) palladium(O) (173mg, 150pmol). The reaction mixture was degassed with nitrogen, heated at 100°C for 18 hours, cooled to room température and concentrated in vacuo. The residue was purifîed by column chromatography on silica gel eluting with 20% EtOAc in toluene to give the title compound as a foam (801 mg) in a 74% yield. Ή NMR (400 MHz, CDCI₃) δ ppm -0.12 (s, 9H), 0.81-0.90 (m, 2H), 1.10 (t, 3H), 1.50 (s, 9H),

1.67-1.83 (m, 3H), 2.12-2.20 (m, 2H), 2.57 (q, 2H), 2.58-2.60 (m, 1H), 2.81-2.84 (m, 2H), 3.4935 3.56 (m, 2H), 3.72-3.82 (m, 3H), 3.95 (s, 3H), 4.01-4.04 (m, 1H), 4.60-4.63 (m, 2H), 5.74-5.76 (m, 1H), 5.83-5.86 (m, 1H), 5.98-6.00 (m, 1H), 6.90 (d, 1H), 7.03 (d, 1H), 7.19 (dd, 1H), 7.46 (s, 1H), 8.42 (d, 1H).

LCMS: m/z 706 M+H*.

Préparation 24

2-r6-(2-Ethvl-5-fluoro-4-methoxy-phenvO-1H-indazol-3-vll-4.5.6.7-tetrahvdro-1H-imidazof4,55 clpyridine trihydrochloride sait

To a solution of 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazol-3yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester (Préparation 23, 801 mg, 1.13mmol) in methanol (20mL) was added concentrated hydrochloric acid (12M, 8mL) and the resulting solution was heated at 60°C for 18 10 hours. The reaction mixture was cooled to room température and concentrated in vacuo to furnish the title compound (739mg).

’H NMR (400 MHz, CD₃OD) δ ppm 1.04 (t, 3H), 2.55 (q, 2H), 3.25-3.26 (m, 2H), 3.62-3.65 (m, 2H), 3.89 (s, 3H), 4.48-4.52 (m, 2H), 6.94 (d, 1H), 7.02 (d, IH), 7.30-7.32 (m, 1H), 7.56 (s, 1H),

8.27-8.29 (m, 1H).

LCMS: m/z 392 M+H⁺.

Préparation 25

5-EÎhvl-2-fluoro-4-[3-(4,5.6.7-tetrahvdro-1H-imidazor4.5-clPvridin-2-vl)-1H-indazol-6-vl1-phenol trihydrobromlde sait

A 1M solution of boron trîbromide in DCM (4.54mL, 4.54mmol) was added dropwise to a solution of 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 H-indazol-3-yl]-4,5,6,7-tetrahydro-1 Himidazo[4,5-c]pyridine (Préparation 24, 739mg, 1.13mmol) in DCM (10mL) at 0°C. The resulting solution was stirred at room température for 18 hours. Further boron trîbromide (4.54mL, 4.54mmol) was added dropwise and the reaction was allowed to stir at room température for 5 25 hours. Precipitated solid was collected by filtration, washed with tBME, then triturated with EtOAc to yield the title compound as the trihydrobromide sait (665mg) in a 94% yield.

¹H NMR (400 MHz, CD₃OD) δ ppm 1.05 (t, 3H), 2.52 (q, 2H), 3.25-3.26 (m, 2H), 3.75-3.76 (m, 2H), 4.60-4.61 (m, 2H), 6.89-6.96 (m, 2H), 7.32-7.41 (m, 1H), 7.58-7.59 (m, 1H), 8.22-8.23 (m, 1H).

LCMS: m/z 378 M+H⁺.

Préparation 26

4,5,7,8-Tetrahydro-imidazof4.5-d1azepine-1.6-dicarboxvlic acid di-tert-butyl ester

To a solution of 1,4,5,6,7,8-Hexahydro-imidazo[4,5-d]azepine (WÛ-2000/063208; 5.0g, 35 23.5mmol) in methanol (60mL) was added DIPEA (5.6mL, 59.6mmol) and a solution of BOCanhydride (13.07g, 59,6mmol) in methanol (30mL). The reaction mixture was stirred at room température for 18 hours and concentrated in vacuo to yield an oil. The residue was

redissolved in DCM (250mL) and the resulting solution was washed with water (100mL) and saturated aqueous ammonium chloride solution (100mL), dried over MgSO₄ and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 50%

EtOAc in heptane to yield the title compound as a brown oil (6.87g) in 85% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.40 (s, 9H), 1.53 (s, 9H), 2.84-2.87 (m, 2H), 3.10-3.12 (m,

2H), 3.50-3.62 (m, 4H), 7.87 (s, 1H).

Préparation 27

4_l5,7,8“Tetrahvdro-1H-imidazof4.5-dlazepine-6-carboxvlic acid tert-butyl ester

To a solution of 4,5,7,8-tetrahydro-imidazo[4,5-d]azepine-1,6-dicarboxylic acid di-tert-butyl ester (Préparation 26, 6.87g, 20.37mmol) in methanol (60ml_) was added an aqueous 1M solution of sodium hydroxide (40.7mL, 40.7mmol). The resulting mixture was stirred at room température for 2 hours and then concentrated in vacuo. The residue was partitioned between DCM (100mL) and water (100mL). The organic layer was dried over MgSO₄ and concentrated in vacuo to give the title compound as a brown foam (4.8g) in a 99% yield.

Ή NMR (400 MHz, CDCI₃) δ ppm 1.46 (s, 9H), 2.78-2.83 (m, 4H), 3.56-3.62 (m, 4H), 7.40 (s, 1H).

Préparation 28

2-lodo-4,5,7,8-tetrahvdro-1H-imidazo[4,5-dlazepine-6-carboxvlic acid tert-butvl ester

To a solution of 4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepine-6-carboxylic acid tert-butyl ester (Préparation 27, 4.8g, 20.23mmol) in THF (60mL) was added NIS (4.78g, 21.24mmol). The reaction was stirred at room température for 18 hours and the solvent was then removed in vacuo. The residue was dissolved in EtOAc (200mL) and the resulting solution was washed with 25 sodium thiosulfate solution (150mL). The aqueous layer was re-extracted with EtOAc (150mL) and the combined organic layers were washed with brine (150mL), dried over MgSO₄ and concentrated in vacuo to give the title compound as a tan solid (6.14g) in an 84% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.46 (s, 9H), 2.79-2.87 (m, 4H), 3.53-3.59 (m, 4H).

LCMS: m/z 364 M+H⁺.

Préparation 29

2-lodo-1-(2-trimethvlsilanvl-ethoxvmethvl)-4,5.7.8-Îetrahvdro-1H-imidazof4,5-dlazepine-6carboxvlic acid tert-butvl ester

To a solution of 2-iodo-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepine-6-carboxylic acid tert-butyl 35 ester (Préparation 28, 2.2g, 6.06mmol) in THF (35mL) was added NaH (60% in paraffin oil,

254mg, 6.36mmol) and the resulting solution was stirred at room température for 1.5 hours.

The reaction mixture was cooled to 0°C and SEM-CI (1.13mL, 6.36mmol) was added dropwise.

The reaction mixture was stirred at room température for 18 hours and then cooled to 0°C and quenched carefully with water (100mL). The resulting solution was extracted with EtOAc (2 x 100mL) and the combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was purified by column chromatography (Biotage SNAP 100g) eluting with 40% EtOAc in DCM to give the title compound (2.34g) in a 78% yield.

Ή NMR (400 MHz, CDCI₃) ô ppm -0.01 (s, 9H), 0.89-0.93 (m, 2H), 1.46 (s, 9H), 2.82-2.92 (m, 4H), 3.54-3.66 (m, 6H), 5.16 (s, 2H).

LCMS: m/z 494 M+H⁺.

Préparation 30

2-[6-(2-Ethvl-5-f luoro-4-methoxv-Dhenyl)-1 -(tetrahvdro-Dvran-2-vl)-1 H-indazol-3-vl1-1 -(2trimethvlsilanvl-ethoxymethvl)-4.5.7,8-Îetrahvdro-1H-imidazor4,5-dlazeDine-6-carboxvlic acid tert-butyl ester

To a solution of 6-(2-ethyl-5-tluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-3trimethylstannanyl-1 H-indazole (Préparation 18, 735mg, 1.53mmol) rn toluene (6mL) was added 2-iodo-1-(2-trimethylsilanyl-ethoxymethyl)-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepine-6carboxylic acid tert-butyl ester (Préparation 29, 829mg, 1.68mmol), copper (I) iodide (60mg, 310pmol) and tetrakis (triphenylphosphine) palladium(O) (173mg, 150pmol). The reaction mixture was degassed with nitrogen, heated at 100°C for 18 hours, cooled to room température and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 20% EtOAc in toluene to give the title compound as a foam (633mg) in a 57% yield.

’H NMR (400 MHz, CDCI₃) δ ppm -0.13 (s, 9H), 0.80-0.84 (m, 2H), 1.09 (t, 3H), 1.50 (s, 9H), 1.65-1.84 (m, 3H), 2.10-2.18 (m, 2H), 2.56 (q, 2H), 2.58-2.64 (m, 1H), 2.91-3.08 (m, 4H), 3.503.54 (m, 2H), 3.63-3.76 (m, 5H), 3.95 (s, 3H), 3.99-4.04 (m, 1H), 5.74 (dd, 1H), 5.83-5.88 (m, 1H), 5.97-6.03 (m, 1H), 6.90 (d, 1H), 7.03 (d, 1H), 7.18 (dd, 1H), 7.45 (S, 1H), 8.40-8.43 (m, 1H). LCMS: m/z 720 M+H⁺.

Préparation 31

2-[6-(2-Ethvl-5-fluoro-4-methoxv-Dhenvl)-1 H-indazol-3-vll-1.4,5,6,7,8-hexahvdro-imidazo[4,5dlazepine trihvdrochloride sait

To a solution of 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazol-3yl]-1-(2-trimethylsilanyl-ethoxymethyl)-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepine-6-carboxylic acid tert-butyl ester (Préparation 30, 633mg, 879pmol) in methanol (20mL) was added concentrated hydrochlorîc acid (12M, 8mL) and the resulting solution was heated at 60°C for 18 hours. A further amount of concentrated hydrochlorîc acid (12M, 4mL) was added and the

reaction mixture was heated at 60°C for a further 1Θ hours. The reaction mixture was cooled to room température and concentrated in vacuo to furnish the title compound (410mg).

'H NMR (400 MHz, CD₃OD) δ ppm 1.07 (t, 3H), 2.60 (q, 2H), 3.35-3.37 (m, 4H), 3.62-3.63 (m, 4H), 3.93 (s, 3H), 6.99 (d, 1H), 7.07 (d, 1H), 7.35 (d, 1H), 7.59 (s, 1H), 8.24 (m, 1H).

LCMS: m/z 406 M+H⁺.

Préparation 32

5-Ethvl-2-fluoro-4-[3-(1,4,5.6.7,8-hexahvdro-imidazo[4,5-dlazeDin-2-ylMH-indazol-6-vll-Dhenol trihydrobromide sait

A 1M solution of boron tribromide in DCM (3.18mL, 3.18mmol)was added dropwise to a solution of 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1H-Îndazol-3-yl]-1 A5,6,7,8-hexahydro-imidazo[4,5djazepine (Préparation 31, 410mg, 796pmol) in DCM (10mL) at 0°C. The resulting solution was stirred at room température for 18 hours. The precipitated solid was collected by filtration, washed with tBME, then triturated with EtOAc to yield the title compound (380mg) in a 75% yield.

¹H NMR (400 MHz, CD₃OD) □ ppm 1.05 (t, 3H), 2.52 (q, 2H), 3.36-3.39 (m, 4H), 3.63-3.66 (m. 4H), 6.89-6.96 (m, 2H), 7.34 (d, 1H), 7.57 (s, 1H), 8.22 (d, 1H).

LCMS: m/z 392 M+H⁺.

Préparation 33 (2-Bromo-4-fluoro-5-methoxv-Dhenyl)-methanol

To a solution of (4-fluoro-3-methoxy-phenyl)-methanol (10.0g, 64.04mmol) in MeCN (160mL) was added a solution of NBS (11.4g, 64.04mmol) in MeCN (50mL) and the resulting mixture was stirred at room température for 18 hours. The reaction mixture was concentrated in vacuo and the residue was suspended in diethyl ether (200mL). Solid material was removed by filtration and washed with further diethyl ether. The filtrate was washed with water (200mL) and brine (100mL), dried over MgSO₄ and concentrated in vacuo to give the title compound as a white solid (14.4g) in a 96% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.94 (t, 1H), 3.90 (s, 3H), 4.70 (d, 2H), 7.14 (d, 1H), 7.27 (d, 1H).

Préparation 34

1-Bromo-2-bromomethyl-5-fluoro-4-methoxv-benzene

Phosphorus tribromide (11.56mL, 122.5mmol)was added to a solution of (2-bromo-4-fluoro-5methoxy-phenyl)-methanol (Préparation 33, 14.4g, 61.26mmol) in DCM (235mL) at 0°C. The reaction was allowed to warm to room température and stirred at that température for 18 hours.

The reaction mixture was cooled to 0°C and quenched by slow addition of saturated sodium

hydrogen carbonate aqueous solution until effervescence had ceased. The layers were separated and the aqueous layer was extracted with DCM (2 x 100mL). The combined organic layers were dried over MgSO₄ and concentrated in vacuo to give the title compound as a white solid (17.48g) in a 96% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 3.89 (s, 3H), 4.55 (s, 2H), 7.04 (d, 1H), 7.29 (d, 1H).

Préparation 35

1-Bromo-5-fluoro-4-meÎhoxv-2-(2,2.2-trifluoro-ethvl)-benzene

To a solution of 1-bromo-2-bromomethyl-5-fluoro-4-methoxy-benzene (Préparation 34, 10.84g, 10 36.4mmol) in DMF (80mL) was added copper (I) iodide (1.746g, 9.09mmol) and the solution was degassed with nitrogen. To this solution was added difluoro-fluorosulfonyl-acetic acid methyl ester (11.57mL, 90.9mmol) and the resulting reaction mixture was heated at 120°C for 4 hours. The reaction mixture was cooled to 0°C, diluted with EtOAc (60mL) and stirred for 10 minutes at 0°C. A solution of ammonium hydroxide (60mL) was added dropwise and the 15 mixture was stirred as it warmed from 0°C to room température over 20 minutes. Ethyl acetate (200mL) and water (100mL) were added and the layers were separated. The aqueous layer was further extracted with EtOAc (2 x 100mL). The combined organic layers were washed with water (100mL) and brîne (100mL), dried over Na₂SO₄ and concentrated in vacuo. The crude residue was purified by column chromatography on silica gel eluting with 20% EtOAc in heptane 20 to give the title compound as a yellow solid (7.356g) in a 70% yield.

’H NMR (400 MHz, CDCI₃) δ ppm 3.56 (q, 2H), 3.89 (s, 3H), 6.94 (d, 1H), 7.32 (d, 1H).

LCMS: m/z 288 M+H*.

Préparation 36

2-[5-Fluoro-4-methoxv-2-(2.2,2-trifluoro-ethvl)-Dhenvll-4,4,5,5-tetramethvl-1,3.2ldioxaborolane

To a solution of 1-bromo-5-fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-benzene (Préparation 35, 7.07g, 26.82mmol) in dioxane (100mL) was added 4,4,5,5,4’,4^,,5',5'-octamethyl· [2,2']bi[[1,3,2]dioxaborolanyl] (8.17g, 32.18mmol) and KOAc (7.9g, 80.46mmol). The mixture was degassed with nitrogen prior to the addition of [1,1'-bis(diphenylphosphino)ferrocenej30 dichloropalladium(ll) (2.3g, 2.68mmol). The reaction mixture was stirred at 110°C for 18 hours, then cooled to room température and concentrated in vacuo. The residue was dissolved in methanol and filtered through Arbocel®, washing with methanol. The frltrate was concentrated in vacuo and then partitioned between EtOAc (200mL) and water (200mL). The aqueous layer was extracted with further EtOAc (2 x 100mL). The combined organic layers were washed with water (200mL) and brine (150mL), dried over Na₂SO₄ and concentrated in vacuo to give the title compound as an oil (8.96g) in a 100% yield.

t

’H NMR (400 MHz, CDCI₃) δ ppm 1.31 (s, 12H), 3.78 (q, 2H), 3.95 (s, 3H), 6.85 (d, 1H), 7.53 (d, 1H).

Préparation 37

645-Fluoro-4-methoxv-2-(2.2,2-trifluoro-eÎhvl)-Dhenvll-1-(tetrahvdro-Dvran-2-vl)-1H-indazole-3carbonitrile

To a solution of 6-bromo-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carbonitrile (Préparation 2, 3.99g, 13.03mmol) and 2-[5-fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-4,4,5,5tetramethyl-[1,3,2]dioxaborolane (Préparation 36, 7.46g, 15.63mmol) in dioxane (60mL) was 10 added a solution of potassium phosphate (18.8g, 39.09mmol) in water (12mL). The mixture was degassed with nitrogen, treated with tetrakis (triphenylphosphine) palladium(O) (3.01g, 2.6mmol) and heated at 110°C for 18 hours. The reaction mixture was concentrated in vacuo and the residue was redissolved in EtOAc (500mL) and filtered through Arbocel®, washing with EtOAc (2 x 500mL). The combined organic phases were washed with water (300mL), dried 15 over MgSO₄ and concentrated in vacuo to give a brown oil. The residue was purified by column chromatography on silica gel, elutïng with 25% EtOAc in heptanes, to give the title compound (1.737g) in a 31% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.68-1.80 (m, 3H), 2.11-2.17 (m, 2H), 2.45-2.53 (m, 1H),

3.27- 3.41 (m, 3H), 3.74 (m, 1H), 3.96 (s, 3H), 5.80 (dd, 1H), 7.06 (m, 2H), 7.24 (m, 1H), 7.84 (s,

1H), 7.87 (d, 1H).

Préparation 38

6-Î5-Fluoro-4-methoxv-2-(2.2.2-trifluoro-ethvl)-DhenvH-1-(tetrahvdro-Dvran-2-vl)-1H-indazole-3carboximidic acid methyl ester

To a solution of 6-[5-fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1-(tetrahydro-pyran-2-yl)1 H-indazole-3-carbonitrile (Préparation 37, 1.737g, 4.00mmol) in méthanol (40mL) was added sodium methoxide (648mg, 12.0mmol) and the reaction mixture was stirred at room température for 18 hours. The reaction mixture was partitioned between EtOAc (50mL) and water (50mL) and the aqueous layer was extracted with further EtOAc (2 x 50mL). The combined organic 30 layers were dried over MgSO₄ and concentrated in vacuo to give the title compound as an oily solid (1.64g) in an 88% yield.

¹H NMR (400 MHz, CDCI₃) δ ppm 1.63-1.78 (m, 3H), 2.07-2.18 (m, 2H), 2.53-2.61 (m, 1H),

3.28- 3.42 (m, 3H), 3.96 (s, 3H), 4.00-4.04 (m, 1H), 4.07 (s, 3H), 5.74 (dd, 1 H), 7.05 (d, 1H), 7.09 (d, 1H), 7.14 (dd. 1H), 7.52 (s, 1H), 8.10 (d, 1H).

Préparation 38

ΘΟ

2-(6-[5-Fluoro-4-methoxv-2-(2_l2.2-trifluoro-ethvl)-phenvll-1 H-indazol-3-vn-4,5.6,7-tetrahvdro-3Himidazo[4,5-clpvridine trihvdrochloride sait

To a solution of 6-[5-fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1-(tetrahydro-pyran-2-yl)1 H-indazole-3-carboximidic acid methyl ester (Préparation 37, 1.64g, 3.78mmol) in éthanol 5 (5mL) was added a solution of 3-amÎno-4,4-diethoxy-piperidine-1 -carboxylic acid tert-butyl ester (US-2004/0229862, 1.15g, 3.97mmol) in éthanol (7.5mL). Acetic acid (430pl_, 7.56mmol) was added and the reaction mixture was heated at 50°C for 18 hours and then concentrated in vacuo to give a brown oil. The oil was dissolved in éthanol (15mL) and the resulting solution was treated with concentrated hydrochloric acid (12M, 4.75mL, 56.7mmol) and then heated at 10 80°C for 18 hours. The solvent was removed in vacuo to yield the title compound (2.03g) in a

97% yield.

¹H NMR (400 MHz, CD₃OD) δ ppm 3.20-3.26 (m, 2H), 3.40-3.54 (m, 2H), 3.66-3.75 (m, 2H), 3.80 (s, 3H), 4.51-4.55 (m, 2H), 7.15 (d, 1H), 7.24 (d, 1H), 7.33 (d, 1H), 7.62 (s, 1H), 8.27 (d, 1H).

LCMS: m/z 446 M+H⁺.

Préparation 39

2-Fluoro-4-r3-(4,5_l6.7-tetrahvdro-1H-imidazor4.5-c1ovridin-2-vO-1H-indazol-6-vll-5-(2.2,2trifluoro-ethvD-phenol dihydrobromide sait

Boron tribromide (750pL, 7.83mmol) was added driowuse to a solution of 2-{6-[5-fluoro-4methoxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1H-indazol-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5cjpyridine trihydrochloride sait (Préparation 38, 2.03g, 3.66mmol) in DCM (25mL) at 0°C. The resulting solution was stirred at room température for 18 hours. Further boron tribromide (2mL, 20.7mmol) was added dropwise and the reaction mixture was allowed to stir at room température for 18 hours. The precipitated solid was collected by filtration, washed with DCM and triturated with EtOAc to yield the title compound as the dihydrobromide sait (1.56g) in a 67% yield.

’H NMR (400 MHz, CD₃OD) δ ppm 3.24 (dd, 2H), 3.41 (q, 2H), 3.75 (dd, 2H), 4.58 (s, 2H), 7.05-7.09 (m, 2H), 7.34 (d, 1H), 7.60 (s, 1H), 8.26 (d, 1H).

LCMS: m/z 432 M+H⁺.

Préparation 40

5-Hvdroxv-pyrazine-2-carboxvlic acid methyl ester

Thionyl chloride (152mL, 2.08mol) was added dropwise at -20 °C to methanol (5L). After the addition was completed, the mixture was stirred at this température for 30 minutes. Then 5hydroxy-pyrazine-2-carboxylic acid (100g, 714mmol) was added, and the mixture was heated at

reflux for 2 hours. The reaction mixture was concentrated in vacuo, and the residue was recrystallised from methanol (400mL) to give 71g (464mmol) of the title compound in 65% yield.

Préparation 41

5-Chloro-Dvrazine-2-carboxvlic acid methyl ester

A mixture of 5-hydroxy-pyrazine-2-carboxylic acid methyl ester (Préparation 40, 50 g, 324mmol) and POCI₃ (500mL, 5.36mol) was heated under reflux for 1.5 hours and then poured onto ice. The resulting mixture was extracted with ether (4x500mL). The organic layers were concentrated in vacuo, and the residue was recrystallised from toluene to give the title 10 compound (30.8g) in a 55% yield.

Préparation 42

5-PiDeridin-1-vl-pvrazine-2-carboxvlic acid methyl ester

To a solution of 5-chloro-pyrazine-2-carboxylic acid methyl ester (Préparation 41, 85g, 15 492mmol) in DMF (365mL) was added DIPEA (129mL, 738mmol) and piperldine (58.4mL,

591 mmol) and the resulting solution was stirred at room température for 18 hours. The réaction mixture was poured onto water (4L) and the resulting precipitate was collected by filtration to give the title compound as a white solid (85.12g) in a 78% yield.

'H NMR (400 MHz, DMSO-d6) δ ppm 1.50-1.56 (m, 4H), 1.60-1.62 (m, 2H), 3.68-3.73 (m, 4H), 20 3.80 (s, 3H), 8.35 (s, 1 H), 8.60 (s, 1 H).

Préparation 43

5-Piperidin-1-vl-pyrazine-2-carboxvlic acid

5-Piperidin-1-yl-pyrazine-2-carboxylic acid methyl ester (Préparation 42, 85.1g, 384mmol) was 25 added to a solution of sodium hydroxide (61.5g, 1.53mol) in water (760mL). The mixture was stirred mechanically for 1 hour at room température. THF (300mL) was added and stirring was continued for 3 hours. The volatile solvents were removed in vacuo and the remaining aqueous solution was adjusted to pH 4. The mixture was cooled on ice to induce précipitation of the product. The resulting solid was collected by filtration and dried in vacuo to give the title 30 compound as a white solid (56g) In a 70% yield.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.43-1.61 (m, 6H), 3.60-3.70 (m, 4H), 8.28 (s, 1H), 8.58 (s, 1H), 12.59 (brs, 1H).

LCMS: m/z 208 [M+H]⁺.

Préparation 44

5-(2-Fluoro-Dhenoxy)-Dvrazine-2-carboxvlic acid methyl ester

2-Fluorophenol (21.6g, 233mmol) was dissolved in DMF (250mL) under a calcium chloride drying tube. The solution was cooled to 0°C, and then 60% NaH in paraffin oil (9.3 g, 233mmol) was added in small portions. After the main portion of NaH had dissolved, 5-chloro-pyrazine-2carboxylic acid methyl ester (Préparation 41, 40.2g, 233mmol) was added. The mixture was refluxed for 1 hour and then poured into water (1L). The aqueous mixture was extracted with ether (3 x 300mL), and the combined organic layers were washed with 2% sodium hydroxide aqueous solution (400mL) and filtered through a layer of silica gel (40/60 μηη). The filtrate was concentrated in vacuo to yield the title compound which was used without further purification.

Préparation 45

5-(2-Fluoro-phenoxv)-pyrazine-2-carboxylic acid

5- (2-Fluoro-phenoxy)-pyrazine-2-carboxylic acid methyl ester (Préparation 44, 57.9g, 233mmol) was added to a solution of KOH (15g, 267mmol) in 78% éthanol (330mL). The solution was stirred at room température for 18 hours, and the formed precipitate was collected by filtration. The resulting solid was dissolved in water (200mL), and the solution was acidified with aqueous hydrochloric acid. The formed precipitate was collected by filtration, dried and recrystallised from 41% éthanol (265mL) to give the title compound (28.3g, 120.8mmol) in 51.8% yield.

¹H NMR (400 MHz, DMSO-d6) δ ppm 7.29-7.48 (m, 4H), 8.75 (s, 2H), 13.51 (s, 1H).

LCMS: m/z 235.1 [M+H]⁺.

Préparation 46

6- Cvano-nicotinovl chloride

6-Cyano-nicotinic acid (120mg, 810pmol) was suspended in toluene (1mL) and thionyl chloride (119pL, 1.62mmol) was added dropwise followed by one drop of DMF. The reaction mixture was refluxed for 2.5 hours and then allowed to cool to room température for 18 hours. The solvents were removed in vacuo and the residue was azeotroped with toluene to furnish the title compound as a brown oil (134mg) which was used in further experiments without purification. LCMS: m/z 167.02 M+H⁺.

The activity of the compounds of formula (I) may be assessed in the following assays.

Préparation 47 (5-chloropvrazin-2-vn(2-(6-(2-ethvl-5-fluoro-4-hvdroxvphenvl)-1H-indazol-3-yl)-6,7dihvdro-1 H-imidazo[4.5-c]pyridin-5(4H)-vl)methanone

To a solution of S-ethyl^-fluonMrfS-^.S^J-tetrahydro-lH-imidazopLS-cjpyridin^-yO-IHindazol-6-yl]-phenol préparation 25 (500mg, 1.326mmol) and 7 (209.54mg, 1.326mmol) in dry DMF (10ml), DIPEA (0.65ml, 3.978mmol) and T3P (2.38 ml, 3.978mmol) were added and the reaction mixture was stirred at room température for 1 h. TLC & LCMS showed product formation. The reaction mixture was evaporated in vacuo, ice water was added to form solid precipitate which was washed with water, saturated sodium bi carbonate and pentane to afford a brown solid (460mg, 67.08%).

1H NMR (400 MHz, DMSO) δ (ppm): 1.04(t, 3H), 2.66-2.81 (m, 2H), 3.72(m, 1H), 4.04(t, 1H), 4.57(s, 1H), 4.74(s, 1H), 6.89-6.92(m, 1H), 6.98-7.13(m, 2H), 7.36(d, 1H), 8.31(d, 1H), 8.75(d, 1H), 8.86-8.87(m, 1 H), 9.82(s, 1H), 12.55(s, 1H), 13.21 (s, 1H);

LCMS: Rt = 2.89min; m/z 518.4 [M+HJ+.

JAK3 isolated enzyme high ATP Caliper endpoint assav

4mM stock solutions of test compounds are prepared and serially diluted in 100% DMSO. A standard curve using PF-00956980-00 at a top concentration of 4mM is also prepared. High percentage effect (HPE) is defined by 500μΜ PF-00956980-00 and 0% effect (ZPE) is defined by 100% DMSO. Greiner 384 well plates are prepared containing 400nl of serially diluted compound, standard and HPE/ZPE. Final top assay concentration is 80μΜ as the assay dilution factor is fifty.

JAK3 enzyme (Invitrogen) stock solution is made up at 4.1μΜ in stérile water. JAK3 enzyme stock is diluted to 2nM in assay buffer (10mM HEPES free acid pH 7.5, 10mM HEPES free base pH 7.5, 10mM MgCL₂, 0.0005% Tween-20, 0.01% BSA) containing 2mM DTT ( all supplïed by Sigma). ATP is made up at 10mM stock in stérile water and diluted to 800μΜ in assay buffer. Peptide (American peptide company) is made up at 30mM in 100% DMSO and diluted to 3μΜ in assay buffer. Stop buffer comprises 140mM HEPES, 22.5mM EDTA (Sigma) and 0.15% coating reagent (Caliper Life Sciences).

Assays are performed in Greiner polypropylene 384 well plates. Following compound préparation within the plate 10μΙ of enzyme in assay buffer containing DTT is added using a

Multidrop Micro. Final assay concentration of enzyme is 1nM. Compound and enzyme are preincubated for 60 minutes at room température using low évaporation lids before addition of 10μΙ

ATP/peptide mixture in assay buffer using a Multidrop Micro. Final assay concentrations are

400μΜ ATP and 1.5μΜ peptide. Plates are foil sealed and incubated for a further 60 minutes at room température. Stop solution is added to the plates (20pl/well) using a Multidrop Micro and

plates are loaded onto the Caliper EZReader II. Data is generated by the shift in mobility of nonphosphorylated peptide substrates and phosphorylated products by electrophoresis within a chip and detected via LED induced fluorescence. Data is analysed using LabChip EZReader software which calculâtes the relative heights of the substrate and product peaks and reports 5 product/product plus substrate peak ratio. Test compound data are subsequently expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to détermine an IC₅₀ from the résultant sigmoid curve.

JAK1 isolated enzyme high ATP Caliper endpoint assay

4mM stock solutions of test compounds are prepared and serially diluted in 100% DMSO. A standard curve using PF-00956980 (commercially available from Sigma Aldrich) at a top concentration of 4mM is also prepared. High percentage effect (HPE) is defined by 500μΜ PF15 00956980 and 0% effect (ZPE) is defined by 100% DMSO. Greiner 384 well plates are prepared containing 400nl of serially diluted compound, standard and HPE/ZPE. Final top assay concentration Is 80μΜ as the assay dilution factor is fifty.

JAK1 enzyme (Invitrogen) stock solution is made up at 5.2μΜ in stérile water. JAK1 enzyme 20 stock is diluted to 20nM in assay buffer (10mM HEPES free acid pH 7.5, 10mM HEPES free base pH 7.5, 10mM MgCL₂, 0.0005% Tween-20, 0.01% BSA) containing 2mM DTT ( ail supplied by Sigma) with the addition of one protease tablet per 25mls buffer (Roche). ATP is made up at 10mM stock in stérile water and diluted to 5mM in assay buffer. Peptide H236 (Caliper Life Sciences) is made up at 1.5mM in 100% DMSO and diluted to 3μΜ in assay buffer.

Stop buffer comprises 140mM HEPES, 22.5mM EDTA (Sigma) and 0.15% coating reagent (Caliper Life Sciences).

Assays are performed in Greiner polypropylene 384 well plates. Following compound préparation within the plate 10μΙ of enzyme in assay buffer containing DTT is added using a 30 Multidrop Micro. Final assay concentration of enzyme is 10nM. Compound and enzyme are preincubated for 30 minutes at room température using low évaporation lids before addition of 10μΙ ATP/peptide mixture in assay buffer using a Multidrop Micro. Final assay concentrations are 2.5mM ATP and 1.5μΜ peptide. Plates are foil sealed and incubated for a further 120 minutes at room température. Stop solution is added to the plates (20pl/well) using a Multidrop Micro 35 and plates are loaded onto the Caliper EZReader II. Data is generated by the shift in mobility of non-phosphorylated peptide substrates and phosphorylated products by electrophoresis within a chip and detected via LED induced fluorescence. Data is analysed using LabChip EZReader

software which calculâtes the relative heïghts of the substrate and product peaks and reports product/product plus substrate peak ratio. Test compound data are subsequently expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to détermine an IC₅₀ from the résultant sigmoid curve.

The following Table shows the available IC₅₀ data for Examples 1-31 in the JAK-1 and JAK-3 isolated enzyme high ATP Caliper endpoint assays described above.

Example number	JAK-3 IC₅₀ (nM)	JAK-1 IC₅₀(nM)
1	<0.6	<0.7
2	0.5	46
3	1.0	3.7
4	0.5	5.4
5	No data	No data
6	1.3	8.4
7	1.5	2.5
8	1.4	2.9
9	1.9	18.9
10	1.3	4.5
11	1.0	2.5
12	1.6	1.2
13	3.6	1.5
14	1.4	0.8
15	1.0	No data
16	1.9	0.7

Example number	JAK-3 IC₅₀ (nM)	JAK-1 IC₅₀(nM)
17	1.4	3.4
18	1.4	4.2
19	2.2	4.3
20	5.6	2.6
21	1.4	5.9
22	2.6	3.0
23	1.2	1.7
24	2.4	6.2
25	1.4	4.0
26	4.1	4.0
27	No data	No data
28	10.9	13.7
29	42	1.1
30	6.7	7.7
31	186	66

As a comparator compound, Example 24(c) of WO-2001/002369 was tested. It gave an IC_S0 of 119 nM in the JAK-3 assay and an IC₅o of 120 nM in the JAK-1 assay.

JAK1/3 whole cell reporter gene assav

4mM stock solutions of test compounds are prepared and serially diluted in 100% DMSO. A standard curve using PF-00956980 at a top concentration of 10mM is also prepared. High percentage effect (HPE) is defined by 10mM PF-00956980 and 0% effect (ZPE) is defined by

100% DMSO. Plates containing 1 μΙ of serially diluted compound, standard and HPE/ZPE are diluted by addition of 39μΙ assay media (Optimem with 100uM NEAA, 10uM sodium pyruvate and 100U penicillin/1 OOug streptomycin (Invitrogen)) using a Multidrop Combi. This dilutes test compounds to a top concentration of 100μΜ. Final top assay concentration is 10μΜ as the assay dilution factor is ten. Final DMSO concentration is 0.25%.

CD40 ligand is a member of the TNF superfamily and activâtes B cells. CD40 (Invitrogen) is prepared at 0.1mg/ml in PBS minus Ca²⁺, minus Mg²⁺. The concentration of CD40 required for activation is predetermined by CD40 titration with the cell line, lnterleukin-4 (IL-4, Invitrogen) is used as the co-activator and functions by binding to the IL-4 receptor complex leading to recruitment and activation of JAK1 and JAK3 tyrosine kinases. IL-4 is prepared at 1mg/ml in stérile water to generate a stock solution. This is further diluted to 100ng/ml in assay media. Inhibition of the STAT6-beta-lactamase reporter response is measured in the presence of IL-4 at an approximate EC_S0 concentration.

Beta lactamase dye reagent comprises three components and is made up by adding 1 part CCF4 dye, 5 parts solution B and 77 parts Live Blazer- substrate mixture.

Assays are performed in Greiner 384 well black polypropylene clear bottomed plates. The Invitrogen Cellsensor STAT6-b/a-RA-1 cell line is thawed, counted and resuspended at 1.88x10^e cells/ml. Cells are stimulated with CD40 ligand by addition of 5.56μΙ of 0.1mg/ml stock per 1ml of cell suspension. Cells are plated out at 60000 cells/well, 32pl/well and incubated at 37°C, 5% CO₂. After 18 hours 4μΙ test compound is added to the plate using a Platemate Plus. Plates are incubated at 37°C, 5% CO₂ for 60 minutes using low évaporation lids before addition of 4μΙ IL-4 at a concentration of 100ng/ml. Plates are incubated at 37°C, 5% CO₂ for a further five hours before addition of 10μΙ beta lactamase dye. After reagent addition plates are incubated at 37°C, 5% CO₂ for 18 hours. Beta lactamase fluorescence signal is read at 460nm (blue) and 530nm (green) and a ratio calculated using an Envision. Test compound data are expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to détermine an IC₅₀ from the résultant sigmoid curve.

Example 4 gave an IC₅₀ of 140 nM in this assay.

JAK1 and JAK2 PathHunter assay

4mM stock solutions of test compounds are prepared and serially diluted in 100% DMSO. A standard curve using PF-00956980 at a top concentration of 10mM is also prepared. High percentage effect (ΗΡΕ) rs defined by 10mM PF-00956980 and 0% effect (ZPE) is defined by 100% DMSO. Plates containing 1 μΙ of serially diluted compound, standard and HPE/ZPE are diluted by addition of 65μΙ compound diluent (PBS minus Ca²⁺, minus Mg²⁺ with 0.05% pluronic F127) using a Multidrop Combi. This dilutes test compounds to a top concentration of 60μΜ. Final top assay concentration is 10μΜ as the assay dilution factor is six. Final DMSO concentration is 0.25%.

Prolactin (Peprotech) is used for the agonist challenge. Prolactin is prepared at 40μΜ in compound diluent to generate a stock solution and further diluted to 6μΜ in compound diluent. A standard curve is prepared in compound diluent. Prolactin is also diluted to a concentration of 15nM (2.5nM fac). Antagonism of the JAK1 or JAK2 prolactin response is measured in the presence of prolactin at an approximate EC_0O concentration for JAK1 and approximately ECi₀₀for JAK2.

PathHunter détection reagent comprises three components and is made up by adding 1 part Galacton Star, 5 parts Emerald II and 19 parts Cell Assay Buffer.

Assays are performed in Greiner white 384 well plates. The PathHunter U2OS cell line expressing the cytosolic tyrosine kinase JAK1 or JAK2 and the membrane bound cytokine receptor prolactin is plated out using OptiMEM (Invitrogen) at 5000 cells/well, 20pl/well and incubated at 37°C, 5% CO2. After 18 hours 5μΙ test compound is added to the plate using a Platemate Plus. Plates are incubated at 37°C, 5% CO₂ for 60 minutes before addition of 5μΙ prolactin at a concentration of 15nM. Plates are incubated at room température for a further 180 minutes before addition of 10μΙ détection reagent. After reagent addition plates are covered and incubated at room température for 60 minutes. Luminescence signal is read using an Envision. Test compound data are expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to détermine an IC₆₀ from the résultant sigmoid curve.

Example 4 gave a JAK-1 IC₅o of 75 nM and a JAK-2 IC₅₀ of 176 nM in this assay.

Functional Assessment of JAK inhibitorv Potencv usina hrlL-2 and haCD3 stimuated IFNy Production in Human Isolated PBMC.

Isolation of human Pencherai Blood Mononuclear Cells (PBMC)

Peripheral venous blood from healthy volunteers of either sex was collected into 50ml centrifuge tubes (Corning) containing 1ml of 5mg/ml heparin (Sigma H3400) in distilled water. The heparininsed blood was diluted using an equal volume of stérile Dulbeccos phosphate buffered saline (PBS: Invitrogen 14190) before decanting into 50ml Leucosep tubes (Sigma A0561). The

Leucosep tubes were centrifuged at 400g for 30min at room température and the buffycoat at the Ficoll:Plamsa interface collected into clean centrifuge tubes and the volum made up to 50ml using PBS and centrifuging at 200g for 10min at room température. The supernatent was discarded and the pellet resuspended in assay media (Dulbeccos Modified Essential Medium (DMEM: Invitrogen 11971025) containing 5% Foetal Bovine Sérum, WOU/ml penicilin/ 100pg/ml streptomycin (Sigma P4458) at 2x10^e lymphocytes per ml for IFNy experiments and at 1x10⁶lymphocytes per ml for the pYSTAT5 experiments.

hrlL2/haCD3 Stimulated IFNy Production

180μΙ of PBMC cell suspension was added to each well of a stérile 96 well, fiat bottomed plate (Corning-Costar 3598). After a 1h incubation at 37°C, 10μΙ of test compound dilution (final assay concentration range of 0.3nM to ΙμΜ in half log incréments) or vehicle (2% DMSO in Hanks Balanced Sait Solution (Sigma H8264)) was added to the appropriate well and the pâtes incubated at 37°C, in 95%0₂/5%C0₂ for 1h. 10μΙ of 200ng/ml IL-2(R&D Systems 202IL):20pg/ml aCD3 (BD Biosciences 555329) (final assay concentrations of 10ng/ml and 1pg/ml respectively) in assay buffer was added and the plates incubated at 37°C, in 95%O₂/5% CO₂ for 18h. Plates were removed from the incubator and centrifuged at 200g for 5min at room température. 100μΙ supernatent was collected, diluted 1:4 and IFNy content determined using a commercially available IFNy ELISA kit (Invitrogen CHC1233) as per the manufacturées instructions. Absorbances were measured using a Spectramax 190/250 plate reader (Molecular Devices). The IFNy concentration of test wells was expressed as % of the IFNy concentration produced in wells exposed to IL-2/aCD3 in the absence of test compound, and IC₅₀ values determined using a 4 parameter curve fit.

Example 4 gave an IC₅₀ of 70 nM in this assay.

hrll_2/haCD3 Stimulated PYSTAT5 in PBMC lymphocytes

90μΙ of PBMC cell suspension was added to each well of a 96 well plate (Corning-Costar 3598) along with 10μΙ of test compound dilution giving a final assay concentration range of 0.03nM to 1μΜ in half log incréments. The plates were incuated at 37°C, in 95%O₂/5% CO₂ for 1h before 10μΙ rhlL2 (3pg/ml final assay concentration) was added to appropriate wells and the plates incubated at the stated conditions for a further 15min. 25μΙ of 20% formaldéhyde (Tousimis) was added to ail wells and the plates left at room température for 10min prior to centrifugation at 400g for 4min at room température. 200μΙ PBS was added to each well and centrifugation repeated as just described. The supernatent was removed and 50μΙ of a 1:50 dilution of Mouse anti-human CD3 (BD Biosciences 555329) in 0.1% BSA (Sigma A7906)/ PBS added to each well (excluding control wells) and the plates incubated at room température in the dark for

30min. 150μΙ of 0.1% BSA/PBS was added to each well and the plate centrifuged at 400g for 4min before the supernatent was discarded and 100μΙ ice-cold Phosflow Perm Buffer III (BD Biosciences 612599) added. The plates were briefly vortexed and incubated on ice in the dark for 30min before 100μΙ of 0.1%BSA/PBS was added and the plates centrifuged again as just described. 20μΙ of a 1:20 dilution of AF647 anti-phospho-STAT5 antibody (in PBS) was added to the wells (excluding controls) and incubated in the dark at room température for 30min before adding 180μΙ of 0.1%BSA/PBS and centrifuging as already described. Once the supernatent was discarded the cells were resuspended in 100μΙ of 2% formaldéhyde and the plates stored at 4°C ovemight. Plates were read the next day on a FACS Canto (Becton Dickinson). Lymphocytes were gated on PE immunofluorescence and the AF647 signal used as a measure of pYSTATS expression. IC₅₀ values were generated in Excel using a four parameter curve fit.

Example 4 gave an IC₅o of 45 nM in this assay.

For détermination of compound duration of action (DoA) cells were incubated with compound at an approximate IC_e0 concentration for 1h before being washed by cenrifugation and resuspension in assay media without compound. At set intervals after wash cells were stimulated with IL-2:aCD3 for 15 min and the plates processed as described above. 100% inhibition was defined as réduction of pYSTATS levels down to basal. DoA was calculated as the time taken for the inhibition to reverse by 50% (T₆₀%).

Example 4 gave a DoA of >8.8 hours in this assay.

Claims

Claims

1. A compound of formula (I):

(D or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or pharmaceutically acceptable sait, wherein:

R¹ is halo;

R² is C_f-C₀ alkyl optionally substituted by one or more fluorine atoms;

X is a bond, -CO-, -SO₂- or -CH₂-;

R³ is Aryl¹, Het¹ or Het², each of which is optionally substituted by 1 substituent -Y-R⁴ and/or 1 -4 substituents each independently selected from R⁶;

n is 1 or 2;

Aryl¹ is phenyl or naphthyl;

Het¹ is (i) a 6-membered aromatic heterocycle containing 1-3 N atoms or (ii) a 5-membered aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms;

9l

Het² is (i) a 10-membered bicyclic aromatic heterocycle containing 1-4 N atoms or (ii) a 9membered bicyclic aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms or (iii) an θ-membered bicyclic aromatic heterocycle containing (a) 14 N atoms or (b) 1 O or S atom and 1-3 N atoms or (c) 2 O or S atoms and 0-2 N atoms;

Y is a bond or -O-;

R⁴ is Aryl² or Het³;

R⁵ is Ci-Ce alkyi, C3-C8 cycloalkyl, halo, -CN, -OR⁶, -NR⁷R⁶, -SR⁶, -SOR⁹, -SO2R⁹, -COR⁶, OCOR⁶, -COOR⁶, -NR⁶COR⁶, -CONR⁷R⁸, -NR⁶SO2R⁹, -SO2NR⁷R⁸, -NR⁶CONR⁷R⁸, NR^eCOOR⁹ or -NR⁶SO₂NR⁷R⁸;

R⁶ is H, Cj-Ce alkyi or C₃-C_B cycloalkyl, said C^Ce alkyi being optionally substituted by halo or C₃-C_s cycloalkyl;

R⁷ and R⁸ are (a) each independently H, Ci-C8 alkyi or C3-C8 cycloalkyl, said CrC6 alkyi being optionally substituted by -NR¹⁰R¹¹, wherein R¹ and R¹¹ are Ci-Ce alkyi or taken together with the nitrogen atom to which they are attached form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1-2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said heterocyclic ring being optionally substituted by one or more CrCe alkyi or C₃-C₈cycloalkyl groups; or, (b) are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1-2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said heterocyclic ring being optionally substituted by one or more Ci-C_e alkyi or C₃-C₈ cycloalkyl groups;

R⁹ is Ci-C₈ alkyi or C₃-C₈ cycloalkyl;

Aryl² is phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1-5 substituents selected from Ci-C8 alkyi, C3-C8 cycloalkyl, halo, -CN, -OR⁶, -NR⁷R⁸, -SR⁶, SOR⁹, -SO2R⁹, -COR⁶, -OCOR⁶, -COOR⁶, -NR⁶COR⁶, -CONR⁷R⁸, -NR⁸SO2R⁹, -SO2NR⁷R⁸, NR⁶CONR⁷R⁸, -NR⁶COOR⁹ and -NR⁶SO₂NR⁷R⁶; and

Het³ is a 3 to 8-membered saturated or partially unsaturated monocyclic heterocycle, containing 1 or 2 heteroatoms selected from O and N, said heterocycle being optionally substituted by 1-5 substituents selected from Ci-C₆ alkyi, C₃-C₈ cycloalkyl, halo, oxo, -OR⁶, 16848

NR⁷R^B, -SR⁶, -SOR , -SO2R⁹, -COR⁶, -OCOR⁶, -COOR⁶, -NR⁶COR⁶, -CONR⁷R⁸, -NR⁶SO2R⁹, -SO2NR⁷R⁶, -NR⁶CONR⁷R⁸, -NR⁶COOR⁹ and -NR⁶SO2NR⁷R⁸.
2. A compound of formula (I), as claimed in claim 1, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein R¹is fluoro.
3. A compound of formula (I), as claimed in claim 1 or claim 2, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein R² is -CH₂CH₃ or -CH₂CF₃..
4. A compound of formula (I), as claimed in any one of claims 1 to 3, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein n is 1.
5. A compound of formula (I), as claimed in claim any one of claims 1 to 3, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein n is 2.
6. A compound of formula (I), as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein X is a bond.
7. A compound of formula (I), as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein X is -CO-.

Θ. A compound of formula (I), as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein X is -SO₂-.
9. A compound of formula (I), as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein X is -CH₂-,
10. A compound of formula (I), as claimed in any one of claims 1 to 9, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, wherein R³ is phenyl, thiazolyl, quinolinyl, pyrimidinyl, [1,8]naphthyridinyl or pyridyl, each of which is optionally substituted by 1 substituent selected from piperdininyl, (fluorophenyl)oxy, phenyloxy and morpholinyl and 1-2 substituents each independently selected from fluoro, chloro, cyano, methoxy and hydroxy
11. A compound of formula (I), as claimed in claim 1, which is: {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol·3-yl]-1,4,6₁7-tetrahydro-imidazo [4,5-c]pyridin-5-yl}-(4-fluoro-phenyl)-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl}-isothiazol-3-yl-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl)-isothiazol-3-yl-methanone;

(2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl}-(5-piperidin-1-yl-pyrazin-2-yl)-methanone;

{2-[6-(2-Ethyl-5-fluorO'4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl}-(6-phenoxy-pyridin-3-yl)-methanone;

5-Ethyl-2-fluoro-4-{3-[5-(6-morpholin-4-yl-pyridine-3-sulfonyl)-4,5,6,7-tetrahydro-1Himidazo[4,5-c]pyridin-2-yl]-1H-indazol-6-yl}-phenol;

5-Ethyl-2-fluoro-4-[3-[5-(6-phenoxy-pyridine-3-sulfonyl)-4,5,6,7-tetrahydro-1H-imidazo [4,5-c]pyridin-2-yl]-1H-indazol-6-yl)-phenol;

(5-Chloro-pyridin-2-yi)-[2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-4,5,7,8tetrahydro-1H-imidazo[4,5-d]azepin-6-yl}-methanone;

2-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-4,5,7,8-tetrahydro-1Himidazo[4,5-d]azepine-6-carbonyl}-isonicotinonitrile;

(2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-4,5,7,8-tetrahydro-1H-imidazo [4,5-d]azepin'6-yl}-(4-fluoro-phenyl)-methanone;

(2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-4,5,7,8-tetrahydro-1H-imidazo [4,5-d]azepin-6-yl)-isothiazol-3-yl-methanone;

5-Ethyl-2-fluoro-4-{3-[5-(4-fluoro-benzenesulfonyl)-4,5,6,7-tetrahydro-1H-imidazo [4,5-c]pyridin-2-yl]-1H-indazol-6-yl]-phenol;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridin-5-yl}-[5-(2-fluoro-phenoxy)-pyrazin-2-yl]-methanone;

4-[3-(6-Benzyl-1,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1H-indazol-6-yl]-5-ethyl-2fluoro-phenol;

(5-Chloro-pyridin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7tetrahydro-imidazo[4,5-c]pyridin-5-yl)-methanone;

5-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo [4,5-c]pyridine-5-carbonyl}-pyridine-2-carbonitrile;

5-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-4,5,7,8-tetrahydro-1Himidazo[4,5-d]azepine-6-carbonyl}-pyridine-2-carbonitrile;

5 5-Ethyl-2-fluoro-4-[3-(5-quinolin-6-ylmethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)1 H-indazol-6-yl]-phenol;

5-Ethyl-2-fluoro-4-{3-[5-(4-hydroxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]1 H-indazol-6-yl)-phenol;

5-Ethyl-2-fluorO4-{3-[5-(3-hydroxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]10 1H-îndazol-6-yl)-phenol;

4- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-ylmethyl}-pyridine-2-carbonitrile;

5- Ethyl-2-fîuoro-4-(3-[5-(3-methoxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]1 H-indazol-6-yl}-phenol;

15 5-Ethyl-2-fluoro-4-[3-(5-quinolin-3-ylmethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)1 H-indazol-6-ylJ-phenol;

5-Ethyl-2-fluoro-4-(3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6₁7-tetrahydro-1H-imidazo[4,5c]pyridin-2-yl]-1H-indazol-6-yl}-phenol;

5-Ethyl-2-fluoro-4-{3-[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-ylmethyl)-4,5,6,720 tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;

3- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-ylmethyl}-pyridine-2-carbonitrile;

5-Ethyl-2-fluoro-4-{3-[5-(4-fluoro-benzyi)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]1 H-indazol-6-yl}-phenol;

25 5-Ethyl-2-fluoro-4-[3-(5-[1,8]naphthyridin-2-ylmethyl-4,5,6,7-tetrahydro-1 H-imidazo[

4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-phenol;

(2-{6-[5-Fluoro-4-hydroxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1H-indazol-3-yl}-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-(5-piperidin-1-yl-pyrazin-2-yl)-methanone;

(2-{6-[5-Fluoro-4-hydroxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1H-indazol-3-yl}-1,4,6,7-tetrahydro30 imidazo[4,5-c]pyridin-5-yl)-(4-fluoro-phenyl)-methanone; or

4- [3-(5-Benzyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-2-fluoro-5(2,2,2-trifluoro-ethyl)-phenol;

or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of

35 said compound or sait.
12. A compound of formula (l), as claimed in claim 1, which is:

{5-[(2-Dimethylamino-ethyl)-methyl-amino]-pyrazin-2-yl}-{2-[6-(2-ethyl-5-fluorO-4-hydroxyphenyl)-1 H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,55 c]pyridin-5-yl}-[5-(2-pyrrolidin-1-yl-ethylamino)-pyrazin-2-yl]-methanone; [5-(2-Dimethylamino-ethylamino)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1Hindazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4_t5-c]pyridin-5-yl)-methanone;

[5-(4-Dimethylamino-piperidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

10 {2-[6-(2-Ethyl·5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1₎4,6_l7-tetrahydro-imidazo[4_l5c]pyridin-5-yl}-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pyrazin-2-yl}-methanone;

[5-((R)-3-Dimethylamino-pyrrolidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone; [5-((S)-3-Dimethylannino-pyrrolidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy15 phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-methanone: {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7etrahydroimidazo[4,5c]pyridin-5-yl}-[5-(2-piperidin-1-yl-ethylamino)-pyrazin-2-yl]-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-yl}-[5-(2-piperazin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;

20 {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5]pyridin-5-yl}-(4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-yl}-(5-morpholin-4-yl-pyrazin-2-yl)-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro25 idazo[4,5c]pyridin-5-yl)-[5-(4-niethyl-piperidin-1-yl)-pyrazin-2-yl]-methanone; (5-Cyclopentylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-

1.4.6.7- tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4_l5c]pyridin-5-yl}-[5-(2-morpholÎn-4-yl-ethylamino)-pyrazin-2-yl]-methanone;

30 {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5c]pyridin-5-yl}-(4-isopropyl-3,4,5,6-tetrahydro-2H-[1,2^,]bipyrazinyl-5'-yl)-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyi)-1H-indazol-3-yl]-1,4_I6,7-tetrahydro-imidazo[4,5c]pyridin-5-yl}-(5-pyrrolidin-1-yl-pyrazin-2-yl)-methanone;

{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,535 ]pyridin-5-yl}-[5-(ethyl-methyl-amino)-pyrazin-2-yl]-methanon; (5-Cyclohexylamino-pyrazin-2-yl)-[2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-

1.4.6.7- tetrahydro-imidazo[4,5-c]pyridin-5-yl)-methanone;

(5-Dimethylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-ylJ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-methanone;

(5-Azetidin-1-yl-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]1 A6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;

5 2-Fluoro-4-{3-[5-(4-fluoro-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 Hindazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yimethyl)-4,5,6,7-tetrahydro-1HimidazoAS-cteyridin^-ylHH-indazol-e-ylJ-S-^^-trifluoro-ethyO-phenol;

2-Fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin10 2-yl]-H-indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(4-methoxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]-1H indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(4-hydroxy-benzyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl]-1Hindazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

15 2-Fluoro-4-{3-[5-(3-methoxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 Hindazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-{3-[5-(3-hydroxy-benzyl)-4,5,6_l7-tetrahydro-1H-imidazo[4_l5-c]pyridin-2-yl]-1Hindazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-[3-(5-quinolin-6-ylmethyl-4_I5,6,7-tetrahydro-1H-imidazo[4₁5-c]pyridin-2-yl)-1H20 indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-[3-(5-quinolin-3-ylmethyl-4,5,6_I7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1Hindazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;

2-Fluoro-4-[3-(5-[1,8]naphthyridin-3-ylrnethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2yl)-1H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;

25 ((3R,5S)-3,5-Dimethyl-3,4,5,6-tetrahydro-2H-[1,2^,]bipyrazinyl-5'-yl)-{2-[6-(2-ethyl-5-fluoro-4hydroxy-phenyO-IH-indazol-S-yn-l^.e^-tetrahydro-imidazo^.S-cjpyridin-S-ylJ-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro4midazo[4,5c]pyridin-5-yl}-((S)-3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)-methanone; ((2S_l5R)-2,5-Dimethyl-3,4₁5,6-tetrahydro-2H-[1,2’]bipyrazinyl-5'-yl)-{2-[6-(2-ethyl-5-fluoro-430 hydroxy-phenyl)-1H-indazol-3-yl]-1,4_l6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5Jpyridin-S-ylHSAS.e-tetrahydro^H-tl^'jbipyrazinyl-S'-yO-methanone;

or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of

35 said compound or sait.
13. A pharmaceutical composition comprising a compound of formula (I), as claimed in any one of daims 1 to 12, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait, and a pharmaceutically acceptable excipient.
14. Use of a compound of formula (I), as claimed in any one of daims 1 to 12, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait in the manufacture of a composition for treating a disease or condition for which a JAK inhibitor is indicated, in a subject in need of such treatment.
15. Use of a compound of formula (I), as claimed in any one of daims 1 to 12, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait in the manufacture of a composition for treating a disease or condition selected from allergie rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma of ail types, chronic obstructive pulmonary disease , chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, chronic éosinophilie pneumonia, adult respiratory distress syndrome, exacerbation of airways hyperreactivity conséquent to other drug therapy, pulmonary vasulcar disease, pulmonary arterial hypertension, acute lung injury, bronchiectasis, sinusitis, allergie conjunctivitis, idiopathic pulmonary fibrosis or atopie dermatitis.
16. Use of a compound of formula (I), as claimed in any one of daims 1 to 12, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait in the manufacture of a composition for treating chronic obstructive pulmonary disease.
17. Use of a compound of formula (I), as claimed in any one of daims 1 to 12, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait in the manufacture of a composition for treating a disease or condition selected from inflammation, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoisosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowei disease, Crohn’s disease, ulcerative colitis, nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabètes (type 1 and type 2), diabetic neurorpathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple scierosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity.muscular dystrophy, polymyositis, Alzheimer’s disease, skin flushing, eczema, psoriasis, atopie dermatitis and sunburn.
18. Use of a compound of formula (I), as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable sait thereof, or a pharmaceutically acceptable solvaté of said compound or sait in the manufacture of a composition for treating psoriasis.